Improved linkers for conjugates

Modified oxime linkers with polyethylene glycol units and heteroaryl moieties enhance stability and reduce off-target toxicity, addressing issues of premature cleavage and heterogeneity in antibody-drug conjugates, resulting in improved therapeutic efficacy and pharmacokinetics.

WO2026234453A1PCT designated stage Publication Date: 2026-11-12LIGACHEM BIOSCIENCES INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/000290
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current linker technologies for antibody-drug conjugates face challenges such as reduced efficacy due to non-specific internalization, premature cleavage leading to off-target effects, and heterogeneity in drug-to-antibody ratios, impacting stability and pharmacokinetics.

Method used

Development of modified oxime linkers with improved stability under low pH conditions, incorporating polyethylene glycol units and heteroaryl moieties, allowing for stable intracellular recycling and reduced off-target toxicity, and enabling conjugates with multiple attachment points for enhanced therapeutic efficacy.

Benefits of technology

The modified linkers provide improved stability, reduced off-target toxicity, and enhanced in vivo efficacy, with potential for co-delivery of synergistic agents, improving pharmacokinetic properties and therapeutic index.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2026000290_12112026_PF_FP_ABST
    Figure IB2026000290_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are antibody-drug conjugates comprising a linker having an oxime, and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No.: LCH-04125

[0002] IMPROVED LINKERS FOR CONJUGATES RELATED APPLICATIONS

[0003] This application claims the benefit of U. S. Provisional Application No. 63 / 802,463, filed May 8, 2025, the contents of which are hereby incorporated by reference herein.

[0004] BACKGROUND

[0005] Conjugate technology allows for the selective targeting of specific cells or tissues by linking a targeting moiety to a functional payload, an approach that enhances the efficacy of the payload while potentially reducing off-target effects. Conjugates can be designed for various applications, such as therapeutics, diagnostics, and research tools.

[0006] One example of conjugate technology is antibody-drug conjugates (ADCs) used in cancer therapy. ADCs combine the specificity of antibodies with potent cytotoxic agents. Another example is folate-drug conjugates, which utilize the overexpression of folate receptors on certain cancer cells to deliver therapeutic payloads. However, conjugate technology extends beyond the aforementioned examples, encompassing various targeting moieties (e.g., peptides, aptamers, small molecules) and payloads (e.g., drugs, imaging agents, nucleic acids).

[0007] The basic structure of a conjugate comprises a “moiety-linker-payload” arrangement. The linker plays a crucial role in connecting the moiety (e.g., a targeting moiety) and the payload, often designed to release the payload under specific conditions. Once a linker is selected for a particular application, typically many methods are available to couple that linker to any desired moiety and payload. The efficacy, safety, and systemic effects of conjugates depend significantly on the stability and properties of the linker.

[0008] Linkers may be classified as non-cleavable or cleavable. When non-cleavable linkers are used, the entire conjugate complex provides the needed activity. Cleavable linkers can be designed to respond to various stimuli, such as pH changes, enzymatic activity, or reducing environments, and may be cleavable inside or outside of a cell. Then, the payload is preferentially released in a target environment. Each type of linker has its advantages and challenges in different applications.

[0009] Current linker technologies face several challenges. Non-cleavable linkers may suffer from reduced efficacy if the conjugate is not efficiently internalized or processed by target cells. Cleavable linkers, while offering controlled release, may be susceptible to premature cleavage in

[0010] -1- FH13329100.6Attorney Docket No.: LCH-04125

[0011] circulation, leading to off-target effects. Some linkers may affect the solubility, stability, or immunogenicity of the conjugate. Additionally, certain conjugation methods may result in heterogeneous products with varying drug-to-antibody ratios, impacting reproducibility and pharmacokinetics.

[0012] In view of the foregoing, there is an ongoing need for new linker technologies.

[0013] SUMMARY OF THE INVENTION

[0014] In certain aspects, the invention relates to antibody-drug conjugates (ADCs) comprising a moiety-linker-payload, wherein the moiety is an antibody and the linker comprises a stabilized oxime moiety. In certain embodiments, this oxime moiety exhibits improved stability under low pH environments compared to conventional oxime linkers. Among the various linker chemistries employed in conjugate design, oxime-based linkers have been utilized for their chemoselective reactivity and relative ease of formation. However, conventional oxime linkers typically exhibit limited stability under acidic conditions, such as those encountered in the endosomal and lysosomal compartments of cells (approximately pH 5.0-6.5). This pH sensitivity can be advantageous for targeted payload release in cancer cells, which internalize ADCs through receptor-mediated endocytosis. Furthermore, conventional oxime linkers may also be susceptible to premature hydrolysis in non-target cells that non-specifically take up the ADC.

[0015] In certain embodiments, the improved stability of the modified oxime linkers disclosed herein under mildly acidic conditions, such as those present in the endosomal compartment (approximately pH 5.0-5.5), enables ADCs comprising such linkers to survive intracellular recycling pathways in non-target cells and return to systemic circulation with the payload substantially intact. Thus, in various embodiments, the modified oxime linkers disclosed herein provide one or more of the following advantageous properties: (i) improved stability under low pH conditions; (ii) improved long-term stability under formulation and storage buffer conditions, which are typically maintained at a pH lower than 7.4 for antibody-containing products; (iii) improved plasma stability; (iv) comparable in vitro potency with reduced off-target toxicity, resulting in a potentially wider therapeutic index; and (v) improved in vivo efficacy relative to ADCs comprising a conventional oxime linker. The linkers of antibody-drug conjugates may be classified as non-cleavable or cleavable. The conjugate may have at least one linker, which can be linear or branched. The primary and / or secondary linker may comprise at least one polyethylene glycol unit, an amido, a heteroaryl or fused heteroaryl moiety, an amino acid, a vinyl pyridine- or -2- FH13329100.6Attorney Docket No.: LCH-04125

[0016] maleimide-derived moiety. In certain aspects, at least one branched linker is covalently coupled to the antibody.

[0017] In certain aspects, the present disclosure provides conjugates comprising a structure represented by formula la or a pharmaceutically acceptable salt thereof:

[0018]

[0019] wherein

[0020] R1is H, alkyl or cycloalkyl; and

[0021] R2is alkyl or cycloalkyl; or R1and R2combine to form a cycloalkyl.

[0022] In certain aspects, the present disclosure provides conjugates comprising a structure represented by formula Ij or a pharmaceutically acceptable salt thereof:

[0023]

[0024] wherein

[0025] X1and X2are each independently N(R4), O, or S; and

[0026] R1and R2are each independently alkyl or cycloalkyl; or R1and R2combine to form a cycloalkyl.

[0027] In certain aspects, the present disclosure provides methods of treating a disease or disorder in a subject, comprising administering a conjugate or composition, or a pharmaceutically acceptable salt thereof, to the subject.

[0028] BRIEF DESCRIPTION OF THE DRAWINGS FIG.l is a graph depicting tumor volume as a function of days post-treatment in an HPAF-II cell-derived xenograft model, showing the anti-tumor efficacy of CEACAM5-ADC1 and CEACAM5-ADC4 at various dosages compared to a vehicle control.

[0029] FIG. 2 is a graph depicting tumor volume as a function of days post-treatment in an MKN-45 cell-derived xenograft model, showing the anti-tumor efficacy of CEACAM5-ADC1 and CEACAM5-ADC5 at various dosages compared to a vehicle control.

[0030] -3- FH13329100.6Attorney Docket No.: LCH-04125

[0031] FIG. 3 is a graph depicting tumor volume as a function of days post-treatment in an MKN-45 cell-derived xenograft model, showing the anti-tumor efficacy of CEACAM5-ADC4 at various dosages compared to a vehicle control.

[0032] FIG. 4 is a graph depicting tumor volume as a function of days post-treatment in an NCI-H2122 cell-derived xenograft model, showing the anti-tumor efficacy of CEACAM5-ADC1 and CEACAM5-ADC5 at various dosages compared to a vehicle control.

[0033] FIG. 5 is a graph depicting tumor volume as a function of days post-treatment in an SW1463 cell-derived xenograft model, showing the anti-tumor efficacy of CEACAM5-ADC1 at various dosages compared to a vehicle control.

[0034] FIG. 6 is a graph depicting tumor volume as a function of days post-treatment in an SW1463 cell-derived xenograft model, showing the anti-tumor efficacy of CEACAM5-ADC4 at various dosages compared to a vehicle control.

[0035] FIG. 7 is a graph depicting change in relative tumor volume as a function of days posttreatment in a LUN-NIC-0087 patient-derived xenograft lung cancer model, showing the antitumor efficacy of CEACAM5-ADC1 at various dosages compared to a vehicle control.

[0036] FIG. 8 is a graph depicting change in relative tumor volume as a function of days posttreatment in a LUN-NIC-0011 patient-derived xenograft lung cancer model, showing the antitumor efficacy of CEACAM5-ADC1 at various dosages compared to a vehicle control.

[0037] FIG. 9 is a graph depicting change in relative tumor volume as a function of days posttreatment in a LUN-NIC-0084 patient-derived xenograft lung cancer model, showing the antitumor efficacy of CEACAM5-ADC1 at various dosages compared to a vehicle control.

[0038] FIG. 10 is a graph depicting change in relative tumor volume as a function of days posttreatment in a CR-LRB-004P patient-derived xenograft colon cancer model, showing the antitumor efficacy of CEACAM5-ADC1 at various dosages compared to a vehicle control.

[0039] FIG. 11 is a graph depicting change in relative tumor volume as a function of days posttreatment in a CR-IGR-048M patient-derived xenograft colon cancer model, showing the antitumor efficacy of CEACAM5-ADC1 at various dosages compared to a vehicle control.

[0040] FIG. 12 is a graph depicting change in relative tumor volume as a function of days posttreatment in a CR-LRB-010P patient-derived xenograft colon cancer model, showing the antitumor efficacy of CEACAM5-ADC1 at various dosages compared to a vehicle control.

[0041] -4- FH13329100.6Attorney Docket No.: LCH-04125

[0042] FIG. 13 is a graph depicting plasma concentration of ADC2 and total antibody as a function of time in an SD rat pharmacokinetic model following intravenous administration at 3 mg / kg.

[0043] FIG. 14 is a graph depicting plasma concentration of ADC5 and total antibody as a function of time in a B6-hCEACAM5 transgenic mouse pharmacokinetic model following intravenous administration at 3 mg / kg.

[0044] FIG. 15 is a graph depicting tumor volume as a function of days post-treatment in an HCT15 cell-derived xenograft model, showing the anti-tumor efficacy of Lewis Y-ADC3 compared to a control.

[0045] FIG. 16 is a graph depicting tumor volume as a function of days post-treatment in an OVCAR3 cell-derived xenograft model, showing the anti-tumor efficacy of Lewis Y-ADC3 at various dosages compared to a control.

[0046] FIG. 17 is a graph depicting tumor volume as a function of days post-treatment in an OVCAR3 cell-derived xenograft model, showing the anti-tumor efficacy of Lewis Y-ADC2, Lewis Y-ADC5, Lewis Y-ADC6, and Lewis Y-ADC7 compared to a control.

[0047] FIG. 18 is a graph depicting tumor volume as a function of days post-treatment in an HCT15 cell-derived xenograft model, showing the anti-tumor efficacy of Lewis Y-ADC2, Lewis Y-ADC6, and Lewis Y-ADC7 compared to a control.

[0048] FIG. 19 is a graph depicting tumor volume as a function of days post-treatment in an NCI-N87 cell-derived xenograft model, showing the anti-tumor efficacy of Lewis Y-ADC2, Lewis Y-ADC4, Lewis Y-ADC5, Lewis Y-ADC6, and Lewis Y-ADC7 compared to a control.

[0049] FIG. 20 is a graph depicting tumor volume as a function of days post-treatment in an HCT15 cell-derived xenograft model, showing the anti-tumor efficacy of Lewis Y-ADIC4 and Lewis Y-ADIC5 compared to a control.

[0050] FIG. 21 is a graph depicting tumor volume as a function of days post-treatment in an SNU840 cell-derived xenograft model, showing the anti- tumor efficacy of Lewis Y-ADIC5 at various dosages compared to a control.

[0051] FIG. 22 is a graph depicting tumor volume as a function of days post-treatment in an OVCAR3 cell-derived xenograft model, showing the anti-tumor efficacy of Lewis Y-ADIC6, Lewis Y-ADIC9, Lewis Y-ADIC10, Lewis Y-ADIC11, Lewis Y-ADIC12, and Lewis Y-AIC1 compared to a control.

[0052] -5- FH13329100.6Attorney Docket No.: LCH-04125

[0053] FIG. 23 is a graph depicting tumor volume as a function of days post-treatment in an HCT15 cell-derived xenograft model, showing the anti-tumor efficacy of Lewis Y-ADIC6, Lewis Y-ADIC10, Lewis Y-ADIC12, and Lewis Y-AIC1 compared to a control.

[0054] FIG. 24 is a graph depicting tumor volume as a function of days post-treatment in an NCI-N87 cell-derived xenograft model, showing the anti-tumor efficacy of Lewis Y-ADIC6, Lewis Y-ADIC9, Lewis Y-ADIC10, Lewis Y-ADIC11, Lewis Y-ADIC12, and Lewis Y-AIC1 compared to a control.

[0055] FIG. 25 is a graph depicting tumor volume as a function of days after grouping in an OPM-2 multiple myeloma xenograft model, showing the anti-tumor efficacy of BCM A- ADC 1 and BCMA-ADC2 compared to a vehicle control.

[0056] FIG. 26 is a graph depicting tumor volume as a function of days after grouping in an OPM-2 multiple myeloma xenograft model, showing the anti-tumor efficacy of BCMA-ADC3 compared to a vehicle control.

[0057] FIG. 27 is a set of graphs depicting percent cancer cell growth as a function of time in SK-BR3 cells, showing the immune-mediated tumor cell killing efficacy of exemplified AICs in the presence and absence of human peripheral blood mononuclear cells (PBMCs).

[0058] FIG. 28 is a set of graphs depicting percent cancer cell growth as a function of time in SK-BR3 cells, showing the immune-mediated tumor cell killing efficacy of TIM-3 AIC compounds in the presence and absence of human peripheral blood mononuclear cells (PBMCs).

[0059] FIG. 29 is a set of graphs depicting percent cancer cell growth as a function of time in SK-BR3 cells, showing the immune-mediated tumor cell killing efficacy of PD-1 AIC compounds in the presence and absence of human peripheral blood mononuclear cells (PBMCs).

[0060] FIG. 30 is a graph depicting percent cell viability as a function of concentration in JIMT1 cells, showing the cytotoxic activity of exemplified ADIC7 compared to control compounds.

[0061] FIG. 31 is a graph depicting percent cell viability as a function of concentration in MDA-MB-468 cells, showing the cytotoxic activity of exemplified ADIC7 and ADIC8 compared to control compounds.

[0062] FIG. 32 is a set of LC-MS chromatograms depicting P-glucuronidase-mediated cleavage of Compound 5-17, showing the release of MMAE payload and formation of intermediate products at 0, 1, and 3 hours.

[0063] -6- FH13329100.6Attorney Docket No.: LCH-04125

[0064] FIG. 33 is a set of LC-MS chromatograms depicting P-glucuronidase-mediated cleavage of Compound 5-18, showing the release of MMAE payload and formation of intermediate products at 0, 1, and 3 hours.

[0065] FIG. 34 is a graph depicting the plasma stability of Compound 5-17 and Compound 5-18 in human plasma over a 7-day incubation period, showing percent remaining as a function of time.

[0066] FIG. 35 is a graph depicting the plasma stability of Compound 5-19, Compound 5-20, and Compound 5-27 in human plasma over a 7-day incubation period, showing percent remaining as a function of time.

[0067] DETAILED DESCRIPTION OF THE INVENTION

[0068] In various aspects, the present disclosure provides linear or branched linkers, and conjugates comprising those linkers, as well as methods for their synthesis and for their use in therapeutic applications. In particular, the disclosure describes conjugates comprising a structure represented by formula la. That structure incorporates multiple attachment points for coupling to active agents, allowing for the delivery of multiple payloads or the combination of different functionalities within a single conjugate. The branched structure may enhance the therapeutic efficacy, improve pharmacokinetic properties, or allow for the co-delivery of synergistic agents. The conjugates described herein may be particularly useful in the context of antibody-drug conjugates, but the technology is broadly applicable to various targeting moieties and payloads.

[0069] In various aspects, the present disclosure provides linkers, and conjugates comprising those linkers, as well as methods for their synthesis and for their use in therapeutic applications. In particular, the disclosure describes conjugates comprising a structure represented by formula la. That structure incorporates multiple attachment points for coupling to active agents, allowing for the delivery of multiple payloads or the combination of different functionalities within a single conjugate. The branched structure may enhance the therapeutic efficacy, improve pharmacokinetic properties, or allow for the co-delivery of synergistic agents. The improved stability under mildly acidic conditions of the modified linkers of the present disclosure may reduce premature payload release in non-target cells. In addition, the conjugates comprising the modified oxime linkers disclosed herein exhibit several advantageous properties compared to conjugates comprising conventional oxime linkers. For example, the modified oxime linkers demonstrated: (1) improved stability under low pH conditions, such as those encountered in the endosomal compartment (approximately pH 5.0-5.5); (2) improved long-term stability under formulation and storage buffer -7- FH13329100.6Attorney Docket No.: LCH-04125

[0070] conditions, which are typically maintained at a pH lower than 7.4 for antibody-containing pharmaceutical products; (3) improved plasma stability; (4) comparable in vitro potency against target-expressing cells with reduced cytotoxicity toward normal cells, resulting in a potentially wider therapeutic index; and (5) in certain models, improved in vivo anti-tumor efficacy relative to ADCs comprising conventional oxime linkers.

[0071] The improved stability also confers therapeutic advantages through multiple mechanisms. For instance, when an ADC is non-specifically taken up by normal cells through pinocytosis or other non-receptor-mediated pathways, the ADC may be trafficked to endosomal compartments where the pH is typically in the range of 5.0-6.5. If the linker remains stable under these conditions, premature payload release may be minimized, and the ADC may be recycled back into systemic circulation through FcRn- mediated or other recycling pathways. Furthermore, improved stability under formulation buffer conditions (which are often maintained at pH values below 7.4 to optimize antibody stability) may enhance the shelf life and pharmaceutical quality of ADC products. Moreover, improved plasma stability may reduce systemic exposure to free payload, potentially reducing off-target toxicity and improving the overall safety profile of the ADC.

[0072] The conjugates described herein may be particularly useful in the context of antibody-drug conjugates, but the technology is broadly applicable to various targeting moieties and payloads. Indeed, the linkers disclosed herein may be used with existing linker technology in multiple ways, as it sits within a well-developed field with numerous available techniques for assembly of conjugates:

[0073] 1. Maleimide conjugation: This method utilizes the reaction between maleimide groups and thiol groups. For example, antibodies can be partially reduced to expose cysteine residues, which then react with maleimide-functionalized linkers or payloads.

[0074] 2. Cysteine Re-bridging: This technology creates homogeneous and stable ADCs by rebridging reduced interchain disulfide bonds with bifunctional linkers, without the need for antibody engineering.

[0075] 3. N-Hydroxysuccinimide (NHS) ester conjugation: NHS esters react with primary amines, such as lysine residues on proteins. This method is commonly used for attaching linkers or payloads to antibodies or other targeting moieties.

[0076] 4. Click chemistry: Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and strain- promoted azide-alkyne cycloaddition (SPAAC) are widely used for bioorthogonal

[0077] -8- FH13329100.6Attorney Docket No.: LCH-04125

[0078] conjugation. These reactions allow for site-specific attachment of payloads to modified targeting moieties. Click chemistry offers high specificity and can be performed under mild conditions, making it suitable for a wide range of biomolecules. Recently, metal- free SPAAC cycloaddition reactions have been investigated, including dibenzocyclooctyne (DBCO)-derived molecules covalently linked to the azide group of a functionalized phenylalanine such as para-azidophenylalanine (pAzF) or para- azidomethylphenylalanine (pAMF). Metal-free SPAAC reactions have been shown as promising conjugation reactions for homogeneous, highly stable conjugates with desirable pharmacokinetics and controlled delivery of the potent payload. See e.g., Xenobiotica 2024, Vol. 54, No. 8, 469–491.

[0079] 5. Enzymatic conjugation: Methods such as sortase- mediated ligation or transglutaminase-catalyzed conjugation enable site-specific attachment of payloads to targeting moieties under mild conditions. Sortase A (SrtA) catalyzes trans peptidation to insert recognition peptides at the C-terminus of antibody chains, followed by payload attachment. Bacterial transglutaminases (BTGs) form amide bonds between lysine and glutamine residues, enabling stable payload attachment. Additional examples include (i) conjugation via formyl glycine-generating enzyme, which inserts a specific sequence, converting cysteine to formyl glycine, that can then be conjugated to aldehyde-containing payloads; and (ii) prenyltransferase-mediated conjugation, wherein farnesyl transferase attaches a ketone-functionalized isoprenoid to a C- terminal CaaX motif, which is then linked to a hydroxylamine-bearing payload via oxime ligation. See e.g., Biomedicine & Pharmacotherapy 161 (2023) 114408.

[0080] 6. Hydrazone and oxime ligation: These methods involve the reaction between aldehydes or ketones with hydrazides or aminooxy groups, respectively. Exemplary methods include using amino-terminal engineered serine at the N-terminus, which is oxidized to an aldehyde for oxime ligation.

[0081] 7. Thiol-ene and thiol-yne reactions: These photoinitiated reactions allow for the conjugation of thiol-containing molecules to alkene or alkyne-functionalized components. These methods offer rapid reaction kinetics and can be performed under mild conditions, making them suitable for sensitive biomolecules.

[0082] -9- FH13329100.6Attorney Docket No.: LCH-04125

[0083] 8. Diels- Alder cycloaddition: This reaction between a diene and a dienophile can be used for bioconjugation, particularly when using cyclic dienes like trans-cyclooctene. The reaction proceeds rapidly and specifically under physiological conditions.

[0084] 9. Staudinger ligation: This method involves the reaction between an azide and a phosphine to form an amide bond; the method offers high chemoselectivity and can be performed in aqueous media, making it suitable for bioconjugation.

[0085] 10. Photoclick chemistry: Light-induced cycloadditions, such as the reaction between tetrazoles and alkenes, provide spatiotemporal control over the conjugation process. This can be particularly useful for in situ labeling or activation of conjugates. 11. Ligation to Fab nucleotide-binding sites: A method which uses indole-based linkers to target lysine residues in the Fab region’s nucleotide-binding pocket for site-specific conjugation. See e.g., Biomedicine & Pharmacotherapy 161 (2023) 114408. Each conjugation method offers unique advantages and presents specific challenges, and the choice of conjugation method may depend on factors, as readily appreciated by the skilled artisan, such as the nature of the targeting moiety, the payload, and the desired properties of the final conjugate. In many cases, the targeting moiety or payload may be modified to introduce specific functional groups that facilitate conjugation. For example, antibodies may be engineered to incorporate non-natural amino acids with bioorthogonal reactive groups, allowing for conjugation.

[0086] The skilled artisan can modulate reaction conditions, such as pH, temperature, and reagent concentrations, to achieve desired conjugation efficiencies and product homogeneity. The use of organic co-solvents, catalysts, or additives may be employed to enhance reaction rates or selectivity. In some cases, multiple conjugation steps may be used to assemble complex conjugates with multiple payloads or functionalities.

[0087] Simply put, notwithstanding the challenges associated with particular linker designs, the conjugation chemistry used to assemble targeting moieties, linkers, and payloads into functional conjugates is a mature field. Indeed, numerous well-characterized methods, such as the methods mentioned above (e.g., maleimide-thiol reactions, click chemistry, NHS ester conjugation, and enzymatic ligation) are available and routinely employed by those of skill in the art. Thus, once the structure and properties of a linker and a synthetic route to the linker are established, the

[0088] -10- FH13329100.6Attorney Docket No.: LCH-04125

[0089] selection and application of appropriate conjugation chemistry to assemble a conjugate is generally routine and predictable.

[0090] In certain aspects, the present disclosure provides a conjugate comprising a structure represented by formula la or a pharmaceutically acceptable salt thereof:

[0091]

[0092] wherein

[0093] R1is H, alkyl or cycloalkyl; and

[0094] R2is alkyl or cycloalkyl; or R1and R2combine to form a cycloalkyl.

[0095] In certain embodiments, R1is alkyl, preferably methyl. In other embodiments, R1is H. In certain embodiments, R2is alkyl, preferably methyl. In certain embodiments, R1and R2combine to form a cycloalkyl, preferably cyclobutyl.

[0096] In certain embodiments, the conjugate comprises a structure represented by formula lb or a pharmaceutically acceptable salt thereof:

[0097]

[0098] wherein

[0099] X1and X2are each independently N(R4), O, or S; and

[0100] R4is H, alkyl, aryl, or aralkyl.

[0101] In certain embodiments, X1is N(R4). In certain embodiments, R4is H. In certain embodiments, X2is O.

[0102] In certain embodiments, the conjugate comprises a structure represented by formula Ic:

[0103]

[0104] -11- FH13329100.6Attorney Docket No.: LCH-04125

[0105] wherein

[0106] L1is a covalent linker;

[0107] T is a cleavage group; and

[0108] nl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0109] In certain embodiments, the conjugate comprises a structure represented by formula Id:

[0110] X2

[0111] . D J-L / °\

[0112] (B) X1XZ

[0113] R1R2

[0114] Id

[0115] wherein

[0116] L1is a covalent linker;

[0117] each B is an active agent (e.g., a drug or a toxin); and

[0118] nl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0119] In certain embodiments, the conjugate comprises a structure represented by formula le:

[0120]

[0121] le

[0122] wherein

[0123] L1is a covalent linker;

[0124] T is a cleavage group;

[0125] each B is an active agent (e.g., a drug or a toxin); and

[0126] nl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0127] In certain embodiments, the conjugate has a structure represented by formula If:

[0128]

[0129] If

[0130] wherein

[0131] -12- FH13329100.6Attorney Docket No.: LCH-04125

[0132] each B is an active agent (e.g., a drug or a toxin);

[0133] L1is a covalent linker;

[0134] L2is a covalent linker;

[0135] Lg is a ligand, an active agent, or a reactive group ( e.g., amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl, or alkynyl); and

[0136] nl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0137] In certain embodiments, an alkenyl is a monovalent straight-chain or branched hydrocarbon radical containing at least one carbon-carbon double bond. In various embodiments, an alkenyl group contains 2 to 20 carbon atoms (C2-C20 alkenyl), 2 to 10 carbon atoms (C2-C10 alkenyl), or 2 to 6 carbon atoms (C2-C6 alkenyl). Representative alkenyl groups include, but are not limited to, vinyl (ethenyl), allyl (prop-2-en-l-yl), propenyl, isopropenyl, butenyl, pentenyl, hexenyl, and prenyl (3-methylbut-2-en-l-yl). In certain embodiments, an alkenyl includes groups having more than one double bond (e.g., dienyl, trienyl). Unless otherwise specified, alkenyl groups may be in either the cis (Z) or trans (E) configuration.

[0138] In certain embodiments, the conjugate has a structure represented by formula Ig:

[0139]

[0140] Ig

[0141] wherein

[0142] each B is an active agent (e.g., a drug or a toxin);

[0143] T is a cleavage group;

[0144] L1is a covalent linker;

[0145] L2is a covalent linker;

[0146] Lg is a ligand, an active agent, or a reactive group ( e.g., amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl, or alkynyl); and

[0147] nl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0148] In certain embodiments, the conjugate has a structure represented by formula Ih or li:

[0149] -13- FH13329100.6Attorney Docket No.: LCH-04125

[0150]

[0151] wherein

[0152] each B is an active agent (e.g., a drug or a toxin);

[0153] T is a cleavage group;

[0154] Rlaand R2aare each independently H, alkyl, alkylene, cycloalkyl, or arylalkyl;

[0155] L1is a covalent linker; and

[0156] nl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0157] In certain embodiments, Rlaand R2aeach independently represent an alkyl (e.g., methyl). In other embodiments, Rlaor R2a, each independently, comprises an isoprenoid unit (e.g.,

[0158]

[0159] In certain embodiments, an isoprenoid unit is a hydrocarbon moiety derived from or having the carbon skeleton of isoprene (2-methylbuta- 1,3 -diene, CsHs). A single isoprenoid unit comprises five carbon atoms in a branched arrangement with the general skeleton. Representative isoprenoid units include, but are not limited to:

[0160] • Prenyl (3-methylbut-2-en-l-yl): (CH3)2C=CH-CH2-;

[0161] • Isopentenyl (3-methylbut-3-en-l-yl): CH2=C(CH3)-CH2-CH2-; and

[0162] • Dimethylallyl (3-methylbut-2-en-l-yl): (CH3)2C=CH-CH2-.

[0163] In certain embodiments, an isoprenoid unit refers to both unsaturated forms (retaining one or more carbon-carbon double bonds) and saturated (hydrogenated) derivatives thereof, unless otherwise specified. An isoprenoid unit may further encompass oligomeric structures comprising

[0164] -14- FH13329100.6Attorney Docket No.: LCH-04125

[0165] two or more head-to-tail linked isoprene units, including but not limited to geranyl (Cio), farnesyl (C15), and geranylgeranyl (C20) groups.

[0166] In certain aspects, the conjugate comprises a structure represented by formula Ij:

[0167]

[0168] wherein

[0169] X1and X2are each independently N(R4), O, or S; and

[0170] R1and R2are each independently alkyl or cycloalkyl; or R1and R2combine to form a cycloalkyl.

[0171] In certain embodiments, R1is alkyl, preferably methyl. In other embodiments, R1is H. In certain embodiments, R2is alkyl, preferably methyl. In certain embodiments, R1and R2combine to form a cycloalkyl, preferably cyclobutyl. In certain embodiments, X1is N(R4). In certain embodiments, R4is H. In certain embodiments, X2is O.

[0172] In certain embodiments, the conjugate comprises a structure represented by formula Ik or a pharmaceutically acceptable salt thereof:

[0173]

[0174] Ik

[0175] wherein

[0176] each B is an active agent (e.g., a drug or a toxin);

[0177] L1is a covalent linker;

[0178] X1and X2are each independently N(R4), O, or S;

[0179] R1and R2are each independently alkyl or cycloalkyl; or R1and R2combine to form a cycloalkyl;

[0180] and

[0181] nl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0182] In certain embodiments, the conjugate comprises a structure represented by formula H or a pharmaceutically acceptable salt thereof:

[0183] -15- FH13329100.6Attorney Docket No.: LCH-04125

[0184]

[0185] II

[0186] wherein

[0187] each B is an active agent (e.g., a drug or a toxin);

[0188] each T is a cleavage group; and

[0189] nl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0190] In certain embodiments, T comprises a structure represented by Formula II:

[0191]

[0192] II

[0193] wherein

[0194] each Rb1, Rb2, Rb3, and Rb4is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rb5is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;

[0195] Wb1is independently -*C(O)-, -*C(O)N(Rb7)-, -*N(Rb7)C(O)-, -*(CH2)taiN(Rb7)C(O)-, -*C(O)O-, -*S(O2)N(Rb7)-, -*P(O)(Rb8)N(Rb7)-, -*S(O)N(Rb7)-, or -*P(O2)N(Rb7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula II,

[0196] Rb7and Rb8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0197] each Jb1and Jb2is independently H or alkyl; or

[0198] -16- FH13329100.6Attorney Docket No.: LCH-04125

[0199] Jb1and Jb2combine to form an oxo;

[0200] tal is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0201] nal is 0, 1, 2, or 3;

[0202] Ab1represents a linkage to B; and

[0203] Ab2represents a linkage to L1.

[0204] In certain embodiments, each Rb1is H. In certain embodiments, each Rb2is H. In certain embodiments, each Rb3is H. In certain embodiments, each Rb4is H. In certain embodiments, each nal is 0. In certain embodiments, each Wb1is -*C(O)N(Rb7)-. In certain embodiments, each Rb7is H. In certain embodiments, Jb1is H. In certain embodiments, Jb2is H. In other embodiments, Jb1and Jb2combine to form oxo. In certain embodiments, each nl is 1. In other embodiments, each nl is 2. In other embodiments, each nl is 3. In other embodiments, each nl is 4. In yet other embodiments, each nl is 5.

[0205] In certain embodiments, L1is linear. In certain embodiments, L1comprises a C1-C100 alkylene. In certain embodiments, L1comprises a C1-C50 alkylene. In certain embodiments, L1further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, or 5 ethylene glycol moieties. In certain preferred embodiments, L1further comprises 5 ethylene glycol moieties. In other embodiments, the oligoethylene glycol comprises 6 ethylene glycol moieties. In certain embodiments, L1further comprises an amido moiety. In certain embodiments, L1comprises 1, 2, 3, 4, 5, or 6 amido moieties. In certain preferred embodiments, L1comprises 1 or 2 amido moieties.

[0206]

[0207] In certain preferred embodiments, the amido moieties have a structure represented by H

[0208] or H, wherein the wavy lines represent connections to the remainder of L1. In certain embodiments, L1further comprises a heteroaryl (e.g., pyrazolyl or triazolyl). In certain embodiments, L1comprises a structure represented by formula Illa or Illb:

[0209]

[0210] -17- FH13329100.6Attorney Docket No.: LCH-04125

[0211] Illa Illb

[0212] wherein

[0213] each Ad1represents a linkage to T or B; and

[0214] each A2represents a linkage to X1.

[0215] In certain embodiments, L1comprises a structure represented by formula IIIc, Illd, or Ille:

[0216]

[0217] IIIc Illd Ille

[0218] wherein

[0219] each A1represents a linkage to B; and

[0220] each A2represents a linkage to X1.

[0221] In certain embodiments, L1comprises a C1-C100 alkylene. In certain embodiments, L1comprises a C1-C50 alkylene. In certain embodiments, L1further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 5 ethylene glycol moieties. In certain embodiments, L1further comprises an amido moiety. In certain embodiments, L1comprises 1, 2, 3, 4, 5, or 6 amido moieties. In certain preferred embodiments, L1comprises 1 or 2 amido moieties. In certain preferred embodiments, the amido moieties have a structure represented by

[0222]

[0223] , wherein the wavy lines represent connections to the remainder of L1. In certain embodiments, L1further comprises at least one amino acid. In certain embodiments, L1further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

[0224] In certain embodiments, L1comprises a structure represented by formula IVa or IVb:

[0225]

[0226] -18- FH13329100.6Attorney Docket No.: LCH-04125

[0227] IVa IVb

[0228] wherein

[0229] each Ae1represents a linkage to T or B; and

[0230] each A4represents a linkage to X1.

[0231] In certain embodiments, L1comprises a structure represented by formula IVc, IVd, or IVe:

[0232]

[0233] IVc IVd IVe

[0234] wherein

[0235] each A3represents a linkage to B; and

[0236] each A4represents a linkage to X1.

[0237] In certain embodiments, L1is substituted with an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl). In certain embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

[0238] In certain embodiments, L1further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids. In certain embodiments, L1comprises 1 amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In certain embodiments, the amino

[0239] -19- FH13329100.6Attorney Docket No.: LCH-04125

[0240] acid(s) are selected from aspartate and glutamate. In certain preferred embodiments, the amino acid(s) are sarcosine.

[0241] In certain embodiments, L1is branched. In some embodiments, the branched linker of the antibody-drug conjugate comprises an amino acid having a side chain with a moiety that bears a charge at neutral pH in aqueous solution, preferably an arginine, aspartate, glutamate, lysine, or ornithine. This amino acid may be present anywhere in the branched linker. For example, it may covalently link an oxime of the branched linker to a polyethylene glycol unit of the branched linker. Alternatively or additionally, such an amino acid may be present in a secondary linker, optionally in each secondary linker.

[0242] The branching unit of the branched linker may comprise an amine or an amino acid having a side chain with a group capable of participating in an amide or ester (preferably amide) bond.

[0243] In some embodiments, the branching unit is a lysine unit. The lysine unit may comprise modifications, such as methylation of the s-amino group, giving methyl-, dimethyl-, and trimethyllysine and even acetylation, sumoylation, and / or ubiquitination. The branching unit may comprise many other amino acids in various embodiments of the invention. For example, an amino acid of the branching unit may be selected from lysine, 5-hydroxylysine, 4-oxalysine, 4-thialysine, 4-selenalysine, 4-thiahomolysine, 5,5-dimethyllysine, 5,5-difluorolysine, trans-4-dehydrolysine, 2,6-diamino-4-hexynoic acid, cA-4-dehydrolysine, 6-A-methyllysine, diaminopimelic acid, ornithine, 3-methylornithine, a-methylornithine, citrulline, and homocitrulline. The branching unit may comprise a L-amino acid or a D-amino acid. The branching unit may comprise an a-amino acid or a P-amino acid. The branching unit may comprise a naturally-occurring amino acid or a non-naturally-occurring amino acid. The branching unit of the antibody-drug conjugate may comprise other amino acids instead of or in addition to lysine.

[0244] In some embodiments, the branched linker comprises a hydrophilic amino acid, e.g., to increase the water solubility of the antibody-drug conjugate, linker, and / or precursors of the antibody-drug conjugate. The hydrophilic amino acid may be located proximal to the active agent, proximal to the antibody, or interposed anywhere along the branched linker, e.g., in the primary linker and / or a secondary linker, preferably each secondary linker. In some embodiments, the hydrophilic amino acid may be, for example, arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, serine, or threonine. In some preferred embodiments, the hydrophilic amino acid is arginine, histidine, lysine, aspartate, or glutamate.

[0245] -20- FH13329100.6Attorney Docket No.: LCH-04125

[0246] In certain embodiments, L1further comprises at least one amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, the amino acid is arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, serine, or threonine. In certain embodiments, the amino acid is arginine, aspartate, glutamate, histidine, lysine, or ornithine. In certain embodiments, the amino acid is aspartate or glutamate. In certain embodiments, L1comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. In certain embodiments, L1comprises 1 amino acid.

[0247] In certain embodiments, a) L1and (B)nior b) L1and (B-T)nicomprise:

[0248] i) a branching unit covalently coupled to X1by a primary linker;

[0249] ii) a first branch, which couples a first active agent, via a first cleavage group, to the branching unit; and

[0250] iiia) a second branch, which couples a second active agent, via a second cleavage group, to the branching unit; or

[0251] iiib) a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.

[0252] In certain embodiments, a) L1and (B)nior b) L1and (B-T)nicomprise a second branch which couples a second active agent, via a second cleavage group, to the branching unit. In certain embodiments, a) L1and (B)nior b) L1and (B-T)nicomprise a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit. In certain embodiments, the branching unit is an amino acid. In certain embodiments, the branching unit has a structure represented by formula Va, Vb, Vc, or Vd:

[0253]

[0254] Va Vb Vc Vd wherein

[0255] -21- FH13329100.6Attorney Docket No.: LCH-04125

[0256] G1, G2, G3are each independently a bond,

[0257]

[0258]

[0259] R30is H or alkyl;

[0260] R40is H, alkyl or L5-CO2R50;

[0261] R50is H or alkyl; and

[0262] L2, L3, L4, and L5are each independently a bond or alkylene.

[0263] In certain embodiments, the branching unit has a structure represented by formula Vd:

[0264]

[0265] Vd

[0266] wherein R30is H or alkyl.

[0267] In certain embodiments, the branching unit has a structure represented by formula Via:

[0268]

[0269] Via

[0270] wherein R30is H or alkyl.

[0271] In certain embodiments, each cleavage group has a structure represented by formula VII or a pharmaceutically acceptable salt thereof:

[0272] -22- FH13329100.6Attorney Docket No.: LCH-04125

[0273]

[0274] VII

[0275] wherein

[0276] Bw is an active agent;

[0277] each Rw2, Rw3, Rw4, and Rw5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rw6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;

[0278] Ww1is independently -*C(O)-, -*C(O)N(Rw7)-, -*N(Rw7)C(O)-, -*(CH2)twiN(Rw7)C(O)-, - *C(O)O-, -*S(O2)N(RW7)-, -*P(O)( RW8)N(RW7)-, -*S(O)N(RW7)-, or -*P(O2)N(Rw7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula VII;

[0279] Rw7and Rw8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0280] twl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0281] nwl is 0, 1, 2, or 3;

[0282] Jw1is H or alkyl;

[0283] Jw2is H or alkyl; or

[0284] Jw1and Jw2combine to form an oxo; and

[0285] Aw2represents a linkage to the secondary linker.

[0286] In certain embodiments, a) L1and (B)nior b) L1and (B-T)nihave a structure represented by formula VIII or a pharmaceutically acceptable salt thereof:

[0287] -23- FH13329100.6Attorney Docket No.: LCH-04125

[0288]

[0289] VIII

[0290] wherein

[0291] L1Acomprises a C1-C100 alkylene;

[0292] X3is -N(R5)C(O)-, -C(O)N(R5)-, -C(O)N(R5)(CH2)Z-, -(CH2)ZC(O)N(R5) -C(O)-, -C(O)O-, -OC(O)-, -S(O2)N(R5)-, -N(R5)S(O2)-, -P(O)(R5)N(R6)-, -N(R6)P(O)(R5)-, -P(O)2N(R6)-, or -N(R6)P(O)2-;

[0293] Y1and Y3are each independently O, N(R7), or S;

[0294] Yais H;

[0295] V1and V3are each independently a bond, N, NH, C, CH, or CH2;

[0296] R5, R6, and R7are each independently H, alkyl, aryl, or aralkyl;

[0297] each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0298] L3and L5each independently comprise an alkylene;

[0299] T1and T3are each independently a bond, -O-, or a cleavage group;

[0300] B1and B3are each independently an active agent (e.g., a drug or atoxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamide, aryl, heteroaryl, or heterocyclyl; or

[0301] VI, T1and B1or V3, T3and B3together represent a branched moiety (e.g., a branched moiety substituted with one or more active agents); and

[0302] ml and m3 are each independently 1, 2, 3, or 4.

[0303] In certain embodiments, a) L1and (B)nior b) L1and (B-T)nihave a structure represented by formula IX or a pharmaceutically acceptable salt thereof:

[0304] -24- FH13329100.6Attorney Docket No.: LCH-04125

[0305]

[0306] IX

[0307] wherein

[0308] L1Acomprises a C1-C100 alkylene;

[0309] X3is -N(R5)C(O)-, -C(O)N(R5)-, -C(O)N(R5)(CH2)Z-, -(CH2)ZC(O)N(R5) -C(O)-, -C(O)O-, - OC(O)-, -S(O2)N(R5)-, -N(R5)S(O2)-, -P(O)(R5)N(R6)-, -N(R6)P(O)(R5)-, -P(O)2N(R6)-, or -N(R6)P(O)2-;

[0310] Y1, Y2, and Y3are each independently O, N(R7), or S;

[0311] V1, V2, and V3are each independently a bond, N, NH, C, CH, or CH2;

[0312] R5, R6, and R7are each independently H, alkyl, aryl, or aralkyl;

[0313] each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0314] L3, L4, and L5each independently comprise an alkylene;

[0315] T1, T2, and T3are each independently a bond, -O-, or a cleavage group;

[0316] B1, B2, and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamide, aryl, heteroaryl, or heterocyclyl; or

[0317] V1, T1and B1; V2, T2and B2; or V3, T3and B3together represent a branched moiety (e.g., a branched moiety substituted with an active agent); and

[0318] ml, m2, and m3 are each independently 1, 2, 3, or 4.

[0319] Those of skill in the art will recognize that variables V1and ml, V2and m2, and V3and m3 are related. For example, those of skill in the art will understand that if ml is 3, then V1will have 3 open valencies. Likewise, if ml is 1, then V1will have at least one open valency. Simply put, the skilled artisan will understand that V1and ml, V2and m2, and V3and m3 will be combined in such a way that stable configurations are obtained based on the valencies required.

[0320] In certain embodiments, L1Acomprises a C1-C50 alkylene.

[0321] -25- FH13329100.6Attorney Docket No.: LCH-04125

[0322] In certain embodiments, Y1is O.

[0323] In certain embodiments, Y2is O.

[0324] In certain embodiments, Y3is O.

[0325] In certain embodiments, X3is -C(O)N(R5)-. In certain embodiments, R5is H.

[0326] In certain embodiments, L3comprises a C1-C100 alkylene. In certain embodiments, L3comprises a C1-C50 alkylene. In certain embodiments, L3further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 5 ethylene glycol moieties. In certain embodiments, L3further comprises amidoalkoxy (e.g., amidomethoxy) or carboxyalkoxy (e.g., carboxymethoxy). In certain embodiments, L3further comprises an amido moiety. In certain embodiments, L3comprises 1, 2, 3, 4, 5, or 6 amido moieties. In certain preferred embodiments, L3comprises 1 or 2 amido moieties. In certain embodiments, L3comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxy alkyl). In certain preferred embodiments, the amido moieties

[0327] have a structure represented by

[0328]

[0329] , wherein the wavy lines represent connections to the remainder of L3. In certain embodiments, L3further comprises a heteroaryl (e.g., pyrazolyl or triazolyl). In certain embodiments, L3comprises a structure represented by formula Xa or Xb:

[0330]

[0331] wherein

[0332] each Ax1represents a linkage to T1; and

[0333] each Ax2represents a linkage to V1.

[0334] In certain embodiments, L3is substituted with an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, the

[0335] -26- FH13329100.6Attorney Docket No.: LCH-04125

[0336] oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl). In certain embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

[0337] In certain embodiments, L3further comprises at least one amino acid. In certain embodiments, L3comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. In certain embodiments, L3comprises 1 amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, the amino acid is arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, serine, or threonine. In certain embodiments, the amino acid is arginine, aspartate, glutamate, histidine, lysine, or ornithine. In certain embodiments, L3further comprises an amino acid (e.g., a hydrophilic amino acid). In certain embodiments, L3further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids. In certain embodiments, L3comprises 1 amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In certain embodiments, the amino acid(s) are selected from aspartate and glutamate. In certain preferred embodiments, the amino acid(s) are sarcosine. In certain embodiments, L3further comprises a polypeptoid (e.g., polysarcosine).

[0338] In certain embodiments, a polypeptoid is a polymer comprising repeating N-substituted glycine units having the general structure -[N(R)-CH2-C(O)]n-, wherein R is independently selected for each repeating unit and represents a side chain substituent attached to the backbone nitrogen, and n represents the number of repeating units. In certain embodiments, R is Ci-Cio alkyl (e.g., methyl, ethyl, propyl, or butyl). In certain preferred embodiments, the polypeptoid is polysarcosine (poly(N-methylglycine)), wherein each R is methyl. In various embodiments, n is 5 to 200, 10 to 100, 20 to 80, or 30 to 50. In certain embodiments, a polypeptoid may encompass both oligomeric and polymeric forms unless otherwise specified.

[0339] In certain embodiments, V1is a bond. In certain embodiments, V1is a bond and ml is 1. In certain embodiments, ml is 1. In other embodiments, ml is 2.

[0340] -27- FH13329100.6Attorney Docket No.: LCH-04125

[0341] In certain embodiments, V1is N and V1, T1, and B1together represent a branched moiety having a structure represented by formula Xia or a pharmaceutically acceptable salt thereof:

[0342]

[0343] Xla

[0344] wherein

[0345] Ax3represents a linkage to L3;

[0346] Lx1and Lx2each independently comprise an alkylene;

[0347] Tx1and Tx2are each independently a bond or a cleavage group; and

[0348] Bx1and Bx2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0349] In certain embodiments, V1is CH and V1, T1, and B1together represent a branched moiety having a structure represented by formula Xlb or a pharmaceutically acceptable salt thereof:

[0350]

[0351] Xlb

[0352] wherein

[0353] Ax3represents a linkage to L3;

[0354] Lx1and Lx2each independently comprise an alkylene;

[0355] Tx1and Tx2are each independently a bond or a cleavage group; and

[0356] Bx1and Bx2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0357] In certain embodiments, V1is CH and V1, T1, and B1together represent a branched moiety having a structure represented by formula XIc or a pharmaceutically acceptable salt thereof:

[0358]

[0359] -28- FH13329100.6Attorney Docket No.: LCH-04125

[0360] wherein

[0361] Ax3represents a linkage to L3; and

[0362] Lx1and Lx2each independently comprise an alkylene;

[0363] O O

[0364] Gx1, Gx2, and Gx3are each independently an alkylene,

[0365]

[0366] ;

[0367] each Rx1is independently H, alkyl, or aralkyl;

[0368] Tx1and Tx2are each independently a bond or a cleavage group; and

[0369] Bx1and Bx2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0370] In certain embodiments, V1is C and V1, T1and B1together represent a branched moiety having a structure represented by formula Xld or a pharmaceutically acceptable salt thereof:

[0371]

[0372] Xld

[0373] wherein

[0374] Ax3represents a linkage to L3;

[0375] Lx1, Lx2, and Lx3each independently comprise an alkylene;

[0376] Tx1, Tx2, and Tx3are each independently a bond or a self-immolative moiety; and

[0377] Bx1, Bx2, and Bx3are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0378] In certain embodiments, the heteroaryl of Bx1, Bx2, or Bx3is further substituted with alkylene or amido. In certain embodiments, the amido of Bx1, Bx2, or Bx3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

[0379] In certain embodiments, Lxl comprises a C1-C100 alkylene. In certain embodiments, Lxl comprises a C1-C50 alkylene. In certain embodiments, Lxl further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain -29- FH13329100.6Attorney Docket No.: LCH-04125

[0380] preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain preferred embodiments, the oligoethylene glycol further comprises 4 ethylene glycol moieties. In certain embodiments, Lx1further comprises a heteroaryl (e.g., triazolyl).

[0381] In certain embodiments, Lx2comprises a C1-C100 alkylene. In certain embodiments, Lx2comprises a C1-C50 alkylene. In certain embodiments, Lx2further comprises an oligoethylene glycol. In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol further comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, Lx2further comprises a heteroaryl (e.g., triazolyl).

[0382] In certain embodiments, Lx3comprises a C1-C100 alkylene. In certain embodiments, Lx3comprises a C1-C50 alkylene. In certain embodiments, Lx3further comprises an oligoethylene glycol. In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol further comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, Lx3further comprises a heteroaryl (e.g., triazolyl).

[0383] In certain embodiments, T1, Tx1, Tx2, or Tx3have a structure represented by formula XII or a pharmaceutically acceptable salt thereof:

[0384]

[0385] XII

[0386] wherein

[0387] each Rx2, Rx3, Rx4, and Rx5is independently H, alkyl, aralkyl, or an oxygen protecting group;

[0388] -30- FH13329100.6Attorney Docket No.: LCH-04125

[0389] each Rx6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;

[0390] Wx1-*C(O)O-,

[0391]

[0392] wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XII; Rx7and Rx8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0393] Ja1is H or alkyl;

[0394] Ja2is H or alkyl; or

[0395] Ja1and Ja2combine to form an oxo;

[0396] tx1is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0397] nx1is 0, 1, 2, or 3;

[0398] Ax4represents a linkage to B1, Bx1, Bx2, or Bx3; and

[0399] Ax5represents a linkage to L3, Lx1, Lx2, or Lx3.

[0400] In certain embodiments, Rx2is H.

[0401] In certain embodiments, Rx3is H.

[0402] In certain embodiments, Rx4is H.

[0403] In certain embodiments, Rx5is H.

[0404] In certain embodiments, nxl is 0.

[0405] In certain embodiments, Wx1is -*C(O)N(Rx7)-. In certain embodiments, Rx7is alkyl optionally substituted with heteroaryl (e.g., triazolyl). In certain embodiments, when substituted, the heteroaryl of Rx7is substituted with oligoethylene glycol. In certain embodiments, Rx7is substituted with oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl. In certain embodiments, the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol. In other embodiments, the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine). In certain embodiments, the polypeptoid is substituted with an acyl. In certain embodiments, the alkyl is substituted with amino and the amino

[0406] -31- FH13329100.6Attorney Docket No.: LCH-04125

[0407] is substituted with hexane-2,3,4.5,6-pentol. In certain embodiments, the oligoethylene glycol is substituted with alkyl (e.g., hydroxy alkyl or carboxy alkyl).

[0408] In certain embodiments, Rx7is H.

[0409] In certain embodiments, Ja1is H. In certain embodiments, Ja2is H. In other embodiments, Ja1and Ja2combine to form oxo.

[0410] In certain embodiments, B1is an active agent.

[0411] In certain embodiments, each T1is a bond.

[0412] In certain embodiments, each B1, Bx Bx2, and Bx3is independently H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., glucuronidyl or morpholinyl). In certain embodiments, each B1is H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., glucuronidyl or morpholinyl).

[0413] In certain embodiments, L4comprises a C1-C100 alkylene. In certain embodiments, L4comprises a C1-C50 alkylene. In certain embodiments, L4further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 5 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol comprises at least 6 ethylene glycol moieties. In certain embodiments, L4further comprises an amido moiety. In certain embodiments, L4comprises 1, 2, 3, 4, 5, or 6 amido moieties. In certain preferred embodiments, L4comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxylamido). In certain embodiments, L4comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxy alkyl).

[0414] In certain preferred embodiments, the amido moieties have a structure represented by

[0415]

[0416] , wherein the wavy lines represent connections to the remainder of L4.

[0417] In certain embodiments, L4is substituted with an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, the

[0418] -32- FH13329100.6Attorney Docket No.: LCH-04125

[0419] oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl). In certain embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

[0420] In certain embodiments, L4further comprises at least one amino acid (e.g., a hydrophilic amino acid). In certain embodiments, L4further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In certain embodiments, L4comprises 1 amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In certain embodiments, the amino acid(s) are selected from aspartate and glutamate. In certain preferred embodiments, the amino acid(s) are sarcosine. In certain embodiments, L4further comprises a polypeptoid (e.g., polysarcosine).

[0421] In certain embodiments, L4further comprises a heteroaryl (e.g., pyrazolyl or triazolyl). In certain embodiments, L4further comprises a structure represented by formula Xllla or Xlllb:

[0422]

[0423] Xllla Xlllb

[0424] wherein

[0425] each Ay1represents a linkage to T2; and

[0426] each Ay2represents a linkage to V2.

[0427] In certain embodiments, m2 is 1. In other embodiments, m2 is 2.

[0428] In certain embodiments, V2is a bond.

[0429] In certain embodiments, V2is a bond and m2 is 1.

[0430] In certain embodiments, V2is N and V2, T2, and B2together represent a branched moiety having a structure represented by formula XlVa or a pharmaceutically acceptable salt thereof:

[0431]

[0432] -33- FH13329100.6Attorney Docket No.: LCH-04125

[0433] XlVa

[0434] wherein

[0435] Ay3represents a linkage to L4;

[0436] Ly1and Ly2each independently comprise an alkylene;

[0437] Ty1and Ty2are each independently a bond, or a cleavage group; and

[0438] By1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0439] In certain embodiments, V2is CH and V2, T2, and B2together represent a branched moiety having a structure represented by formula XlVb or a pharmaceutically acceptable salt thereof:

[0440]

[0441] XlVb

[0442] wherein

[0443] Ay3represents a linkage to L4;

[0444] Ly1and Ly2each independently comprise an alkylene;

[0445] Ty1and Ty2are each independently a bond or a cleavage group; and

[0446] By1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0447] In certain embodiments, V2is CH and V2, T2, and B2together represent a branched moiety having a structure represented by formula XIVc or a pharmaceutically acceptable salt thereof:

[0448]

[0449] XIVc

[0450] wherein

[0451] Ay3represents a linkage to L4;

[0452] Ly1and Ly2each independently comprise an alkylene;

[0453] -34- FH13329100.6Attorney Docket No.: LCH-04125

[0454] Gy1, Gy2, and Gy3are each independently an alkylene,

[0455]

[0456] each Ry1is independently H, alkyl, or aralkyl;

[0457] Ty1and Ty2are each independently a bond or a cleavage group; and

[0458] By1and By2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0459] In certain embodiments, m2 is 3.

[0460] In certain embodiments, V2is C and V2, T2and B2together represent a branched moiety having a structure represented by formula XlVd or a pharmaceutically acceptable salt thereof:

[0461]

[0462] XlVd

[0463] wherein

[0464] Ay3represents a linkage to L4;

[0465] Ly1, Ly2, and Ly3each independently comprise an alkylene;

[0466] Ty1, Ty2, and Ty3are each independently a bond or a cleavage group; and

[0467] By1, By2, and By3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0468] In certain embodiments, the heteroaryl of By1, By2, or By3is further substituted with alkylene or amido. In certain embodiments, the amido of By1, By2, or By3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

[0469] In certain embodiments, Ly1comprises a C1-C100 alkylene. In certain embodiments, Ly1comprises a C1-C50 alkylene. In certain embodiments, Ly1further comprises a heteroaryl (e.g., triazolyl). In certain embodiments, Ly1further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15

[0470] -35- FH13329100.6Attorney Docket No.: LCH-04125

[0471] ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0472] In certain embodiments, Ly2comprises a C1-C100 alkylene. In certain embodiments, Ly2comprises a C1-C50 alkylene. In certain embodiments, Ly2further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0473] In certain embodiments, Ly3comprises a C1-C100 alkylene. In certain embodiments, Ly3comprises a C1-C50 alkylene. In certain embodiments, Ly3further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, Ly3further comprises a heteroaryl (e.g., triazolyl).

[0474] In certain embodiments, T2, Ty1, Ty2, or Ty3has a structure represented by formula XV or a pharmaceutically acceptable salt thereof:

[0475]

[0476] wherein

[0477] each Ry2, Ry3, Ry4, and Ry5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Ry6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;

[0478] -36- FH13329100.6Attorney Docket No.: LCH-04125

[0479] Wy1is independently -*C(O)O-, -*S(O2

[0480]

[0481] wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XV,

[0482] Ry7and Ry8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0483] Jb1is H or alkyl;

[0484] Jb2is H or alkyl; or

[0485] Jb1and Jb2combine to form an oxo;

[0486] tyl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0487] nyl is 0, 1, 2, or 3;

[0488] Ay4represents a linkage to B2, By1, By2, or By3; and

[0489] Ay5represents a linkage to L4, Ly1, Ly2, or Ly3.

[0490] In certain embodiments, Ry2is H.

[0491] In certain embodiments, Ry3is H.

[0492] In certain embodiments, Ry4is H.

[0493] In certain embodiments, Ry5is H.

[0494] In certain embodiments, each nyl is 0.

[0495] In certain embodiments, Wy1is -*C(O)N(Ry7)-. In certain embodiments, Ry7is alkyl optionally substituted with heteroaryl (e.g., triazolyl). In certain embodiments, when substituted, the heteroaryl of Ry7is substituted with oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl. In certain embodiments, the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol. In other embodiments, the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine). In certain embodiments, the polypeptoid is substituted with an acyl. In certain embodiments, the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol. In certain embodiments, the oligoethylene glycol is substituted with alkyl (e.g., hydroxyalkyl or carboxyalkyl).

[0496] In certain embodiments, Ry7is H.

[0497] -37- FH13329100.6Attorney Docket No.: LCH-04125

[0498] In certain embodiments, Jc1is H. In certain embodiments, Jc2is H. In certain embodiments, Jc1and Jc2combine to form oxo.

[0499] In certain embodiments, B2is an active agent.

[0500] In certain embodiments, m2 is 1. In other embodiments, m2 is 2. In yet other embodiments, m2 is 3.

[0501] In certain embodiments, each T2is a bond.

[0502] In certain embodiments, each B2, By1, By2, and By3is independently H, hydroxyl, guanidyl, sulfate, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., glucuronidyl or morpholinyl). In certain embodiments, each B2is H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), or heterocyclyl (e.g., glucuronidyl or morpholinyl).

[0503] In certain embodiments, B2is alkyl (e.g., ethyl) substituted with phosphonate. In other embodiments, B2is alkyl (e.g., ethyl) substituted with phosphatyl. In certain embodiments, B2is alkyl substituted with hydroxyl (e.g., 1, 2, 3, 4, 5, or 6 hydroxyl groups). In certain embodiments, B2is amido (e.g., piperazineamido). In certain embodiments, B2is heterocyclyl (e.g., piperazyl). In certain embodiments, B2is alkoxy (e.g., methoxy). In certain embodiments, B2is carboxyl. In certain embodiments, B2is heteroaryl (e.g., tetrazolyl). In certain embodiments, B2is hydroxyl. In certain embodiments, B2is amino (e.g., dimethyl amino).

[0504] In certain embodiments, L5comprises a C1-C100 alkylene. In certain embodiments, L5comprises a C1-C50 alkylene. In certain embodiments, L5further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 6 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol further comprises at least one amido moiety. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, or 6 amido moieties. In certain preferred embodiments, the oligoethylene glycol comprises 1 or 2 amido moieties. In certain embodiments, L5comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxy alkyl).

[0505] -38- FH13329100.6Attorney Docket No.: LCH-04125

[0506] In certain preferred embodiments, the amido moieties have a structure represented by O O

[0507]

[0508] , wherein the wavy lines represent connections to the remainder of L5.

[0509] In certain embodiments, L5further comprises a heteroaryl (e.g., pyrazolyl or triazolyl). In certain embodiments, L5comprises a structure represented by formula XVIa or XVIb:

[0510]

[0511] XVIa XVIb

[0512] wherein

[0513] each Az1represents a linkage to T3; and

[0514] each Az2represents a linkage to V3.

[0515] In certain embodiments, L5is substituted with an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl). In certain embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

[0516] In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In certain embodiments, the amino acid(s) are selected from aspartate and glutamate. In certain preferred embodiments, the amino acid(s) are sarcosine. In certain embodiments, L5further comprises a polypeptoid (e.g., polysarcosine).

[0517] In certain embodiments, m3 is 1. In other embodiments, m3 is 2.

[0518] In certain embodiments, V3is a bond. In certain embodiments, V3is a bond and m3 is 1. In certain embodiments, V3is N and V3, T3, and B3together represent a branched moiety having a structure represented by formula XVIIa or a pharmaceutically acceptable salt thereof:

[0519]

[0520] -39- FH13329100.6Attorney Docket No.: LCH-04125

[0521] XVIIa

[0522] wherein

[0523] Az3represents a linkage to L5;

[0524] Lz1and Lz2each independently comprise an alkylene;

[0525] Tz1and Tz2are each independently a bond or a cleavage group; and

[0526] Bz1and Bz2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0527] In certain embodiments, V3is CH and V3, T3, and B3together represent a branched moiety having a structure represented by formula XVIIb or a pharmaceutically acceptable salt thereof:

[0528]

[0529] XVIIb

[0530] wherein

[0531] Az3represents a linkage to L5;

[0532] Lz1and Lz2each independently comprise an alkylene;

[0533] Tz1and Tz2are each independently a bond or a cleavage group; and

[0534] Bz1and Bz2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0535] In certain embodiments, V3is CH and V3, T3, and B3together represent a branched moiety having a structure represented by formula XVIIc or a pharmaceutically acceptable salt thereof:

[0536]

[0537] XVIIc

[0538] wherein

[0539] Az3represents a linkage to L5; and

[0540] Lz1and Lz2each independently comprise an alkylene;

[0541] -40- FH13329100.6Attorney Docket No.: LCH-04125

[0542] Gz1, Gz2, and Gz3are each independently an alkylene,

[0543]

[0544] ;

[0545] each Rz1is independently H, alkyl, or aralkyl;

[0546] Lz1and Lz2each independently comprise an alkylene;

[0547] Tz1and Tz2are each independently a bond or a cleavage group; and

[0548] Bz1and Bz2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0549] In certain embodiments, V3is C and V3, T3, and B3together represent a branched moiety having a structure represented by formula XVIId or a pharmaceutically acceptable salt thereof:

[0550]

[0551] XVIId

[0552] wherein

[0553] Az3represents a linkage to L5;

[0554] Lz1, Lz2, and Lz3each independently comprise an alkylene;

[0555] Tz1, Tz2, and Tz3are each independently a bond or a self-immolative moiety; and

[0556] Bz1, Bz2, and Bz3are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

[0557] In certain embodiments, the heteroaryl of Bz1, Bz2, or Bz3is further substituted with alkylene or amido. In certain embodiments, the amido of Bz1, Bz2, or Bz3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

[0558] In certain embodiments, Lz1comprises a C1-C100 alkylene. In certain embodiments, Lz1comprises a C1-C50 alkylene. In certain embodiments, Lz1further comprises a heteroaryl (e.g., triazolyl). In certain embodiments, Lz1further comprises an oligoethylene glycol. In certain embodiments, Lz1comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, Lz1comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0559] -41- FH13329100.6Attorney Docket No.: LCH-04125

[0560] In certain embodiments, Lz2comprises a C1-C100 alkylene. In certain embodiments, Lz2comprises a C1-C50 alkylene. In certain embodiments, Lz2further comprises a heteroaryl (e.g., triazolyl). In certain embodiments, Lz2further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol further comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0561] In certain embodiments, Lz3comprises a C1-C100 alkylene. In certain embodiments, Lz3comprises a C1-C50 alkylene. In certain embodiments, Lz3further comprises a heteroaryl (e.g., triazolyl). In certain embodiments, Lz3further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol further comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0562] In certain embodiments, T3, Tz1, Tz2, or Tz3have a structure represented by formula XVIII or a pharmaceutically acceptable salt thereof:

[0563]

[0564] wherein

[0565] each Rz2, Rz3, Rz4, and Rz5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rz6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;

[0566] -42- FH13329100.6Attorney Docket No.: LCH-04125

[0567] Wz1-*C(O)O-,

[0568]

[0569] wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XVIII, Rz7and Rz8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0570] Jc1is H or alkyl;

[0571] Jc2is H or alkyl; or

[0572] Jc1and Jc2combine to form an oxo;

[0573] tzl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0574] nzl is 0, 1, 2, or 3;

[0575] Az4represents a linkage to B3, Bz1, Bz2, or Bz3; and

[0576] Az5represents a linkage to L5, Lz1, Lz2, or Lz3.

[0577] In certain embodiments, Rz2is H.

[0578] In certain embodiments, Rz3is H.

[0579] In certain embodiments, Rz4is H.

[0580] In certain embodiments, Rz5is H.

[0581] In certain embodiments, nzl is 0.

[0582] In certain embodiments, Wz1is -*C(O)N(Rz7)-.

[0583] In certain embodiments, Rz7is H. In certain embodiments, Rz7is alkyl optionally substituted with heteroaryl (e.g., triazolyl). In certain embodiments, when substituted, the heteroaryl of Rz7is substituted with oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl. In certain embodiments, the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol. In other embodiments, the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine). In certain embodiments, the polypeptoid is substituted with an acyl. In certain embodiments, the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol. In certain embodiments, the oligoethylene glycol is substituted with alkyl (e.g., hydroxyalkyl or carboxy alkyl).

[0584] In certain embodiments, Jc1is H. In certain embodiments, Jc2is H. In other embodiments, Jc1and Jc2combine to form oxo.

[0585] -43- FH13329100.6Attorney Docket No.: LCH-04125

[0586] In certain embodiments, B3is an active agent.

[0587] In certain embodiments, T3is a bond.

[0588] In certain embodiments, each B3, Bz1, Bz2, and Bz3is independently H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., glucuronidyl or morpholinyl).

[0589] In certain embodiments, each B3is H, hydroxyl, amino, ( e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., glucuronidyl or morpholinyl).

[0590] In certain embodiments, the conjugate comprises a structure selected from:

[0591]

[0592] -44- FH13329100.6Attorney Docket No.: LCH-04125

[0593]

[0594] -45- FH13329100.6Attorney Docket No.: LCH-04125

[0595]

[0596] -46- FH13329100.6Attorney Docket No.: LCH-04125

[0597]

[0598] -47- FH13329100.6Attorney Docket No.: LCH-04125

[0599]

[0600] FH13329100.6Attorney Docket No.: LCH-04125

[0601]

[0602] FH13329100.6Attorney Docket No.: LCH-04125

[0603]

[0604] -50- FH13329100.6Attorney Docket No.: LCH-04125

[0605]

[0606] -51- FH13329100.6Attorney Docket No.: LCH-04125

[0607]

[0608] -52- FH13329100.6Attorney Docket No.: LCH-04125

[0609]

[0610] -53- FH13329100.6Attorney Docket No.: LCH-04125

[0611]

[0612] -54- FH13329100.6Attorney Docket No.: LCH-04125

[0613]

[0614] -55- FH13329100.6Attorney Docket No.: LCH-04125

[0615]

[0616] -56- FH13329100.6Attorney Docket No.: LCH-04125

[0617]

[0618] -57- FH13329100.6Attorney Docket No.: LCH-04125

[0619]

[0620] -58- FH13329100.6

[0621]

[0622]

[0623] Attorney Docket No.: LCH-04125

[0624]

[0625] -60- FH13329100.6Attorney Docket No.: LCH-04125

[0626]

[0627] -61- FH13329100.6Attorney Docket No.: LCH-04125

[0628]

[0629] -62- FH13329100.6Attorney Docket No.: LCH-04125

[0630]

[0631] -63- FH13329100.6Attorney Docket No.: LCH-04125

[0632]

[0633] -64- FH13329100.6Attorney Docket No.: LCH-04125

[0634]

[0635] -65- FH13329100.6Attorney Docket No.: LCH-04125

[0636]

[0637] -66- FH13329100.6Attorney Docket No.: LCH-04125

[0638]

[0639] -67- FH13329100.6Attorney Docket No.: LCH-04125

[0640]

[0641] -68- FH13329100.6Attorney Docket No.: LCH-04125

[0642]

[0643] -69- FH13329100.6Attorney Docket No.: LCH-04125

[0644]

[0645] -70- FH13329100.6Attorney Docket No.: LCH-04125

[0646]

[0647] -71- FH13329100.6Attorney Docket No.: LCH-04125

[0648]

[0649] -72- FH13329100.6Attorney Docket No.: LCH-04125

[0650]

[0651] -73- FH13329100.6Attorney Docket No.: LCH-04125

[0652]

[0653] -74- FH13329100.6Attorney Docket No.: LCH-04125

[0654]

[0655] -75- FH13329100.6Attorney Docket No.: LCH-04125

[0656]

[0657] -76- FH13329100.6Attorney Docket No.: LCH-04125

[0658]

[0659] FH13329100.6Attorney Docket No.: LCH-04125

[0660]

[0661] and

[0662] -78- FH13329100.6Attorney Docket No.: LCH-04125

[0663]

[0664] or a pharmaceutically acceptable salt thereof.

[0665] In certain embodiments, L2comprises a C1-C100 alkylene. In certain embodiments, L2comprises a C1-C50 alkylene. In certain embodiments, L2further comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, L2is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide. In certain embodiments, L2

[0666] -79- FH13329100.6Attorney Docket No.: LCH-04125

[0667] further comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In certain embodiments, L2comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxy alkyl). In certain preferred embodiments, the amido moieties have a structure represented

[0668] by

[0669]

[0670] , wherein the wavy lines represent connections to the remainder of L2In certain embodiments, L2further comprises at least one amino acid. In certain embodiments, L2further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids. In certain embodiments, L2comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. In certain embodiments, L2comprises 1 amino acid. In certain embodiments, the amino acid is a naturally occurring amino acid. In certain embodiments, the amino acid is a hydrophilic amino acid. In certain embodiments, the amino acid is arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, or threonine. In certain embodiments, the amino acid is arginine, aspartate, glutamate, histidine, lysine, or ornithine. In certain preferred embodiments, the amino acid is aspartate or glutamate. In certain embodiments, the amino acid is sarcosine.

[0671] In certain embodiments, L2further comprises a heteroaryl (e.g., pyrazolyl or triazolyl). In certain embodiments, L2 comprises a structure represented by formula XIXa or XlXb:

[0672]

[0673] XIXa XIXb

[0674] wherein

[0675] each At1represents a linkage to X1; and

[0676] each A6represents a linkage to Lg.

[0677] In certain embodiments, L2comprises a structure represented by formula XXa, XXb, or XXc:

[0678]

[0679] -80- FH13329100.6Attorney Docket No.: LCH-04125

[0680] XXa XXb XXc

[0681] wherein

[0682] each A5represents a linkage to X1; and

[0683] each A6represents a linkage to Lg.

[0684] In certain embodiments, L2further comprises a structure represented by formula XXI:

[0685]

[0686] wherein pl is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;

[0687] each A7represents a linkage to X1; and

[0688] each A8represents a linkage to Lg.

[0689] In certain embodiments, pl is 1, 2, 3, 4, or 5.

[0690] In certain embodiments, L2is substituted with an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl). In certain embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

[0691] In certain embodiments, Lg is a reactive group. In certain embodiments, Lg is amino, azido, hydroxylamino, halo, keto, aldehyde, ester, amido, alkenyl, or alkynyl. In other embodiments, Lg is vinylpyridyl. In yet other embodiments, Lg is maleimidyl. In yet other embodiments, Lg is azido.

[0692] In yet other embodiments, Lg is alkynyl (e.g.,

[0693]

[0694] in certain embodiments, Lg is

[0695]

[0696] In certain embodiments, Lg is an antibody. In certain embodiments, the antibody is a humanized antibody or a human antibody. In certain embodiments, the antibody is selected from a monoclonal antibody, a domain antibody (dAb), a single chain antibody (scAb), a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an scFab fragment, an Fv fragment, a dsFv fragment, a single -81- FH13329100.6Attorney Docket No.: LCH-04125

[0697] chain variable fragment (scFv), an scFv-Fc fragment, a single domain heavy chain antibody, a single domain light chain antibody, a variant antibody, a multimeric antibody, a minibody, a diabody, a bispecific antibody, and a multispecific antibody.

[0698] In certain embodiments, each active agent is independently a chemotherapeutic agent or a toxin, or a combination thereof. In certain embodiments, each active agent is a chemotherapeutic compound, a cytotoxic compound, an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, an antiparasitic agent, and a combination thereof.

[0699] In certain embodiments, each of B1, B2, B3, Bx1, Bx2, By1, By2, Bz1, or Bz2is independently

[0700]

[0701] -82- FH13329100.6Attorney Docket No.: LCH-04125

[0702]

[0703] In certain embodiments, each active agent is a cytotoxic compound selected from a mitotic inhibitor, a DNA alkylating agent, an RNA targeting agent and a topoisomerase inhibitor, or a

[0704] -83- FH13329100.6Attorney Docket No.: LCH-04125

[0705] combination thereof. In certain embodiments, the cytotoxic compound is a thailanstatin or an amatoxin. In certain embodiments, the cytotoxic compound is selected from an auristatin, a maytansinoid, a tubulisin, a calicheamicin, a duocarmycin, a pyrrolobenzodiazepine, and a camptothecin, or a combination thereof.

[0706] In other embodiments, the active agent is selected from:

[0707] (a) erlotinib, bortezomib, fulvestrant, sunitinib, letrozole, imatinib mesylate, PTK787 / ZK 222584, oxaliplatin, 5-fluorouracil, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, AG1478, AG1571, thiotepa, cyclophosphamide, busulfan, improsulfan, piposulfan, benzodepa, carboquone, meturedepa, uredepa, ethylenimine, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolmelamine, bullatacin, bullatacinone, camptothecin, topotecan, deruxtecan, SN- 38, bryostatin, callystatin, CC-1065, adozelesin, carzelesin, bizelesin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, KW-2189, CB1-TM1, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotoxin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, calicheamicin gamma 1, calicheamicin omega 1, dynemicin, dynemicin A, clodronate, esperamicin, neocarzinostatin chromophore, aclacinomysins, actinomycin, antimycin, azaserine, bleomycins, carabicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, liposomal doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacytidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, folinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatrexate, demecolcine, diaziquone,

[0708] -84- FH13329100.6Attorney Docket No.: LCH-04125

[0709] eflornithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, maytansine, ansamitocins, mitoguazone, mitoxantrone, mopidanmol, pentostatin, phenamet, pirarubicin, losoxantrone, 2-ethylhydrazide, procarbazine, polysaccharide-k, razoxane, rhizoxin, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2, 2’, 2” -trichlorotriethylamine, T-2 toxin, verracurin A, roridin A, and anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, arabinoside, paclitaxel, albumin-engineered nanoparticle formulation of paclitaxel, docetaxel, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, etoposide, vincristine, vinorelbine, novantrone, teniposide, daunomycin, aminopterin, ibandronate, CPT-11, topoisomerase inhibitor RFS 2000, difluoromethylornithine, retinoic acid, capecitabine, or pharmaceutically acceptable salts, solvates or acids of any of the foregoing;

[0710] (b) monokine, a lymphokine, a traditional polypeptide hormone, parathyroid hormone, thyroxine, relaxin, prorelaxin, a glycoprotein hormone, follicle stimulating hormone, thyroid stimulating hormone, luteinizing hormone, hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a, tumor necrosis factor-p, Mullerian inhibiting substance, mouse gonadotropin associated peptide, inhibin, activin, vascular endothelial growth factor, thrombopoietin, erythropoietin, an osteoinductive factor, an interferon, interferon-oc, interferon-P, interferon-y, a colony stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage-CSF, granulocyte-CSF, an interleukin (IL), IL- 1, IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, a tumor necrosis factor, polypeptide factor, LIF, kit ligand, or a combination of any of the foregoing;

[0711] (c) diphtheria toxin, botulinum toxin, tetanus toxin, dysentery toxin, cholera toxin, amanitin a- amanitin, pyrrolobenzodiazepine, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, an auristatin, tubulysin, geldanamycin, maytansinoid, SG2285, SG2057, cryptophycin, an enediyne antibiotic, epothilone, taltobulin, azonafide, a toxoid, or a combination of any of the foregoing;

[0712] (d) an affinity ligand, wherein the affinity ligand is a substrate, an inhibitor, a stimulating agent, a neurotransmitter, a radioisotope, or a combination of any of the foregoing;

[0713] (e) a radioactive label,32P,35S, a fluorescent dye, an electron dense reagent, an enzyme, biotin, streptavidin, digoxigenin, a hapten, an immunogenic protein, a nucleic acid molecule with

[0714] -85- FH13329100.6Attorney Docket No.: LCH-04125

[0715] a sequence complementary to a target, or a combination of any of the foregoing;

[0716] (f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, and an anti-parasitic agent, or a combination of any of the foregoing;

[0717] (g) tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, LY117018, onapristone, or toremifene;

[0718] (h) 4(5)-imidazoles, megestrol acetate, exemestane, or anastrozole;

[0719] (i) flutamide, nilutamide, bicalutamide, leuprolide, goserelin, or troxacitabine;

[0720] (j) an aromatase inhibitor;

[0721] (k) a protein kinase inhibitor;

[0722] (l) a lipid kinase inhibitor;

[0723] (m) an antisense oligonucleotide;

[0724] (n) a ribozyme;

[0725] (o) a vaccine; and

[0726] (p) an anti-angiogenic agent.

[0727] In certain embodiments, the active agent is pyrrolobenzodiazepine.

[0728] In certain embodiments, each active agent is selected from GENZ-644282, exatecan, monomethyl auristatin (e.g., monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF)), FL118, Dxd derivative (e.g., Dxd2), a stimulator of interferon genes agonist, and Tolllike receptor agonist (e.g., TLR7 / 8), or a combination thereof. In certain embodiments, each active agent is selected from exatecan, monomethyl auristatin ( e.g., monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF)), FL118, Dxd derivative (e.g., Dxd2), a stimulator of interferon genes agonist, and Toll-like receptor agonist (e.g., TLR7 / 8), or a combination thereof. In certain embodiments, the active agent is exatecan. In certain embodiments, each active agent is monomethyl auristatin such as monomethyl auristatin E (MMAE). In certain embodiments, each active agent is monomethyl auristatin F (MMAF). In certain embodiments, each active agent is FL118. In certain embodiments, each active agent is Dxd2. In certain embodiments, each active agent is a stimulator of interferon genes agonist (STINGa). In certain embodiments, the Toll-like receptor agonist is a TLR7 / 8 agonist. In certain embodiments, the Toll-like receptor agonist is a TLR7 agonist. In certain embodiments, the Toll-like receptor agonist is a TLR8 agonist. In certain embodiments, a first active agent is exatecan and a second active agent is a STINGa. In certain

[0729] -86- FH13329100.6Attorney Docket No.: LCH-04125

[0730] embodiments, a first active agent is MMAE and a second active agent is a STINGa. In certain embodiments, a first active agent is MMAF and a second active agent is a STINGa.

[0731]

[0732] , first active agent

[0733]

[0734] second active agent is a STINGa. In certain embodiments, a first active agent is MMAE and a second active agent is exatecan. In certain embodiments, a first active agent is GENZ-644282 and a second active agent is a STINGa. In certain embodiments, a first active agent is taltobulin and a second active agent is a STINGa.

[0735] In certain embodiments, the conjugate comprises at least 3 active agents. In certain embodiments, a first active agent is STINGa and a second active agent and a third active agent are each exatecan.

[0736] In certain embodiments, a first active agent is STINGa and a second active agent and a third active agent are each MMAE. In certain embodiments, a first active agent is STINGa and a second active agent and a third active agent are each MMAF. In certain embodiments, a first active agent is MMAE and a second active agent and a third active agent are each exatecan. In certain embodiments, a first active agent is MMAF and a second active agent and a third active agent are each exatecan. In certain embodiments, a first active agent is MMAE and a second active agent and a third active agent are each a TLR7 / 8 agonist. In certain embodiments, a first active agent is MMAE or MMAF and a second active agent and a third active agent are each

[0737] -87- FH13329100.6Attorney Docket No.: LCH-04125

[0738]

[0739] certain embodiments, a first active agent is MMAF and a second active agent and a third active agent are each a TLR7 / 8 agonist.

[0740] In certain embodiments, the present disclosure provides a pharmaceutical composition comprising a conjugate disclosed herein and a pharmaceutically acceptable excipient.

[0741] In certain embodiments, the present disclosure provides a method of treating a disease or disorder in a subject, comprising administering a conjugate or composition disclosed herein. In certain embodiments, the disease or disorder is cancer.

[0742] In certain embodiments, L1Acomprises a C1-C100 alkylene. In certain embodiments, L1Acomprises a C1-C50 alkylene. In certain embodiments, L1Afurther comprises an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, L1Ais substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide. In certain embodiments, L1Afurther comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In certain preferred embodiments, L1Acomprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxy alkyl). In certain embodiments, L1Afurther comprises a heteroaryl (e.g., pyrazolyl or triazolyl). In certain embodiments, L1Acomprises a structure represented by formula XXIIa or XXIIb:

[0743]

[0744] XXIIa XXIIb

[0745] wherein

[0746] each At1represents a linkage to X1; and

[0747] -88- FH13329100.6Attorney Docket No.: LCH-04125

[0748] each A9represents a linkage to Lg.

[0749] In certain embodiments, L1Acomprises a structure represented by formula XXIIIa, XXIIIb, or XXIIIc:

[0750]

[0751] XXIIIa XXIIIb XXIIIc

[0752] wherein

[0753] each A10represents a linkage to X1; and

[0754] each A11represents a linkage to Lg.

[0755] In certain embodiments, L1Afurther comprises a structure represented by formula XXIV:

[0756]

[0757] XXIV

[0758] wherein p2 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;

[0759] each A12represents a linkage to X1; and

[0760] each A13represents a linkage to Lg.

[0761] In certain embodiments, p2 is 1, 2, 3, 4, or 5.

[0762] In certain embodiments, L1Ais substituted with an oligoethylene glycol. In certain embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In certain preferred embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In certain embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl). In other embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

[0763] In certain embodiments, L1Afurther comprises an amino acid (e.g., a hydrophilic amino acid). In certain embodiments, L1Afurther comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In certain embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In certain embodiments, the amino -89- FH13329100.6Attorney Docket No.: LCH-04125

[0764] acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In certain preferred embodiments, the amino acid(s) are selected from aspartate and glutamate. In certain embodiments, the amino acid(s) are sarcosine. In certain embodiments, L1Afurther comprises a polypeptoid (e.g., polysarcosine).

[0765] In certain embodiments, the conjugate is selected from:

[0766]

[0767] -90- FH13329100.6Attorney Docket No.: LCH-04125

[0768]

[0769] -91- FH13329100.6Attorney Docket No.: LCH-04125

[0770]

[0771] pharmaceutically acceptable salt thereof.

[0772] In certain embodiments, the conjugate is selected from:

[0773]

[0774] -92- FH13329100.6Attorney Docket No.: LCH-04125

[0775]

[0776] -93- FH13329100.6Attorney Docket No.: LCH-04125

[0777]

[0778] -94- FH13329100.6Attorney Docket No.: LCH-04125

[0779]

[0780] -95- FH13329100.6Attorney Docket No.: LCH-04125

[0781]

[0782] -96- FH13329100.6Attorney Docket No.: LCH-04125

[0783]

[0784] -97- FH13329100.6Attorney Docket No.: LCH-04125

[0785]

[0786] -98- FH13329100.6Attorney Docket No.: LCH-04125

[0787]

[0788] -99- FH13329100.6Attorney Docket No.: LCH-04125

[0789]

[0790] -100- FH13329100.6Attorney Docket No.: LCH-04125

[0791]

[0792] -101- FH13329100.6Attorney Docket No.: LCH-04125

[0793]

[0794] -102- FH13329100.6Attorney Docket No.: LCH-04125

[0795]

[0796] -103- FH13329100.6Attorney Docket No.: LCH-04125

[0797]

[0798] -104- FH13329100.6Attorney Docket No.: LCH-04125

[0799]

[0800] -105- FH13329100.6Attorney Docket No.: LCH-04125

[0801]

[0802] -106- FH13329100.6Attorney Docket No.: LCH-04125

[0803]

[0804] -107- FH13329100.6Attorney Docket No.: LCH-04125

[0805]

[0806] -108- FH13329100.6Attorney Docket No.: LCH-04125

[0807]

[0808] -109- FH13329100.6Attorney Docket No.: LCH-04125

[0809]

[0810] -110- FH13329100.6Attorney Docket No.: LCH-04125

[0811]

[0812] -Ill- FH13329100.6Attorney Docket No.: LCH-04125

[0813]

[0814] -112- FH13329100.6Attorney Docket No.: LCH-04125

[0815]

[0816] -113- FH13329100.6Attorney Docket No.: LCH-04125

[0817]

[0818] -114- FH13329100.6Attorney Docket No.: LCH-04125

[0819]

[0820] -115- FH13329100.6Attorney Docket No.: LCH-04125

[0821]

[0822] -116- FH13329100.6Attorney Docket No.: LCH-04125

[0823]

[0824] -117- FH13329100.6Attorney Docket No.: LCH-04125

[0825]

[0826] -118- FH13329100.6Attorney Docket No.: LCH-04125

[0827]

[0828] -119- FH13329100.6Attorney Docket No.: LCH-04125

[0829]

[0830] -120- FH13329100.6Attorney Docket No.: LCH-04125

[0831]

[0832] -121- FH13329100.6Attorney Docket No.: LCH-04125

[0833]

[0834] -122- FH13329100.6Attorney Docket No.: LCH-04125

[0835]

[0836] -123- FH13329100.6Attorney Docket No.: LCH-04125

[0837]

[0838] -124- FH13329100.6Attorney Docket No.: LCH-04125

[0839]

[0840] -125- FH13329100.6Attorney Docket No.: LCH-04125

[0841]

[0842] -126- FH13329100.6Attorney Docket No.: LCH-04125

[0843]

[0844] and

[0845] -127- FH13329100.6Attorney Docket No.: LCH-04125

[0846]

[0847] ; or a pharmaceutically acceptable salt thereof.

[0848] Pharmaceutical Compositions

[0849] The compositions and methods of the present invention may be utilized to treat an individual in need thereof. In certain embodiments, the individual is a mammal such as a human, or a non-human mammal. When administered to an animal, such as a human, the composition or the conjugate is preferably administered as a pharmaceutical composition comprising, for example, a conjugate of the invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils

[0850] -128- FH13329100.6Attorney Docket No.: LCH-04125

[0851] such as olive oil, or injectable organic esters. In preferred embodiments, when such pharmaceutical compositions are for human administration, particularly for invasive routes of administration (i.e., routes, such as injection or implantation, that circumvent transport or diffusion through an epithelial barrier), the aqueous solution is pyrogen-free, or substantially pyrogen-free. The excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in dosage unit form such as tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophile for reconstitution, powder, solution, syrup, suppository, injection or the like. The composition can also be present in a transdermal delivery system, e.g., a skin patch. The composition can also be present in a solution suitable for topical administration, such as a lotion, cream, or ointment.

[0852] A pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a conjugate such as a conjugate of the invention. Such physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. The choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent, depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition can be a self-emulsifying drug delivery system or a selfmicroemulsifying drug delivery system. The pharmaceutical composition (preparation) also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a conjugate of the invention. Liposomes, for example, which comprise phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

[0853] The phrase "pharmaceutically acceptable" is employed herein to refer to those conjugates, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0854] The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be "acceptable" in the sense of being

[0855] -129- FH13329100.6Attorney Docket No.: LCH-04125

[0856] compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

[0857] A pharmaceutical composition (preparation) can be administered to a subject by any of a number of routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue); absorption through the oral mucosa (e.g., sublingually); subcutaneously; transdermally (for example as a patch applied to the skin); and topically (for example, as a cream, ointment or spray applied to the skin). The conjugate may also be formulated for inhalation. In certain embodiments, a conjugate may be simply dissolved or suspended in sterile water. Details of appropriate routes of administration and compositions suitable for same can be found in, for example, U. S. Pat. Nos.

[0858] 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, as well as in patents cited therein.

[0859] The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the conjugate which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient,

[0860] -130- FH13329100.6Attorney Docket No.: LCH-04125

[0861] preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.

[0862] Methods of preparing these formulations or compositions include the step of bringing into association an active conjugate, such as a conjugate of the invention, with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a conjugate of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0863] Formulations of the invention suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and / or as mouth washes and the like, each containing a predetermined amount of a conjugate of the present invention as an active ingredient. Compositions or conjugates may also be administered as a bolus, electuary or paste.

[0864] To prepare solid dosage forms for oral administration (capsules (including sprinkle capsules and gelatin capsules), tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium conjugates; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; (10) complexing agents, such as, modified and unmodified cyclodextrins; and (11) coloring agents. In the case of capsules (including sprinkle capsules and gelatin capsules), tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also

[0865] -131- FH13329100.6Attorney Docket No.: LCH-04125

[0866] be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

[0867] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered conjugate moistened with an inert liquid diluent.

[0868] The tablets, and other solid dosage forms of the pharmaceutical compositions, such as dragees, capsules (including sprinkle capsules and gelatin capsules), pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the abovedescribed excipients.

[0869] Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, cyclodextrins and derivatives thereof, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 -butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

[0870] -132- FH13329100.6Attorney Docket No.: LCH-04125

[0871] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0872] Suspensions, in addition to the active conjugates, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0873] Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active conjugate may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.

[0874] The ointments, pastes, creams and gels may contain, in addition to an active conjugate, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

[0875] Powders and sprays can contain, in addition to an active conjugate, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0876] Transdermal patches have the added advantage of providing controlled delivery of a conjugate of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the active conjugate in the proper medium. Absorption enhancers can also be used to increase the flux of the conjugate across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the conjugate in a polymer matrix or gel.

[0877] The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. Pharmaceutical compositions suitable for parenteral administration comprise one or more active conjugates in combination with one or more pharmaceutically acceptable sterile isotonic

[0878] -133- FH13329100.6Attorney Docket No.: LCH-04125

[0879] aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

[0880] Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0881] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.

[0882] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

[0883] Injectable depot forms are made by forming microencapsulated matrices of the subject conjugates in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.

[0884] -134- FH13329100.6Attorney Docket No.: LCH-04125

[0885] For use in the methods of this invention, active conjugates can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.

[0886] Methods of introduction may also be provided by rechargeable or biodegradable devices. Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinaceous biopharmaceuticals. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a conjugate at a particular target site.

[0887] Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0888] The selected dosage level will depend upon a variety of factors including the activity of the particular conjugate or combination of conjugates employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular conjugate(s) being employed, the duration of the treatment, other drugs, conjugates and / or materials used in combination with the particular conjugate(s) employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[0889] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the pharmaceutical composition or conjugate at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. By “therapeutically effective amount” is meant the concentration of a conjugate that is sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of the conjugate will vary according to the weight, sex, age, and medical history of the subject. Other factors which influence the effective amount may include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the conjugate, and, if desired, another type of therapeutic agent being administered with the conjugate of the invention. A larger total dose can be delivered by multiple

[0890] -135- FH13329100.6Attorney Docket No.: LCH-04125

[0891] administrations of the agent. Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison’s Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).

[0892] In general, a suitable daily dose of an active conjugate used in the compositions and methods of the invention will be that amount of the conjugate that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.

[0893] If desired, the effective daily dose of the active conjugate may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In certain embodiments of the present invention, the active conjugate may be administered two or three times daily. In preferred embodiments, the active conjugate will be administered once daily.

[0894] The patient receiving this treatment is any animal in need, including primates, in particular humans; and other mammals such as equines, cattle, swine, sheep, cats, and dogs; poultry; and pets in general.

[0895] In certain embodiments, conjugates of the invention may be used alone or conjointly administered with another type of therapeutic agent.

[0896] The present disclosure includes the use of pharmaceutically acceptable salts of conjugates of the invention in the compositions and methods of the present invention. In certain embodiments, contemplated salts of the invention include, but are not limited to, alkyl, dialkyl, trialkyl or tetraalkyl ammonium salts. In certain embodiments, contemplated salts of the invention include, but are not limited to, L-arginine, benethamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydrabamine, IH-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, l-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In certain embodiments, contemplated salts of the invention include, but are not limited to, Na, Ca, K, Mg, Zn or other metal salts. In certain embodiments, contemplated salts of the invention include, but are not limited to, 1 -hydroxyl-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, 1-ascorbic acid, 1-aspartic acid, benzenesulfonic acid, benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid,

[0897] -136- FH13329100.6Attorney Docket No.: LCH-04125

[0898] capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, d-glucoheptonic acid, d-gluconic acid, d-glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, 1-malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, 1-pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, 1-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, and undecylenic acid salts.

[0899] The pharmaceutically acceptable acid addition salts can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, and the like. Mixtures of such solvates can also be prepared. The source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent.

[0900] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

[0901] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alphatocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0902] Definitions

[0903] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics and protein and nucleic acid chemistry, described herein, are those well known and commonly used in the art.

[0904] -137- FH13329100.6Attorney Docket No.: LCH-04125

[0905] The methods and techniques of the present disclosure are generally performed, unless otherwise indicated, according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout this specification. See, e.g. “Principles of Neural Science”, McGraw-Hill Medical, New York, N. Y. (2000); Motulsky, “Intuitive Biostatistics”, Oxford University Press, Inc. (1995); Lodish et al., “Molecular Cell Biology, 4th ed.”, W. H. Freeman & Co., New York (2000); Griffiths et al., “Introduction to Genetic Analysis, 7th ed.”, W. H. Freeman & Co., N. Y. (1999); and Gilbert et al., “Developmental Biology, 6th ed.”, Sinauer Associates, Inc., Sunderland, MA (2000).

[0906] Chemistry terms used herein, unless otherwise defined herein, are used according to conventional usage in the art, as exemplified by “The McGraw-Hill Dictionary of Chemical Terms”, Parker S., Ed., McGraw-Hill, San Francisco, C. A. (1985).

[0907] All of the above, and any other publications, patents and published patent applications referred to in this application are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control.

[0908] The term “agent” is used herein to denote a chemical compound (such as an organic or inorganic compound, a mixture of chemical compounds), a biological macromolecule (such as a nucleic acid, an antibody, including parts thereof as well as humanized, chimeric and human antibodies and monoclonal antibodies, a protein or portion thereof, e.g., a peptide, a lipid, a carbohydrate), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues. Agents include, for example, agents whose structure is known, and those whose structure is not known.

[0909] A “patient,” “subject,” or “individual” are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (including bovines, porcines, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).

[0910] “Treating” a condition or patient refers to taking steps to obtain beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and

[0911] -138- FH13329100.6Attorney Docket No.: LCH-04125

[0912] remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.

[0913] The term “preventing” is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and / or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and / or clinically significant amount.

[0914] “Administering” or “administration of’ a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art. For example, a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct). A compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent. Administration can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.

[0915] Appropriate methods of administering a substance, a compound or an agent to a subject will also depend, for example, on the age and / or the physical condition of the subject and the chemical and biological properties of the compound or agent (e.g., solubility, digestibility, bioavailability, stability and toxicity). In some embodiments, a compound or an agent is administered orally, e.g., to a subject by ingestion. In some embodiments, the orally administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.

[0916] As used herein, the phrase “conjoint administration” refers to any form of administration of two or more different therapeutic agents such that the second agent is administered while the previously administered therapeutic agent is still effective in the body (e.g., the two agents are

[0917] -139- FH13329100.6Attorney Docket No.: LCH-04125

[0918] simultaneously effective in the patient, which may include synergistic effects of the two agents). For example, the different therapeutic compounds can be administered either in the same formulation or in separate formulations, either concomitantly or sequentially. Thus, an individual who receives such treatment can benefit from a combined effect of different therapeutic agents.

[0919] A “therapeutically effective amount” or a “therapeutically effective dose” of a drug or agent is an amount of a drug or an agent that, when administered to a subject will have the intended therapeutic effect. The full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations. The precise effective amount needed for a subject will depend upon, for example, the subject’s size, health and age, and the nature and extent of the condition being treated, such as cancer or MDS. The skilled worker can readily determine the effective amount for a given situation by routine experimentation.

[0920] As used herein, the terms “optional” or “optionally” mean that the subsequently described event or circumstance may occur or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances in which it does not. For example, “optionally substituted alkyl” refers to the alkyl may be substituted as well as where the alkyl is not substituted.

[0921] It is understood that substituents and substitution patterns on the compounds of the present invention can be selected by one of ordinary skill in the art to result in chemically stable compounds which can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.

[0922] As used herein, the term “optionally substituted” refers to the replacement of one to six hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: hydroxyl, hydroxyalkyl, alkoxy, halogen, alkyl, nitro, silyl, acyl, acyloxy, aryl, cycloalkyl, heterocyclyl, amino, aminoalkyl, cyano, haloalkyl, haloalkoxy, -OCO-CH2-O-alkyl, -OP(O)(O-alkyl)2 or -CH2-OP(O)(O-alkyl)2. Preferably, “optionally substituted” refers to the replacement of one to four hydrogen radicals in a given structure with the substituents mentioned above. More preferably, one to three hydrogen radicals are replaced by the substituents as mentioned above. It is understood that the substituent can be further substituted.

[0923] -140- FH13329100.6Attorney Docket No.: LCH-04125

[0924] As used herein, the term “alkyl” refers to saturated aliphatic groups, including but not limited to C1-C10 straight-chain alkyl groups or C1-C10 branched-chain alkyl groups. Preferably, the “alkyl” group refers to Ci-Ce straight-chain alkyl groups or Ci-Ce branched-chain alkyl groups. Most preferably, the “alkyl” group refers to C1-C4 straight-chain alkyl groups or C1-C4 branched-chain alkyl groups. Examples of “alkyl” include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, 1-hexyl, 2-hexyl, 3-hexyl, 1-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 1-octyl, 2-octyl, 3-octyl or 4-octyl and the like. Moreover, the term “alkyl” as used throughout the specification, examples, and claims is intended to include both unsubstituted and substituted alkyl groups, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc.

[0925] As used herein, the term “alkylene” refers to a bivalent saturated aliphatic groups, including but not limited to C1-C10 straight-chain alkyl groups or C1-C10 branched-chain alkylene groups. Preferably, the “alkylene” group refers to Ci-Ce straight-chain alkylene groups or Ci-Ce branched-chain alkyl groups. Most preferably, the “alkylene” group refers to C1-C4 straight-chain alkyl groups or C1-C4 branched-chain alkylene groups. Examples of “alkylene” include, but are not limited to, methylene, ethylene, 1 -propylene, 2-propylene, n-butylene, sec -butylene, tert-butylene, 1 -pentylene, 2-pentylene, 3-pentylene, neo-pentylene, 1 -hexylene, 2-hexylene, 3-hexylene, 1-heptylene, 2-heptylene, 3-heptylene, 4-heptylene, 1 -octylene, 2-octylene, 3-octylene or 4-octylene and the like. The “alkylene” group may be optionally substituted.

[0926] The term “acyl” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.

[0927] The term “acylamino” is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(O)NH-.

[0928] The term “acyloxy” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)O-, preferably alkylC(O)O-.

[0929] The term “alkoxy” refers to an alkyl group having an oxygen attached thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.

[0930] The term “alkoxyalkyl” refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O- alkyl.

[0931] -141- FH13329100.6Attorney Docket No.: LCH-04125

[0932] The term “Cx.y” or “Cx-Cy”, when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain. Coalkyl indicates a hydrogen where the group is in a terminal position, a bond if internal. A Ci-ealkyl group, for example, contains from one to six carbon atoms in the chain.

[0933] The term “alkylamino”, as used herein, refers to an amino group substituted with at least one alkyl group.

[0934] The term “alkylthio”, as used herein, refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-.

[0935] The term “amido”, as used herein, refers to a group such as

[0936]

[0937] wherein R9and R10each independently represent a hydrogen or hydrocarbyl group, or R9and R10taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.

[0938] The terms “amine” and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by

[0939]

[0940] wherein R9, R10, and R10’ each independently represent a hydrogen or a hydrocarbyl group, or R9and R10taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.

[0941] The term “aminoalkyl”, as used herein, refers to an alkyl group substituted with an amino group.

[0942] The term “aralkyl”, as used herein, refers to an alkyl group substituted with an aryl group. The term “aryl” as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. Preferably the ring is a 5- to 7-membered ring, more preferably a 6-membered ring. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein

[0943] -142- FH13329100.6Attorney Docket No.: LCH-04125

[0944] at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.

[0945] The term “carbamate” is art-recognized and refers to a group

[0946]

[0947] wherein R9and R10independently represent hydrogen or a hydrocarbyl group.

[0948] The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.

[0949] The term “carbocycle” includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated and aromatic rings. Carbocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings. The term “fused carbocycle” refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused carbocycle may be selected from saturated, unsaturated and aromatic rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits, is included in the definition of carbocyclic. Exemplary “carbocycles” include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2, 3, 4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane. Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-lH-indene and bicyclo[4.1.0]hept-3-ene. “Carbocycles” may be substituted at any one or more positions capable of bearing a hydrogen atom.

[0950] The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.

[0951] The term “carbonate” is art-recognized and refers to a group -OCO2-.

[0952] The term “carboxy”, as used herein, refers to a group represented by the formula -CO2H.

[0953] The term “cleavage group” refers to a chemical moiety which dissociates when subjected to a stimulus, such as acidic conditions, basic conditions, reducing conditions, oxidizing conditions, light, or heat, or an enzyme, such as an esterase.

[0954] -143- FH13329100.6Attorney Docket No.: LCH-04125

[0955] The term “cycloalkyl” includes substituted or unsubstituted non-aromatic single ring structures, preferably 4- to 8-membered rings, more preferably 4- to 6-membered rings. The term “cycloalkyl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is cycloalkyl and the substituent (e.g., R100) is attached to the cycloalkyl ring, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, benzodioxane, tetrahydroquinoline, and the like.

[0956] The term “ester”, as used herein, refers to a group -C(O)OR9wherein R9represents a hydrocarbyl group.

[0957] The term “ether”, as used herein, refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O-heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.

[0958] The term “guanidinyl”, as used herein, refers to a group of the formula -NRa-C(=NRb)-NRbRc, wherein Ra, Rb, and Rcare each independently H or hydrocarbyl.

[0959] The terms “halo” and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.

[0960] The terms “hetaralkyl” and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.

[0961] The terms “heteroaryl” and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heteroaryl” and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.

[0962] -144- FH13329100.6Attorney Docket No.: LCH-04125

[0963] The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.

[0964] The term “heterocyclylalkyl”, as used herein, refers to an alkyl group substituted with a heterocycle group.

[0965] The terms “heterocyclyl”, “heterocycle”, and “heterocyclic” refer to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heterocyclyl” and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.

[0966] The term “hydrocarbyl”, as used herein, refers to a group that is bonded through a carbon atom that does not have a =O or =S substituent, and typically has at least one carbon-hydrogen bond and a primarily carbon backbone, but may optionally include heteroatoms. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and even trifluoromethyl are considered to be hydrocarbyl for the purposes of this application, but substituents such as acetyl (which has a =O substituent on the linking carbon) and ethoxy (which is linked through oxygen, not carbon) are not. Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.

[0967] The term “hydroxyalkyl”, as used herein, refers to an alkyl group substituted with a hydroxy group.

[0968] The term “hydroxylamino” is art-recognized and refers to a group

[0969] „Ck Ry

[0970] RzN

[0971] l

[0972] Rx, wherein Rx, Ry, and Rzindependently represent hydrogen or a hydrocarbyl group.

[0973] The term “lower” when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer atoms in the substituent, preferably six or fewer. A “lower alkyl”, for example, refers to an alkyl group that contains ten or fewer carbon atoms, preferably six or fewer. In certain embodiments, acyl, acyloxy,

[0974] -145- FH13329100.6Attorney Docket No.: LCH-04125

[0975] alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within the aryl group are not counted when counting the carbon atoms in the alkyl substituent).

[0976] The terms “polycyclyl”, “polycycle”, and “polycyclic” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are “fused rings”. Each of the rings of the polycycle can be substituted or unsubstituted. In certain embodiments, each ring of the poly cycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.

[0977] The term “sulfate” is art-recognized and refers to the group -OSO3H, or a pharmaceutically acceptable salt thereof.

[0978] The term “sulfonamide” is art-recognized and refers to the group represented by the general formulae

[0979]

[0980] wherein R9and R10independently represent hydrogen or hydrocarbyl.

[0981] The term “sulfoxide” is art-recognized and refers to the group-S(O)-.

[0982] The term “sulfonate” is art-recognized and refers to the group SO3H, or a pharmaceutically acceptable salt thereof.

[0983] The term “sulfone” is art-recognized and refers to the group -S(O)2-.

[0984] The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same

[0985] -146- FH13329100.6Attorney Docket No.: LCH-04125

[0986] or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamide, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.

[0987] The term “thioalkyl”, as used herein, refers to an alkyl group substituted with a thiol group. The term “thioester”, as used herein, refers to a group -C(O)SR9or -SC(O)R9wherein R9represents a hydrocarbyl.

[0988] The term “thioether”, as used herein, is equivalent to an ether, wherein the oxygen is replaced with a sulfur.

[0989] The term “urea” is art-recognized and may be represented by the general formula

[0990]

[0991] wherein R9and R10independently represent hydrogen or a hydrocarbyl.

[0992] The term “modulate” as used herein includes the inhibition or suppression of a function or activity (such as cell proliferation) as well as the enhancement of a function or activity.

[0993] The phrase “pharmaceutically acceptable” is art-recognized. In certain embodiments, the term includes compositions, excipients, adjuvants, polymers and other materials and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0994] “Pharmaceutically acceptable salt” or “salt” is used herein to refer to an acid addition salt or a basic addition salt which is suitable for or compatible with the treatment of patients.

[0995] The term “pharmaceutically acceptable acid addition salt” as used herein means any nontoxic organic or inorganic salt of any base compounds represented by Formula la. Illustrative

[0996] -147- FH13329100.6Attorney Docket No.: LCH-04125

[0997] inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids. Either the mono or di- acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of compounds of Formula la are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection of the appropriate salt will be known to one skilled in the art. Other non-pharmaceutically acceptable salts, e.g., oxalates, may be used, for example, in the isolation of compounds of Formula la for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.

[0998] The term “pharmaceutically acceptable basic addition salt” as used herein means any nontoxic organic or inorganic base addition salt of any acid compounds represented by Formula la or any of their intermediates. Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide. Illustrative organic bases which form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art.

[0999] Many of the compounds useful in the methods and compositions of this disclosure have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30. The disclosure contemplates all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds, salts, prodrugs or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g., WO 01 / 062726.

[1000] Furthermore, certain compounds which contain alkenyl groups may exist as Z (zusammen) or E (entgegen) isomers. In each instance, the disclosure includes both mixture and separate individual isomers.

[1001] “Prodrug” or “pharmaceutically acceptable prodrug” refers to a compound that is metabolized, for example hydrolyzed or oxidized, in the host after administration to form the

[1002] -148- FH13329100.6Attorney Docket No.: LCH-04125

[1003] compound of the present disclosure ( e.g., compounds of formula la). Typical examples of prodrugs include compounds that have biologically labile or cleavable (protecting) groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound. Examples of prodrugs using ester or phosphoramidate as biologically labile or cleavable (protecting) groups are disclosed in U. S. Patents 6,875,751, 7,585,851, and 7,964,580, the disclosures of which are incorporated herein by reference. The prodrugs of this disclosure are metabolized to produce a compound of Formula la. The present disclosure includes within its scope, prodrugs of the compounds described herein. Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in “Design of Prodrugs” Ed. H. Bundgaard, Elsevier, 1985.

[1004] The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material useful for formulating a drug for medicinal or therapeutic use.

[1005] The term “Log of solubility”, “LogS” or “logS” as used herein is used in the art to quantify the aqueous solubility of a compound. The aqueous solubility of a compound significantly affects its absorption and distribution characteristics. A low solubility often goes along with a poor absorption. LogS value is a unit stripped logarithm (base 10) of the solubility measured in mol / liter.

[1006] EXAMPLES

[1007] The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention and are not intended to limit the invention.

[1008] Abbreviations

[1009] Ac: acetyl

[1010] aq.: aqueous

[1011] Bu: butyl

[1012] t-Bu: tert-butyl

[1013] -149- FH13329100.6Attorney Docket No.: LCH-04125

[1014] Boc: / -butoxycarbonyl

[1015] Bn: benzyl

[1016] brine: saturated aq. sodium chloride solution

[1017] Cbz: benzyloxycarbonyl

[1018] DMAP: 4-(dimethylamino)pyridine

[1019] DMSO: dimethyl sulfoxide

[1020] Et: ethyl

[1021] Fmoc: 9-fluorenylmethyloxycarbonyl

[1022] HO: hydrogen chloride

[1023] HPLC: high performance liquid chromatography

[1024] Me: methyl

[1025] MMAE: monomethyl auristatin E

[1026] MMAF: monomethyl auristatin F

[1027] MMAF-OMe: monomethyl auristatin F methyl ester

[1028] NaHCCh: sodium bicarbonate

[1029] NaOH: sodium hydroxide

[1030] NH4CI: ammonium chloride

[1031] PMB: 4-methoxybenzyl

[1032] Ts: p-toluenesulfonyl

[1033] TIPS: triisopropylsilyl

[1034] Teoc: 2-(trimethylsilyl)ethoxycarbonyl

[1035] THPTA: tris(3-hydroxypropyltriazolymethyl)amine

[1036] TBAF: tetrabutylammonium fluoride

[1037] wt: weight

[1038] Example 1: Preparation of Compound 1-2

[1039]

[1040] Preparation of Compound 1-1

[1041] -150- FH13329100.6Attorney Docket No.: LCH-04125

[1042] To a solution of / V-Boc-hydroxylamine (5 g, 37.55 mmol) in / V. / V-dimethylfomiamide (20 mL) were added potassium carbonate (8.8 g, 63.84 mmol) and ethyl-2-bromoisobutyrate (15.38 g, 78.86 mmol). After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NH4CI solution (50 mL), distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 1-1 (10.5 g, quant.).1H-NMR (400 MHz, CDCl3) 84.21 (p, J = 6.8 Hz, 2H), 1.49 (s, 6H), 1.47 (s, 9H), 1.31 (q, J = 6.9 Hz, 3H).

[1043] Preparation of Compound 1-2

[1044] To a solution of Compound 1-1 (47 g, 190.1 mmol) in methanol (400 mL) was added lithium hydroxide monohydrate (16 g, 380 mmol) in water (100 mL). After stirring at room temperature for 3 hours, the reaction mixture was adjusted to pH 3 with aq. 1 M HO solution and concentrated. Then the reaction mixture was extracted with ethyl acetate (200 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and triturated with ether. The resulting solid was filtered to afford Compound 1-2 (38 g, 91%) as a white solid. 'H-NMR (400 MHz, CDCl3) 87.32 (s, 1H), 1.53 (s, 6H), 1.49 (s, 9H).

[1045] Example 2: Preparation of Compound 1-7

[1046]

[1047] Preparation of Compound 1-3

[1048] To a solution of bis(2-hydroxyethyl) ether (20 g, 188.5 mmol) in dichloromethane (400 mL) were added p-toluenesulfonyl chloride (79 g, 414.6 mmol) and potassium hydroxide (42 g, 753.9 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was washed with saturated aq. NH4CI solution (100 mL x 2) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under

[1049] -151- FH13329100.6Attorney Docket No.: LCH-04125

[1050] reduced pressure. The residue was purified by column chromatography to afford Compound 1-3 (78 g, 99%) as a white solid.1H-NMR (400 MHz, CDCl3) 87.79-7.77 (m, 4H), 7.36-7.34 (m, 4H), 4.10-4.08 (m, 4H), 3.62-3.60 (m, 4H), 2.45 (s, 6H).

[1051] Preparation of Compound 1-4

[1052] To a solution of Compound 1-3 (78 g, 188.2 mmol) in / V, / V-di methylformamide (470 mL) was added sodium azide (61 g, 940.9 mmol) under N2. After stirring at 80 °C for 18 hours, the reaction mixture was diluted with ethyl acetate (1 L) and washed with saturated aq. NH4CI solution (500 mL x 2) and brine (500 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-4 (24 g, 83%) as a pale yellow oil. 'H-NMR (400 MHz, CDCl3) 83.70-3.67 (m, 4H), 3.43-3.40 (m, 4H).

[1053] Preparation of Compound 1-5

[1054] To a solution of Compound 1-4 (24 g, 153.7 mmol) in ethyl acetate (500 mL) were added triphenylphosphine (40 g, 153.7 mmol) and aq. 1 M HC1 solution (284 mL) at 0 °C under N2. After stirring at room temperature for 17 hours, the reaction mixture was concentrated under reduced pressure and then the residue was adjusted to pH 10 with 1 M sodium hydroxide solution. The residue was extracted with dichloromethane (100 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-5 (9.6 g, 48%) as a colorless oil.1H-NMR (400 MHz, CDCl3) 83.90 (t, J = 4.8 Hz, 2H), 3.68 (t, J = 4.8 Hz, 2H), 3.54 (t, J = 4.8 Hz, 2H), 3.40 (t, J = 4.8 Hz, 2H), 1.37 (bs, 2H).

[1055] Preparation of Compound 1-6

[1056] To a solution of Compound 1-5 (8.9 g, 68.4 mmol) in dichloromethane (150 mL) were added Compound 1-2 (15 g, 68.4 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 33.8 g, 88.95 mmol), and N, A-di isopropylethyl amine (23.8 mL, 137 mmol) under N2. After stirring at room temperature for 14 hours, the reaction mixture was washed with saturated aq. NH4CI solution (20 mL), saturated aq. NaHCCL solution (20 mL), and brine (40 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-6 (20 g, 88%) as a yellow oil. ESI-MS m / z:

[1057] -152- FH13329100.6Attorney Docket No.: LCH-04125

[1058] [M+H]+332.25.1H-NMR (400 MHz, CDCl3) 57.04 (s, 1H), 3.66 (t, J = 5.0 Hz, 2H), 3.58 (s, 2H), 3.47 (t, 7= 5.6 Hz, 2H), 3.41 (t, 7 = 5.0 Hz, 2H), 1.48 (s, 9H), 1.46 (s, 6H).

[1059] Preparation of Compound 1-7

[1060] To a solution of Compound 1-6 (21 g, 63.3 mmol) in tetrahydrofuran (150 mL) were added triphenylphosphine (18 g, 69.7 mmol) and distilled water (22 mL) at 0 °C under N2. After stirring at 80 °C for 20 hours, the reaction mixture was concentrated, and the resulting residue was purified by column chromatography to afford Compound 1-7 (15 g, 77%) as a yellow oil. ESI-MS m / z:

[1061] [M+H]+306.28. 'H-NMR (400 MHz, CDCl3) 83.56 (t, 7 = 5.4 Hz, 2H), 3.53-3.48 (m, 4H), 3.46 (q, 7 = 5.5 Hz, 2H), 2.90 (t, 7= 5.0 Hz, 2H), 1.48 (s, 9H), 1.46 (s, 6H).

[1062] Example 3: Preparation of Compound 1-10

[1063]

[1064] Preparation of Compound 1-9

[1065] To a solution of Compound 1-7 (1.38 g, 4.54 mmol) in dichloromethane (20 mL) were added Compound 1-8 (2 g, 4.12 mmol; prepared by the method described in US Patent No.

[1066] 11,173,214 B2), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HC1, 831 mg, 4.33 mmol), 1 -hydroxybenzotriazole (HOBt, 613 mg, 4.54 mmol) and A-methy I morpholine (0.91 mL, 8.25 mmol) under N2. After stirring at room temperature for 12 hours, the reaction mixture was washed with saturated aq. NaHCO3solution (30 mL) and saturated aq. NH4CI solution (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-9 (2.2 g, 69%) as a colorless oil. ESI-MS m / z: [M+H]+772.74.1H-NMR (400 MHz, DMSO-d6) 8 9.82 (s, 1H), 7.93-7.86 (m, 2H), 7.57 (d, 7 = 2.3 Hz, 1H), 7.39 (dd, 7 = 8.6, 2.3 Hz, 1H), 7.11 (d, 7 = 8.5 Hz, 1H), 5.78-5.66 (m, 2H), 5.49 (t, 7 = 9.7 Hz, 1H), 5.27-5.15 (m, 2H), 5.07 (t, 7 = 9.8 Hz, 1H), 4.74 (d, 7 = 9.9 Hz, 1H), 4.45 (d, 7 = 4.3 Hz, 2H), 3.64 (s, 3H), 3.48 (dt, 7 = 21.5, 6.4 Hz, 6H), 3.25 (q, 7 = 6.0 Hz, 3H), 2.01 (d, 7 = 6.0 Hz, 9H), 1.42 (s, 9H), 1.26 (s, 6H).

[1067] Preparation of Compound 1-10

[1068] -153- FH13329100.6Attorney Docket No.: LCH-04125

[1069] To a solution of Compound 1-9 (1 g, 1.29 mmol) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (613 mg, 1.55 mmol) and pyridine (0.21 mL, 2.59 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with dichloromethane (100 mL) and washed with saturated aq. NaHCO3solution (50 mL), aq. 0.5 N HO solution (50 mL), and aq. 2% NaOH solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-10 (1 g, crude), which was used for the next step without further purification. ESI-MS m / z: [M+H]+982.60. 'H-NMR (400 MHz, DMSO-d6) 87.99 (t, J= 5.6 Hz, 1H), 7.92 (s, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.59 (d, J = 8.9 Hz, 1H), 7.22 (d, J = 8.6 Hz, 1H), 5.76 (d, J = 7.8 Hz, 1H), 5.49 (t, J = 9.6 Hz, 1H), 5.38 (s, 2H), 5.26-5.17 (m, 1H), 5.08 (t, J = 9.8 Hz, 1H), 4.76 (d, J = 9.9 Hz, 1H), 3.64 (s, 3H), 3.53-3.51 (m, 4H), 3.30-3.22 (m, 4H), 2.01 (d, J = 6.1 Hz, 9H), 1.41 (s, 9H), 1.26 (s, 6H).

[1070] Example 4: Preparation of Compound 1-13

[1071]

[1072] Preparation of Compound 1-11

[1073] To a solution of Compound 1-10 (150 mg, 0.15 mmol) and Monomethyl auristatin E (MMAE, 100 mg, 0.14 mmol) in A-di methylformamide (5 mL) were added l-hydroxy-7-azabenzotriazole (HOAt, 1.9 mg, 0.013 mmol) and A. A-diisopropylethylamine (0.07 mL, 0.41 mmol) at 0 °C under N2. After stirring at room temperature for 20 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (30 mL), distilled water (30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-11 (190 mg, 90%). ESI-MS m / z: [M+H]+1515.23.

[1074] -154- FH13329100.6Attorney Docket No.: LCH-04125

[1075] Preparation of Compound 1-12

[1076] To a solution of Compound 1-11 (190 mg, 0.13 mmol) in methanol (4 mL) was added lithium hydroxide monohydrate (47 mg, 0.11 mmol) in water (4 mL) at -78 °C. The reaction mixture was stirred at -5 °C for 5 hours. The reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure to afford Compound 1-12 (234 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1375.45.

[1077] Preparation of Compound 1-13

[1078] To a solution of Compound 1-12 (180 mg, 0.13 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (1 mL) at 0 °C. The reaction mixture was stirred at room temperature for 5 hours and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-13 (140 mg, 80%) as a white solid. ESI-MS m / z: [M+H]+1275.59.

[1079] Example 5: Preparation of Compound 1-19

[1080]

[1081] Preparation of Compound 1-14

[1082] To a solution of pentaethylene glycol (10 g, 41.97 mmol) in dichloromethane (45 mL) w ere added p-toluenesulfonyl chloride (16 g, 83.94 mmol) and potassium hydroxide (18.84 g, 335.74 mmol) at 0 °C. The reaction mixture was warmed to room temperature under N2. After 16 hours, the reaction mixture was diluted with dichloromethane (80 mL) and washed with distilled water (80 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-14 (24 g, quant.) as a clear oil,

[1083] -155- FH13329100.6Attorney Docket No.: LCH-04125

[1084] which was used for the next step without further purification.1H-NMR (400 MHz, CDCl3) 87.79 (d, J = 6.4 Hz, 4H), 7.34 (d, J = 8.0 Hz, 4H), 4.15 (t, J = 4.8 Hz, 4H), 3.68 (t, J = 4.8 Hz, 4H), 3.60 (s, 4H), 3.58 (s, 8H), 2.45 (s, 6H).

[1085] Preparation of Compound 1-15

[1086] Compound 1-14 (28 g, 51.22 mmol) and sodium azide (13.32 g, 204.88 mmol) were diss olved in / V. / V-dimethylfomiamide (100 mL). The reaction mixture was then heated to 80 °C. After stirring for 16 hours, the reaction mixture was diluted with ethyl acetate (150 mL) and washed with saturated aq. NH4CI solution (85 mL) and distilled water (80 mL x 3). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-15 (14.3 g, 96.8%) as a clear oil, which was used for the next step without further purification. ESI-MS m / z: [M+H]+311.41. ’H-NMR (400 MHz, CDCl3) 83.72-3.64 (m, 16H), 3.39 (t, J = 4.8 Hz, 4H).

[1087] Preparation of Compound 1-16

[1088] To a solution of Compound 1-15 (14.3 g, 49.60 mmol) in ethyl acetate (180 mL) were added triphenylphosphine (13 g, 49.60 mmol) and aq. 1 N HC1 solution (91.76 mL, 91.76 mmol) at 0 °C under N2. After stirring at room temperature for 16 hours, the reaction mixture was concentrated under reduced pressure and then the residue was adjusted to pH 14 with 1 M aq. sodium hydroxide solution. The reaction mixture was extracted with dichloromethane (100 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-16 (11 g, 84%) as a clear oil, which was used for the next step without further purification. ESI-MS m / z: [M+H]+263.43.

[1089] Preparation of Compound 1-17

[1090] To a solution of Compound 1-16 (1.04 g, 3.96 mmol) in A, A-dimethylformamide (15 mL) were added Compound 1-2 (955 mg, 4.35 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 2.25 g, 5.94 mmol), and A. A-diisopropylethylamine (1.37 mL, 7.91 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (60 mL) and washed with saturated aq. NH4CI solution (60 mL), saturated aq. NaHCCL solution (60 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-17 (923 mg,

[1091] -156- FH13329100.6Attorney Docket No.: LCH-04125

[1092] 50%). ESI-MS m / z: [M+H]+464.42.

[1093] Preparation of Compound 1-18

[1094] To a solution of Compound 1-17 (923 mg, 1.99 mmol) in tetrahydrofuran (20 mL) were added triphenylphosphine (1.56 g, 5.97 mmol) and distilled water (0.35 mL, 19.9 mmol) at 0 °C under N2. The reaction mixture was heated to 85 °C and stirred for 16 hours. After the completion of reaction, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-18 (703 mg, 80%). ESI-MS m / z:

[1095] [M+H]+438.22.

[1096] Preparation of Compound 1-19

[1097] To a solution of Compound 1-18 (703 mg, 1.61 mmol) in A, A-di methylformamide (8 mL) were added Compound 1-8 (702 mg, 1.45 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 916 mg, 2.41 mmol) and A. A-diisopropylethylamine (0.56 mL, 3.22 mmol) under N2 at 0 °C. After stirring at room temperature for 6 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4CI solution (50 mL) and distilled water (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-19 (780 mg, 53%). ESI-MS m / z: [M+H]+904.28.

[1098] -157- FH13329100.6Attorney Docket No.: LCH-04125

[1099] Example 6: Preparation of Compound 1-25

[1100]

[1101] Preparation of Compound 1-21

[1102] To a solution of Compound 1-20 (500 mg, 0.35 mmol; prepared by the method described in US Patent No. 11,654,197 B2), in dichloromethane (20 mL) were added triphosgene (41 mg, 0.14 mmol), MA-diisopropylethylamine (0.03 mL, 1.05 mmol) and dibutyltin dilaurate (0.02 mL, 0.04 mmol) at 0 °C under N2. After stirring at 0 °C for 10 min, a solution of Compound 1-19 (411 mg, 0.45 mmol) and A'-diisopropylethylamine (0.03 mL, 1.05 mmol) in dichloromethane (20 mL) were added to the reaction mixture at 0 °C under N2. After stirring at room temperature for 17 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. sodium bicarbonate solution (20 mL) and distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-21 (403 mg, 48%). ESI-MS m / z: [M / 2+H]+1177.32.

[1103] Preparation of Compound 1-22

[1104] To a solution of Compound 1-21 (403 mg, 0.17 mmol) in tetrahydrofuran (5 mL) and water (5 mL) was added acetic acid (5 mL) at 0 °C under N2. After stirring at room temperature for 20 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated -158- FH13329100.6Attorney Docket No.: LCH-04125

[1105] aq. sodium bicarbonate solution (50 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-22 (360 mg, 98%). ESI-MS m / z:

[1106] [M+H]+2121.94.

[1107] Preparation of Compound 1-23

[1108] To a solution of Compound 1-22 (360 mg, 0.16 mmol) in dichloromethane (30 mL) was added Dess-Martin periodinane (86 mg, 0.20 mmol) at 0 °C under N2. After stirring at room temperature for 5 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with saturated aq. sodium bicarbonate solution (30 mL) and distilled water (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 1-23 (326 mg, 95%). ESI-MS m / z: [M+H]+2117.86.

[1109] Preparation of Compound 1-24

[1110] To a solution of Compound 1-23 (326 mg, 0.15 mmol) in tetrahydrofuran / methanol (12 mL / 12 mL) was added lithium hydroxide monohydrate (116 mg, 2.77 mmol) in distilled water (12 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 2 hours at this temperature. The reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure to afford Compound 1-24 (310 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1837.75.

[1111] Preparation of Compound 1-25

[1112] To a solution of Compound 1-24 (160 mg, 0.08 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.6 mL) at 0 °C. The reaction mixture was stirred at room temperature for 5 hours and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-25 (81 mg, 52%) as a white solid. ESI-MS m / z: [M+H]+1738.41, [M / 2+H]+869.77.

[1113] -159- FH13329100.6Attorney Docket No.: LCH-04125

[1114] Example 7: Preparation of Compound 1-38

[1115]

[1116] Preparation of Compound 1-27

[1117] To a solution of Compound 1-26 (1 g, 2.37 mmol; prepared by the method described in WO 2021 / 137646 Al) in AW-dimethylformamide (10 mL) were added potassium carbonate (654 mg, 4.73 mmol) and 1,3-dibromopropane (1.2 mL, 11.83 mmol). After stirring at room temperature for 18 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 1-27 (1.1 g, 86%). ESI-MS m / z: [M+H]+545.51.1H-NMR (400 MHz, CDCl3) 87.74 (d, J = 8.1 Hz, 1H), 6.75 (s, 1H), 5.09 (d, J = 8.3 Hz,

[1118] -160- FH13329100.6Attorney Docket No.: LCH-04125

[1119] 1H), 4.98 (s, 1H), 4.83 (s, 1H), 4.56 (d, J = 15.8 Hz, 1H), 4.28-4.20 (m, 2H), 3.94 (d, J = 1.5 Hz, 3H), 3.75 (d, J = 16.6 Hz, 2H), 3.63 (t, J = 6.3 Hz, 2H), 3.35-3.26 (m, 1H), 2.83-2.73 (m, 1H), 2.68 (d, J = 15.8 Hz, 1H), 2.40 (p, J = 6.1 Hz, 2H), 0.89 (d, J = 1.4 Hz, 6H), 0.78 (d, J = 1.3 Hz, 3H), 0.08 (d, J = 2.0 Hz, 4H), -0.12 (d, J = 13.6 Hz, 2H).

[1120] Preparation of Compound 1-29

[1121] To a solution of Compound 1-27 (1.1 g, 2.02 mmol) and Compound 1-28 (964 mg, 2.02 mmol; prepared by the method described in WO 2021 / 137646 Al) in AW-dimethylformamide (10 mL) was added potassium carbonate (559 mg, 4.05 mmol). After stirring at 50 °C for 18 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 1-29 (1.3 g, 68%). ESI-MS m / z: [M+H]+939.94. 'H-NMR (400 MHz, CDCl3) 87.99-7.70 (m, 2H), 6.94-6.66 (m, 2H), 6.11-5.81 (m, 1H), 5.33 (d, J= 17.2 Hz, 1H), 5.26-5.19 (m, 1H), 5.07 (d, J = 8.3 Hz, 1H), 4.97 (s, 1H), 4.82 (s, 1H), 4.61 (d, J = 4.1 Hz, 3H), 4.33-4.24 (m, 3H), 4.18 (d, J = 14.0 Hz, 1H), 3.92 (d, J = 1.8 Hz, 3H), 3.88 (s, 1H), 3.80 (s, 2H), 3.73 (d, J = 15.8 Hz, 2H), 3.29 (d, J = 8.1 Hz, 1H), 2.72 (d, J = 19.7 Hz, 3H), 2.40 (t, J = 6.1 Hz, 2H), 0.87 (d, J = 7.0 Hz, 12H), 0.77 (s, 6H), 0.08 (d, J = 1.6 Hz, 8H), -0.13 (d, J = 12.4 Hz, 4H).

[1122] Preparation of Compound 1-30

[1123] To a solution of Compound 1-29 (1.3 g, 1.38 mmol) in ethyl acetate (10 mL) and ethanol (20 mL) were added zinc powder (1.8 g, 27.68 mmol) and acetic acid (1.6 mL, 27.68 mmol) at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was filtered through a celite pad. The filtrate was diluted with ethyl acetate (100 mL) and washed with saturated aq. NaHCO3solution (50 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 1-30 (1.1 g, 91%). ESI-MS m / z: [M+H]+909.84. 'H-NMR (400 MHz, CDCl3) 87.86 (s, 1H), 6.82 (s, 1H), 6.74 (s, 1H), 6.34 (s, 1H), 5.95 (ddt, J = 16.5, 11.0, 5.7 Hz, 1H), 5.40-5.31 (m, 1H), 5.24 (d, J = 10.6 Hz, 1H), 4.97 (s, 2H), 4.90 (s, 1H), 4.62 (d, J = 4.6 Hz, 2H), 4.36 (s, 1H), 4.30-4.18 (m, 6H), 4.07 (s, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 3.63 (s, 1H), 2.69 (s, 3H), 2.38 (t, J = 6.3 Hz, 2H), 0.87 (s, 18H), 0.03 (s, 12H).

[1124] Preparation of Compound 1-32

[1125] -161- FH13329100.6Attorney Docket No.: LCH-04125

[1126] To a solution of Compound 1-30(1.1 g, 1.26 mmol) in tetrahydrofuran (5 mL) were added triphosgene (150 mg, 0.51 mmol) and 1 -methylimidazole (0.3 mL, 3.79 mmol) at 0 °C under N2. After stirring at 0 °C for 1 hour, Compound 1-31 (753 mg, 1.39 mmol; prepared by the method described in US Patent No. 11,654,197 B2) was added to the reaction mixture at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. sodium bicarbonate solution (20 mL) and distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-32 (912 mg, 49%). ESI-MS m / z: [M+H]+1477.36.

[1127] Preparation of Compound 1-33

[1128] To a solution of Compound 1-32 (912 mg, 0.62 mmol) in dichloromethane (7 mL) were added tetrakis(triphenylphosphine)palladium (0) (71 mg, 0.06 mmol) and pyrrolidine (0.08 mL, 0.93 mmol) at 0 °C under N2. After stirring at room temperature for 1 hour, the reaction mixture was diluted with dichloromethane (50 mL) and washed with distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-33 (726 mg, 84%). ESI-MS m / z: [M+H]+1393.29.

[1129] Preparation of Compound 1-34

[1130] To a solution of Compound 1-33 (390 mg, 0.28 mmol) in dichloromethane (5 mL) were added triphosgene (33 mg, 0.11 mmol) and 1 -methylimidazole (0.07 mL, 0.84 mmol) at 0 °C under N2. After stirring at 0 °C for 1 hour, Compound 1-9 (238 mg, 0.31 mmol) was added to the reaction mixture at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq. sodium bicarbonate solution (20 mL) and distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-34 (230 mg, 37%). ESI-MS m / z:

[1131] [M+H]+2191.84.

[1132] Preparation of Compound 1-35

[1133] To a solution of Compound 1-34 (230 mg, 0.11 mmol) in tetrahydrofuran (1 mL) and distilled water (1 mL) was added acetic acid (1 mL) at 0 °C under N2. After stirring at room

[1134] -162- FH13329100.6Attorney Docket No.: LCH-04125

[1135] temperature for 20 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. sodium bicarbonate solution (10 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-35 (128 mg, 62%). ESI-MS m / z: [M+H]+1962.61.

[1136] Preparation of Compound 1-36

[1137] To a solution of Compound 1-35 (128 mg, 0.07 mmol) in dichloromethane (3 mL) was added Dess-Martin periodinane (61 mg, 0.14 mmol) at 0 °C under N2. After stirring at room temperature for 20 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with saturated aq. sodium bicarbonate solution (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-36 (122 mg, 95%). ESI-MS m / z: [M+H]+1958.47.

[1138] Preparation of Compound 1-37

[1139] To a solution of Compound 1-36 (122 mg, 0.06 mmol) in tetrahydrofuran (1 mL) and methanol (0.5 mL) was added lithium hydroxide monohydrate (18 mg, 0.44 mmol) in water (1.5 mL) at -78 °C. After stirring at 0 °C for 3 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-37 (76 mg, 72%). ESI-MS m / z: [M+H]+1678.20.

[1140] Preparation of Compound 1-38

[1141] To a solution of Compound 1-37 (76 mg, 0.05 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.1 mL) at 0 °C under N2. After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-38 (53 mg, 74%). ESI-MS m / z: [M+H]+1578.18.

[1142] -163- FH13329100.6Attorney Docket No.: LCH-04125

[1143] Example 8: Preparation of Compound 1-41

[1144]

[1145] 1-40 1-41

[1146] Preparation of Compound 1-39

[1147] To a solution of Compound 1-10 (269 mg, 0.24 mmol) and Monomethyl auristatin F methyl ester (MMAF-OMe, 200 mg, 0.27 mmol) in A, A-dimethylformamide (3 mL) were added l-hydroxy-7-azabenzotriazole (HO At, 3.6 mg, 0.027 mmol) and A, A-di isopropylethylamine (0.09 mL, 0.54 mmol) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (30 mL), distilled water (30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-39 (394 mg, 95%). ESI-MS m / z: [M+H]+1544.78.

[1148] Preparation of Compound 1-40

[1149] To a solution of Compound 1-39 (314 mg, 0.20 mmol) in methanol (5.7 mL) / tetrahydrofuran (5.7 mL) was added lithium hydroxide monohydrate (43 mg, 1.02 mmol) in water (8.5 mL) at -78 °C. The reaction mixture was stirred at -5 °C for 5 hours. The reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure to afford Compound 1-40 (283 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1391.07.

[1150] Preparation of Compound 1-41

[1151] To a solution of Compound 1-40 (282 mg, 0.21 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (1 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-41 (160 mg, 56%) as a white solid. ESI-MS m / z: [M+H]+1290.58.

[1152] -164- FH13329100.6Attorney Docket No.: LCH-04125

[1153] Example 9: Preparation of Compound 1-44

[1154]

[1155] Preparation of Compound 1-42

[1156] To a solution of Compound 1-10 (200 mg, 0.20 mmol) in A, / V-di methylformamide (20 mL) were added exatecan mesylate (119 mg, 0.22 mmol) and MA-diisopropylethylamine (0.17 ml, 1.01 mmol). After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with distilled water (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-42 (250 mg, 98%), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1233.97.

[1157] Preparation of Compound 1-43

[1158] To a solution of Compound 1-42 (250 mg, 0.20 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (34 mg, 0.81 mmol) in water (3 mL) at -78 °C. After stirring at 0 °C for 2 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure to afford Compound 1-43 (221 mg, 98%), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1093.83.

[1159] Preparation of Compound 1-44

[1160] To a solution of Compound 1-43 (221 mg, 0.20 mmol) in acetonitrile (3 mL) was added phosphoric acid (85%, 4 mL) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-44 (150 mg, 68%) as a yellow solid.

[1161] -165- FH13329100.6Attorney Docket No.: LCH-04125

[1162] ESI-MS m / z: [M+H]+993.95.

[1163] Example 10: Preparation of Compound 1-49

[1164]

[1165] Preparation of Compound 1-46

[1166] To a solution of Compound 1-45 (300 mg, 0.39 mmol; prepared by the method described in WO 2021 / 137646 Al) in tetrahydrofuran (10 mL) were added triphosgene (42 mg, 0.14 mmol), Compound 1-9 (183 mg, 0.91 mmol) and triethylamine (0.2 mL, 3.63 mmol) at 0 °C under N2. After stirring at room temperature for 17 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with brine (20 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-46 (320 mg, 62%) as a yellow solid. ESI-MS m / z: [M+H]+1318.53, [M / 2+H]+659.46.

[1167] Preparation of Compound 1-47

[1168] To a solution of Compound 1-46 (320 mg, 0.24 mmol) in tetrahydrofuran (5 mL) / water (5 mL) was added acetic acid (5 mL) at 0 °C under N2. After stirring at room temperature for 20 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-47 (250 mg, 85%) as a yellow solid. ESI-MS m / z: [M+H]+1203.14, [(M-Boc) / 2+H]+552.20.

[1169] -166- FH13329100.6Attorney Docket No.: LCH-04125

[1170] Preparation of Compound 1-48

[1171] To a solution of Compound 1-47 (250 mg, 0.21 mmol) in dichloromethane (10 mL) was added Dess-Martin periodinane (132 mg, 0.31 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with aq.

[1172] 1 N NaOH solution (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-48 (190 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1201.18, [(M-Boc) / 2+H]+551.26.

[1173] Preparation of Compound 1-49

[1174] To a solution of Compound 1-48 (150 mg, crude) in A, A-dimethylformamide (20 mL) were added tetrakis(triphenylphosphine)palladium (0) (58 mg, 0.05 mmol) and pyrrolidine (0.01 mL, 0.13 mmol) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with aq. NH4CI solution (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The resulting residue was purified by column chromatography to afford Compound 1-49 (62 mg, 43% in 2 steps) as a yellow oil. ESI-MS m / z: [M+H]+1161.42, [(M-Boc) / 2+H]+531.34.

[1175] -167- FH13329100.6Attorney Docket No.: LCH-04125

[1176] Example 11: Preparation of Compound 1-55

[1177]

[1178] Preparation of Compound 1-51

[1179] To a solution of Compound 1-50 (6.7 g, 22.96 mmol; prepared by the method described in WO 2021 / 137646 Al) in A, A-dimethylformamide (20 mL) were added 3-amino-l -propanol (2.2 g, 29.84 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 10 g, 27.55 mmol), and AW-diisopropylethylamine (8.0 mL, 45.92 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NH4CI solution (30 mL x 2) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-51 (3.5 g, 43%). ES MS m / z: [M+H]+350.46.

[1180] Preparation of Compound 1-52

[1181] To a solution of Compound 1-51 (200 mg, 0.57 mmol) in methanol (10 mL) was added palladium / charcoal (10 wt.%, 6.1 mg) under hydrogen atmosphere. After stirring at room temperature for 18 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-52 (179 mg, 98%). ESI-MS m / z: [M+H]+320.33.

[1182] -168- FH13329100.6Attorney Docket No.: LCH-04125

[1183] Preparation of Compound 1-53

[1184] To a solution of Compound 1-49 (50 mg, 0.04 mmol) in / V, / V-dimethylformamide (1 mL) were added Compound 1-52 (18 mg, 0.06 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 24 mg, 0.06 mmol), and / V. / V-diisopropylethylamine (0.03 mL, 0.17 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (40 mL) and washed with saturated aq. NH4CI solution (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-53 (30 mg, 48%) as a yellow oil. ES MS m / z: [M+Na]+1484.88, [M / 2+Na]+732.14.

[1185] Preparation of Compound 1-54

[1186] To a solution of Compound 1-53 (30 mg, 0.02 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (3.5 mg, 0.08 mmol) in water (2 mL) at -78 °C. The reaction mixture was stirred at -5 °C for 3 hours. The reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-54 (10 mg, 37%) as a white solid. ESI-MS m / z: [M+Na]+1344.66, [(M-Boc) / 2+H]+611.92.

[1187] Preparation of Compound 1-55

[1188] To a solution of Compound 1-54 (10 mg, 0.008 mmol) in acetonitrile (1 mL) was added phosphoric acid (85%, 0.2 mL) at 0 °C. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 1-55 (5.2 mg, 56%) as a white solid. ESIMS m / z: [M+H]+1222.55, [M / 2+H]+611.80.

[1189] Example 12: Preparation of Compound 1-59

[1190]

[1191] Preparation of Compound 1-56

[1192] To a solution of l-amino-3,6,9-trioxaundecanyLll-ol (1.37 g, 7.09 mmol) in

[1193] -169- FH13329100.6Attorney Docket No.: LCH-04125

[1194] dichloromethane (25 mL) were added triethylamine (3.0 mL, 21.27 mmol) and di-tert-butyl dicarbonate (2.44 mL, 10.63 mmol) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-56 (1.70 g, 81%). ESI-MS m / z: [M+Na]+316.53.

[1195] Preparation of Compound 1-57

[1196] To a solution of Compound 1-56 (653 mg, 2.23 mmol) in acetonitrile (20 mL) were added ethyl propiolate (0.45 mL, 4.45 mmol) and N-methylmorpholine (0.03 mL, 0.45 mmol) at 0 °C under N2. After stirring at room temperature for 16 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-57 (786 mg, 90%). ESI-MS m / z: [M+H]+392.58.

[1197] Preparation of Compound 1-58

[1198] To a solution of Compound 1-57 (786 mg, 2.01 mmol) in ethyl acetate (20 mL) was added palladium / charcoal (10 wt. %, 78.6 mg) under hydrogen atmosphere. After stirring at room temperature for 12 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-58 (525 mg, 66%) as a colorless oil. ESI-MS m / z: [M+Na]+416.56.

[1199] Preparation of Compound 1-59

[1200] To a solution of Compound 1-58 (938 mg, 2.38 mmol) in tetrahydrofuran (8 mL) was added lithium hydroxide monohydrate (43 mg, 1.02 mmol) in water (4 mL) at 0 °C. After stirring at room temperature for 18 hours, the reaction mixture was diluted with dichloromethane (40 mL) and washed with distilled water (30 mL) and brine (30 mL). The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-59 (664 mg, 76%). ESI-MS m / z: [M+H]+1544.78.

[1201] -170- FH13329100.6Attorney Docket No.: LCH-04125

[1202] Example 13: Preparation of Compound 1-66

[1203]

[1204] Preparation of Compound 1-60

[1205] To a solution of l-phenyl-2,5,8,1 l,14,17-hexaoxanonadecan-19-ol (4.9 g, 13.16 mmol) in acetonitrile (100 mL) were added ethyl propiolate (2.67 mL, 26.31 mmol) and N-methylmorpholine (0.18 mL, 2.63 mmol) at 0 °C under N2. After stirring at room temperature for 16 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-60 (4 g, 65%). ESI-MS m / z: [M+H]+471.62.

[1206] Preparation of Compound 1-61

[1207] To a solution of Compound 1-60 (4 g, 8.50 mmol) in ethyl acetate (80 mL) was added palladium / charcoal (10 wt. %, 400 mg) under hydrogen atmosphere. After stirring at room temperature for 16 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-61 (2.5 g, 77%) as a colorless oil. ESI-MS m / z: [M+H]+383.52.

[1208] Preparation of Compound 1-62

[1209] To a solution of Compound 1-61 (2.4 g, 6.3 mmol) in dichloromethane (60 mL) was added Dess-Martin periodinane (3.99 g, 9.41 mmol) under N2. After stirring at room temperature for 15 hours, saturated aq. sodium thiosulfate pentahydrate solution (30 mL) and saturated aq. NaHCCL

[1210] -171- FH13329100.6Attorney Docket No.: LCH-04125

[1211] solution (40 mL) were added to the reaction mixture. The reaction mixture was stirred until the solid completely dissolved. The resulting mixture was diluted with dichloromethane (50 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 1-62 (2.22 g, 93%). ESI-MS m / z: [M+H]+381.51.

[1212] Preparation of Compound 1-63

[1213] To a solution of Compound 1-5 (1.88 g, 14.46 mmol) in 1,2-dichloroethane (35 mL) were added / V-diisopropylethylamine (5.04 mL, 28.9 mmol), Compound 1-62 (2.2 g, 5.78 mmol) and sodium triacetoxyborohydride (1.47 g, 6.94 mmol) at 0 °C under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (70 mL) and washed with aq. NaHCCL solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-63 (664 mg, 23%). ESI-MS m / z: [M+H]+495.69.

[1214] Preparation of Compound 1-64

[1215] To a solution of Compound 1-63 (644 mg, 1.30 mmol) in A, A-di methylformamide (15 mL) were added Compound 1-59 (476 mg, 1.30 mmol), l-[bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 743 mg, 1.95 mmol), and A, A-diisopropylethylamine (0.68 mL, 3.91 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (30 mL), saturated aq. NaHCCL solution (30 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-64 (723 mg, 66%). ESI-MS m / z: [M+H]+842.96.

[1216] Preparation of Compound 1-65

[1217] To a solution of Compound 1-64 (723 mg, 0.86 mmol) in tetrahydrofuran (7 mL) were added triphenylphosphine (270 mg, 1.03 mmol) and distilled water (0.23 mL, 12.88 mmol) at 0 °C under N2. After stirring at 65 °C for 15 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-65 (632 mg, 91%). ESI-MS m / z: [M+H]+871.00.

[1218] Preparation of Compound 1-66

[1219] -172- FH13329100.6Attorney Docket No.: LCH-04125

[1220] To a solution of Compound 1-65 (632 mg, 0.77 mmol) in A-dimethylformamide (10 mL) were added Compound 1-8 (563 mg, 1.16 mmol), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HC1, 223 mg, 1.16 mmol), 1 -hydroxybenzotriazole (HOBt, 157 mg, 1.16 mmol) and / V-methy I morpholine (0.43 mL, 3.87 mmol) under N2. After stirring at room temperature for 12 hours, the reaction mixture was washed with saturated aq. NaHCO3solution (40 mL) and saturated aq. NH4CI solution (40 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 1-66 (518 mg, 52%) as a white foam solid. ESI-MS m / z: [M+H]+1283.48.

[1221] Example 14: Preparation of Compound 1-71

[1222]

[1223] -173- FH13329100.6Attorney Docket No.: LCH-04125

[1224]

[1225] Preparation of Compound 1-67

[1226] To a solution of Compound 1-66 (518 mg, 0.40 mmol) in dichloromethane (3 mL) were added bis(pentafluorophenyl)carbonate (207 mg, 0.53 mmol) and / V. / V-diisopropylethylamine (0.21 mL, 1.21 mmol) at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with dichloromethane (15 mL) and washed with 1% aq. NaOH solution (20 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-67 (621 mg, crude), which was used for the next step without further purification. ES MS m / z: [M+H]+1493.57.

[1227] Preparation of Compound 1-68

[1228] To a solution of Compound 1-67 (171 mg, 0.11 mmol) in N, A-di methylformamide (3 mL) were added exatecan mesylate (67 mg, 0.13 mmol) and N, A-diisopropylethylamine (0.05 mL, 0.34 mmol). After stirring at room temperature for 18 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with distilled water (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 1-68 (186 mg, 93%). ESI-MS m / z: [(M-Boc) / 2+H]+823.04.

[1229] -174- FH13329100.6Attorney Docket No.: LCH-04125

[1230] Preparation of Compound 1-69

[1231] To a solution of Compound 1-68 (279 mg, 0.16 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The resulting residue was concentrated under reduced pressure to afford amine intermediate, which was used without further purification. To a solution of amine intermediate in A'-dimethylfonriamide (3 mL) were added Compound 1-2 (400 mg, 0.18 mmol), N, N, N’, N’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 692 mg, 0.18 mmol), andA, / V-diisopropylethylamine(0.13 mL, 0.76mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4CI solution (40 mL), saturated aq. NaHCCL solution (40 mL) and brine (40 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 1-69 (311 mg, crude), which was used for the next step without further purification. ES MS m / z: [(M-Boc) / 2+H]+873.57.

[1232] Preparation of Compound 1-70

[1233] To a solution of Compound 1-69 (311 mg, 0.17 mmol) in methanol (1.5 mL) / THF (1.5 mL) was added lithium hydroxide monohydrate (35 mg, 0.84 mmol) in water (1.5 mL) at -78 °C. The reaction mixture was stirred at -5 °C for 5 hours. The reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The reaction mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 1-70 (112 mg, 40%) as a white solid. ESI-MS m / z:

[1234] [M / 2+H]+839.58.

[1235] Preparation of Compound 1-71

[1236] To a solution of Compound 1-70 (112 mg, 0.07 mmol) in acetonitrile (1.5 mL) was added phosphoric acid (85%, 1.5 mL) at 0 °C. After stirring at room temperature for 3 hours, the reaction mixture was purified by HPLC to afford Compound 1-71 (92 mg, 81%) as a white solid. ESI-MS m / z: [M / 2+H]+789.39.

[1237] -175- FH13329100.6Attorney Docket No.: LCH-04125

[1238] Example 15: Preparation of Compound 2-5

[1239]

[1240] 2-4 2-5

[1241] Preparation of Compound 2-1

[1242] To a mixture of hexaethylene glycol (30 g, 106 mmol), silver (I) oxide (29.55 g, 128 mmol) and potassium iodide (1.76 g, 10.6 mmol) in dichloromethane (2 L) was added p-toluenesulfonyl chloride (20.26 g, 106 mmol) at 0 °C. The reaction mixture was warmed to room temperature under N2. After 16 hours, the reaction mixture was filtered through a celite pad, concentrated under reduced pressure and purified by column chromatography to afford Compound 2-1 (28.5 g, 61%) as a colorless oil. ESI-MS m / z: [M+H]+437.79. 'H-NMR (400 MHz, CDCl3) 87.80 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 4.16 (m, 2H), 3.72-3.58 (m, 22H), 2.97 (br, 1H), 2.45 (s, 3H).

[1243] Preparation of Compound 2-2

[1244] Compound 2-1 (28 g, 64.1 mmol) and sodium azide (6.25 g, 96.2 mmol) were dissolved in A, A-di methylformamide (70 mL). Then the reaction mixture was heated to 100 °C. After stirring for 3 hours, the reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 2-2 (11.3 g, 57%) as a colorless oil. ESI-MS m / z: [M+H]+308.65. 'H-NMR (400 MHz, CDCl3) 8 3.77-3.69 (m, 2H), 3.71-3.63 (m, 18H), 3.67-3.58 (m, 2H), 3.40 (t, J = 5.1 Hz, 2H).

[1245] Preparation of Compound 2-3

[1246] To a solution of Compound 2-2 (10 g, 32.5 mmol) in tetrahydrofuran (60 mL) were added triphenylphosphine (9.39 g, 35.8 mmol) and distilled water (5.9 mL, 325 mmol) at 0 °C under N2. The reaction mixture was heated to 85 °C and stirred for 4 hours. After the completion of reaction, the reaction mixture was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 2-3 (7.7 g, 84%) as a colorless oil. ESI- -176- FH13329100.6Attorney Docket No.: LCH-04125

[1247] MS m / z: [M+H]+282.34.1H-NMR (400 MHz, CDCl3) 83.75-3.57 (m, 22H), 3.56-3.49 (m, 2H), 2.92-2.83 (m, 2H).

[1248] Preparation of Compound 2-4

[1249] To a solution of Compound 2-3 (7.7 g, 27.4 mmol) in acetonitrile (50 mL) were added benzyl chloroformate (4.7 mL, 32.8 mmol) and an aq. solution of sodium bicarbonate (6.9 g, 82.1 mmol) in distilled water (60 mL). After stirring at room temperature for 16 hours, the reaction mixture was diluted with dichloromethane (100 mL) and washed with distilled water (30 mL x 3). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-4 (9.27 g, 82%). ESI-MS m / z: [M+H]+416.34.1H-NMR (400 MHz, CDCl3) 87.35 (d, J = 4.7 Hz, 5H), 5.10 (d, J = 3.8 Hz, 2H), 3.77-3.50 (m, 22H), 3.40 (t, J = 5.6 Hz, 2H), 3.01 (d, 7 = 6.5 Hz, 1H).

[1250] Preparation of Compound 2-5

[1251] To a solution of Compound 2-4 (2.2 g, 5.30 mmol) in dichloromethane (50 mL) were added triethylamine (2.23 mL, 15.89 mmol) and p-toluenesulfonyl chloride (1.31 g, 6.88 mmol) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with aq. 10% citric acid solution (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-5 (1.9 g, 63%) as a colorless oil. ESI-MS m / z: [M+H]+570.07.

[1252] Example 16: Preparation of Compound 2-7

[1253]

[1254] Preparation of Compound 2-6

[1255] To a solution of hexaethylene glycol (65.37 g, 232 mmol) in tetrahydrofuran (100 mL) was added sodium hydride (60% dispersion in mineral oil, 151 mg, 6.29 mmol) at 0 °C. After stirring at 0 °C for 30 minutes, the reaction mixture was added tert-butyl acrylate (10 mL, 68.7 mmol).

[1256] -177- FH13329100.6Attorney Docket No.: LCH-04125

[1257] After stirring at room temperature for 16 hours, the reaction mixture was quenched with acetic acid (1 mL) and concentrated under reduced pressure. Then, the resulting residue was diluted with distilled water (500 mL) and extracted with ethyl acetate (500 mL x 4). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-6 (28 g, quant.) as a colorless oil, which was used for the next step without further purification. ESI-MS m / z: [M+Na]+433.18.

[1258] Preparation of Compound 2-7

[1259] To a solution of Compound 2-6 (900 mg, 2.19 mmol) in dichloromethane (20 mL) were added triethylamine (0.92 mL, 6.58 mmol) and p-toluenesulfonyl chloride (627 mg, 3.29 mmol) at 0 °C. After stirring at room temperature for 25 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. ammonium chloride solution (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-7 (900 mg, 73%) as a pale yellow oil. ESI-MS m / z:

[1260] [M+Na]+587.33. 'H-NMR (400 MHz, CDCl3) 87.83-7.76 (m, 2H), 7.37-7.31 (m, 2H), 4.19-4.12 (m, 2H), 3.75-3.66 (m, 4H), 3.66-3.43 (m, 22H), 2.50 (t, J = 6.6 Hz, 2H), 2.45 (s, 4H), 1.45 (s, 9H).

[1261] -178- FH13329100.6Attorney Docket No.: LCH-04125

[1262] Example 17: Preparation of Compound 2-14

[1263]

[1264] Preparation of Compound 2-8

[1265] -179- FH13329100.6Attorney Docket No.: LCH-04125

[1266] To a solution of methyl 3,4.5-trihydroxybenzoate (methyl gallate, 70 g, 380.1 mmol) in / V. / V-dimethylfomiamide (600 mL) were added 4-methoxybenzyl chloride (51.8 mL, 380.1 mmol), potassium bicarbonate (114.17 g, 1140.4 mmol), and potassium iodide (0.38 g, 0.006 mmol). The reaction mixture was heated to 60 °C under N2. After 16 hours, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting residue was diluted with water (300 mL) and extracted with dichloromethane (300 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-8 (58.17 g, 50%) as a white solid. ESI-MS m / z: [M+H]+305.31. 'H-NMR (400 MHz, CDCl3) 8 7.30 (d, J = 8.0 Hz, 2H), 7.19 (s, 2H), 6.90 (d, J = 8.0 Hz, 2H), 5.40 (s, 2H), 5.05 (s, 2H), 3.88 (s, 3H), 3.82 (s, 3H).

[1267] Preparation of Compound 2-9

[1268] To a solution of Compound 2-8 (1.5 g, 4.93 mmol) in A, A-dimethylformamide (10 mL) were added potassium bicarbonate (3.41 g, 24.6 mmol) and Compound 2-5 (6.46 g, 11.34 mmol) under N2. After stirring at 80 °C for 17 hours, the reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate (30 mL). The organic layer was washed with saturated aq. NH4CI solution (30 mL), saturated aq. NaHCCL solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 2-9 (5.6 g, quant.) as a yellow oil. ESI-MS m / z: [M+H]+1100.46.

[1269] Preparation of Compound 2-10

[1270] To a solution of Compound 2-9 (3.6 g, 3.28 mmol) in dichloromethane (30 mL) were added anisole (5.3 mL, 49.1 mmol) and trifluoroacetic acid (1.3 mL) at 0 °C under N2. After stirring at room temperature for 40 minutes, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-10 (3.6 g, quant.) as a pale yellow oil. ESI-MS m / z: [M+H]+979.45.

[1271] Preparation of Compound 2-11

[1272] To a solution of Compound 2-10 (2 g, 2.04 mmol) in A. A-dimethylformamide (10 mL) were added potassium bicarbonate (1.02 g, 10.21 mmol) and Compound 2-7 (1.6 g, 2.86 mmol) under N2. The reaction mixture was stirred at 65 °C for 12 hours. The reaction mixture was

[1273] -180- FH13329100.6Attorney Docket No.: LCH-04125

[1274] concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate (30 mL). The organic layer was washed with saturated aq. NH4CI solution (10 mL x 3), saturated aq. NaHCCh solution (10 mL x 3), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated and purified by column chromatography to afford Compound 2-11 (1.9 g, 68%) as a pale yellow oil. ESI-MS m / z: [M+H]+1371.69.

[1275] Preparation of Compound 2-12

[1276] To a solution of Compound 2-11 (1.8 g, 1.31 mmol) in methanol (12 mL) was added aq.

[1277] 1 N NaOH solution (6.56 mL, 6.56 mmol) at 0 °C under N2. After 7 hours, the reaction mixture was titrated with aq. 1 N HO solution to pH 3-4 at 0 °C, and the mixture was extracted with dichloromethane (30 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-12 (914 mg, 51%) as a yellow oil. ESI-MS m / z: [M+Na]+1379.60.

[1278] Preparation of Compound 2-13

[1279] To a solution of Compound 2-12 (190 mg, 0.14 mmol) in A. A-dimethylformamide (5 mL) were added Compound 1-7 (45 mg, 0.15 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 69 mg, 0.18 mmol), and N, A-di isopropylethyl amine (0.06 mL, 0.42 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (30 mL), saturated aq. NaHCCL solution (30 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-13 (140 mg, 61%). ESI-MS m / z: [M+H]+1645.04, [M / 2+H]+823.39.

[1280] Preparation of Compound 2-14

[1281] To a solution of Compound 2-13 (140 mg, 0.09 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 15 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-14 (90 mg, 77%) as a yellow oil. ESI-MS m / z:

[1282] [M+H]+1376.80, [M / 2+H]+689.21.

[1283] -181- FH13329100.6Attorney Docket No.: LCH-04125

[1284] Example 18: Preparation of Compound 2-18

[1285]

[1286] Preparation of Compound 2-16

[1287] To a solution of Compound 2-15 (5 g, 8.70 mmol; prepared by the method described in US Patent No. 11,173,214 B2) in dichloromethane (100 mL) were added bis(pentafluorophenyl)carbonate (4.11 g, 10.44 mmol) and / V. / V-di isopropylethyl amine (1.35 ml, 10.44 mmol) at 0 °C under N2. After stirring at room temperature for 5 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with distilled water (70 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-16 (6.4 g, 94%). ESI-MS m / z: [M+Na]+806.79.

[1288] Preparation of Compound 2-17

[1289] To a solution of Compound 2-16 (6.4 g, 8.16 mmol) in MA-dimethylformamide (20 mL) were added exatecan mesylate (5.20 g, 9.79 mmol) and M / V-diisopropylethylamine (3.41 mL, 19.58 mmol). After stirring at room temperature for 1 hour, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (70 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-17 (7.66 g, 90%). ESI-MS m / z: [M+H]+1035.85.

[1290] Preparation of Compound 2-18

[1291] To a solution of Compound 2-17 (6.6 g, 6.37 mmol) in dichloromethane (5 mL) and

[1292] -182- FH13329100.6Attorney Docket No.: LCH-04125

[1293] methanol (20 mL) were added palladium / charcoal (10 wt. %, 330 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-18 (4.7 g, 77%). ESI-MS m / z: [M+H]+945.78.1H-NMR(400 MHz, DMSO-d6), 8 8.07 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 11.2 Hz, 1H), 7.65 (s, 1H), 7.58 (d, J = 8.8 Hz, 1H), 7.31 (s, 1H), 7.22 (d, J = 8.4 Hz, 1H), 6.52 (s, 1H), 5.76 (s, 1H), 5.61 (d, 7= 8.0 Hz, 1H), 5.49-5.39 (m, 3H), 5.31-5.22 (m, 3H), 5.18-5.03 (m, 4H), 4.74 (d, J = 9.6 Hz, 1H), 3.63 (s, 3H), 3.3-3.05 (m, 3H), 2.38 (s, 3H), 2.35-2.15 (m, 2H), 2.02 (s, 3H), 1.98 (s, 6H), 0.88 (t, J = 7.2 Hz, 3H).

[1294] -183- FH13329100.6Attorney Docket No.: LCH-04125

[1295] Example 19: Preparation of Compound 2-21

[1296]

[1297] -184- FH13329100.6Attorney Docket No.: LCH-04125

[1298]

[1299] Preparation of Compound 2-19

[1300] To a solution of Compound 2-14 (170 mg, 0.10 mmol) and Compound 2-18 (199 mg, 0.21 mmol) in A, / V-di methylformamide (4 mL) were added A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 95 mg, 0.25 mmol) and N, N- diisopropylethylamine (0.087 mL, 0.50 mmol) at 0 °C. After stirring at room temperature for 2 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL), and brine (50 mL), and dried over anhydrous sodium sulfate. The organic layer was filtered, concentrated under reduced pressure, and purified by column chromatography to afford Compound 2-19 (223 mg, 71%). ESI-MS m / z: [M / 2+H]+1616.94, [M / 3+H]+1078.32.

[1301] Preparation of Compound 2-20

[1302] To a solution of Compound 2-19 (223 mg, 0.069 mmol) in tetrahydrofuran / methanol (1.5 mL / 1.5 mL) was added lithium hydroxide monohydrate (23 mg, 0.55 mmol) in water (1.5 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 3 hours at this temperature. Then the reaction mixture was neutralized with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-20 (115 mg, 56%). ESI-MS m / z: [M / 2+H]+1476.80, [M / 3+H]+937.17.

[1303] Preparation of Compound 2-21

[1304] To a solution of Compound 2-20 (115 mg, 0.039 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-21 (75 mg, 69%) as a yellow solid. ESL

[1305] -185- FH13329100.6Attorney Docket No.: LCH-04125

[1306] MS m / z: [M / 2+H]+1398.80, [M / 3+H]+932.86.

[1307] Example 20: Preparation of Compound 2-26

[1308]

[1309] Preparation of Compound 2-22

[1310] To a solution of Compound 2-11 (1.10 g, 0.802 mmol) in dichloromethane (2 mL) was added HO (4 M in 1,4-dioxane, 2 mL, 26.1 mmol) at 0 °C under N2. After 4 hours, the reaction mixture was concentrated under reduced pressure to afford Compound 2-22 (1 g, 95%) as a brown oil, which was used for the next step without further purification. ESI-MS m / z: [M+H]+1315.79.

[1311] -186- FH13329100.6Attorney Docket No.: LCH-04125

[1312] Preparation of Compound 2-23

[1313] To a solution of Compound 2-22 (1 g, 0.760 mmol) in / V, / V-dimethylformamide (20 mL) were added l-(terLbutoxycarbonyl)piperazine (170 mg, 0.912 mmol), A. M / V’. A’-tetramethyl-O-(IH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 346 mg, 0.912 mmol), and N, N-diisopropylethylamine (0.32 mL, 2.28 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4CI solution (50 mL), saturated aq. NaHCCL solution (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-23 (835 mg, 74%). ES MS m / z: [M+H]+1485.05.

[1314] Preparation of Compound 2-24

[1315] To a solution of Compound 2-23 (835 mg, 0.563 mmol) in methanol (5 mL) was added aq. 1 N NaOH solution (2.81 mL, 2.81 mmol) at 0 °C under N2. After 3 hours, the reaction mixture was titrated with aq. 1 N HO solution to pH 3-4 at 0 °C and extracted with ethyl acetate (30 mL x 2). The organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-24 (748 mg, 90%) as a brown oil, which was used for the next step without further purification. ESI-MS m / z: [M+H]+1471.00.

[1316] Preparation of Compound 2-25

[1317] To a solution of Compound 2-24 (975 mg, 0.66 mmol) and Compound 1-7 (405 mg, 1.32 mmol) in A, A-dimethylformamide (20 mL) were added A, A, A’, A’-tetramethyLO-( 1 H-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 377 mg, 0.99 mmol) and N, N-diisopropylethylamine (0.35 mL, 1.99 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (40 mL) and washed with saturated aq. NH4CI solution (25 mL), saturated aq. NaHCCL solution (25 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-25 (350 mg, 30%). ESI-MS m / z: [M / 2+H]+879.01.

[1318] Preparation of Compound 2-26

[1319] To a solution of Compound 2-25 (349 mg, 0.20 mmol) in methanol (12 mL) was added palladium / charcoal (10 wt. %, 150 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated

[1320] -187- FH13329100.6Attorney Docket No.: LCH-04125

[1321] under reduced pressure to afford Compound 2-26 (297 mg, quant.) as a pale yellow oil. ESI-MS m / z: [M / 2+H]+745.61.

[1322] -188- FH13329100.6Attorney Docket No.: LCH-04125

[1323] Example 21: Preparation of Compound 2-29

[1324]

[1325] -189- FH13329100.6Attorney Docket No.: LCH-04125

[1326]

[1327] Preparation of Compound 2-27

[1328] To a solution of Compound 2-26 (297 mg, 0.20 mmol) and Compound 2-18 (415 mg, 0.44 mmol) in / V. / V-dimethylfonriamide (10 mL) were added A. M / V’. A’-tetramethyl-O-i I / / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 189 mg, 0.50 mmol) and N, N- diisopropylethylamine (0.17 mL, 0.20 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (40 mL) and washed with saturated aq. NH4CI solution (30 mL), saturated aq. NaHCCL solution (30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-27 (428 mg, 64%) as a pale yellow solid. ES MS m / z: [M / 2+H]+1672.06, [M / 3+H]+1115.08.

[1329] Preparation of Compound 2-28

[1330] To a solution of Compound 2-27 (428 mg, 0.13 mmol) in tetrahydrofuran (4 mL) and methanol (4 mL) was added lithium hydroxide monohydrate (42.9 mg, 1.02 mmol) in water (5 mL) at -78 °C. After stirring at 5 °C for 3 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-28 (250 mg, 63%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1532.03, [M / 3+H]+1021.77.

[1331] Preparation of Compound 2-29

[1332] To a solution of Compound 2-28 (120 mg, 0.04 mmol) in acetonitrile (2 mL) was added -190- FH13329100.6Attorney Docket No.: LCH-04125

[1333] phosphoric acid (85%, 2 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-29 (89 mg, 76%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1431.77, [M / 3+H]+955.00.

[1334] Example 22: Preparation of Compound 2-36

[1335]

[1336] Preparation of Compound 2-30

[1337] To a solution of Compound 2-2 (2 g, 6.51 mmol) in dichloromethane (15 mL) were added triethylamine (1.37 mL, 9.76 mmol) and p-toluenesulfonyl chloride (1.49 g, 7.81 mmol) at 0 °C.

[1338] -191- FH13329100.6Attorney Docket No.: LCH-04125

[1339] After stirring at room temperature for 4 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq. NH4Cl solution (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-30 (2.04 g, 70%) as a pale yellow oil. ESI-MS m / z:

[1340] [M+Na]+484.243.1H-NMR (400 MHz, CDCl3) 87.80 (m, J = 8.1, 4.3 Hz, 2H), 7.35 (m, J = 7.6, 4.2 Hz, 2H), 4.16 (d, J = 5.5 Hz, 2H), 3.84-3.48 (m, 21H), 3.39 (d, J = 5.3 Hz, 2H), 2.45 (d, J = 4.0 Hz, 3H).

[1341] Preparation of Compound 2-31

[1342] To a solution of Compound 2-8 (30 g, 98.6 mmol) in N, N-dimethylformamide (300 mL) were added cesium carbonate (70.67 g, 217 mmol) and Compound 2-30 (104.66 g, 227 mmol) under N2. After stirring at 50 °C for 4 hours, the reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate (300 mL). The organic layer was washed with saturated aq. NH4Cl solution (100 mL), saturated aq. NaHCO3solution (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 2-31 (82 g, 94%) as a yellow oil. ESI-MS m / z: [M+H]+855.77.

[1343] Preparation of Compound 2-32

[1344] To a solution of Compound 2-31 (88 g, 99.7 mmol) in dichloromethane (250 mL) were added anisole (162 mL, 1495 mmol) and trifluoroacetic acid (38 mL) at 0 °C under N2. After stirring at room temperature for 40 minutes, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-32 (63 g, 83%) as a pale yellow oil. ESI-MS m / z: [M+H]+763.68.

[1345] Preparation of Compound 2-33

[1346] To a solution of Compound 2-32 (23 g, 30.2 mmol) in N, N-dimethylformamide (150 mL) were added cesium carbonate (14.74 g, 45.2 mmol) and Compound 2-7 (20.43 g, 36.2 mmol) under N2. After stirring at 50 °C for 4 hours, the reaction mixture was concentrated under reduced pressure and the residue was diluted with ethyl acetate (300 mL). The organic layer was washed with saturated aq. NH4Cl solution (100 mL), saturated aq. NaHCO3solution (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 2-33 (20 g, 57%) as a

[1347] -192- FH13329100.6Attorney Docket No.: LCH-04125

[1348] yellow oil. ESI-MS m / z: [M+Na]+1178.06.

[1349] Preparation of Compound 2-34

[1350] To a solution of Compound 2-33 (20 g, 17.3 mmol) in isopropyl alcohol / distilled water (250 mL / 250 mL) was added NaOH (1.04 g, 26.0 mmol) at 0 °C under N2. After stirring 5 hours, the reaction mixture was titrated with aq. 1 N HCl solution to pH 3-4 at 0 °C and extracted with ethyl acetate (250 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-34 (19 g, 96%) as a brown oil, which was used for the next step without further purification. ESI-MS m / z:

[1351] [M+Na]+1164.04.

[1352] Preparation of Compound 2-35

[1353] To a solution of Compound 2-34 (19 g, 16.6 mmol) in N, N-dimethylformamide (100 mL) were added Compound 1-7 (6.10 g, 20.0 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 7.58 g, 20.0 mmol), and A. A-diisopropylethylamine (14 mL, 83.2 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (300 mL) and washed with saturated aq. NH4CI solution (200 mL), saturated aq. NaHCO3solution (200 mL) and brine (200 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-35 (19.6 g, 82%). ESI-MS m / z: [M+H]+1430.42.

[1354] Preparation of Compound 2-36

[1355] To a solution of Compound 2-35 (5.00 g, 3.50 mmol) in methanol (20 mL) was added aq.

[1356] 1 N NaOH solution (28 mL, 28.0 mmol) at 0 °C under N2. After 24 hours, the reaction mixture was titrated with aq. 1 N HCl solution to pH 3-4 at 0 °C and extracted with dichloromethane (30 mL x 2). The organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-36 (5 g, quant.) as a yellow oil. ESI-MS m / z: [M+Na]+1395.22.

[1357] -193- FH13329100.6Attorney Docket No.: LCH-04125

[1358] Example 23: Preparation of Compound 2-41

[1359]

[1360] -194- FH13329100.6Attorney Docket No.: LCH-04125

[1361] Preparation of Compound 2-37

[1362] To a solution of tris(hydroxymethyl)aminomethane (5 g, 41.2 mmol) in dimethyl sulfoxide (20 mL) was added aq. 5 M NaOH solution (1.05 mL, 5.25 mmol) at 0 °C. Then tert-butyl acrylate (60 mL, 412 mmol) was added slowly at 0 °C. The reaction mixture was gradually warmed to room temperature. After stirring for 16 hours, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-37 (12.8 g, 61%). ESI-MS m / z: [M+H]+506.62.1H-NMR (400 MHz, CDCl3) 83.64 (t, J = 4.2 Hz, 6H), 3.32 (s, 6H), 2.45 (t, J = 4.1 Hz, 6H), 1.45 (s, 27H).

[1363] Preparation of Compound 2-38

[1364] To a solution of Compound 2-36 (4.80 g, 3.50 mmol) in N, N-dimethylformamide (50 mL) were added Compound 2-37 (2.65 g, 5.25 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 1.99 g, 5.25 mmol), and A, A-di isopropylethylamine (3 mL, 17.5 mmol) under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NH4Cl solution (100 mL), saturated aq. NaHCO3solution (100 mL) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-38 (4.22 g, 65%). ESI-MS m / z: [M+H]+1860.82.

[1365] Preparation of Compound 2-39

[1366] To a solution of Compound 2-38 (4.22 g, 2.27 mmol) in tetrahydrofuran (30 mL) were added triphenylphosphine (1.43 g, 5.44 mmol) and distilled water (0.82 mL, 45.4 mmol) at 0 °C under N2. After stirring at 60 °C for 12 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-39 (4 g, 97%). ESI-MS m / z: [M+H]+1808.21.

[1367] Preparation of Compound 2-40

[1368] To a solution of Compound 1-8 (525 mg, 1.08 mmol; prepared by the method described in US Patent No. 11,173,214 B2) in N, N-dimethylformamide (4 mL) were added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HC1, 283 mg, 1.48 mmol), 1-hydroxybenzotriazole (HOBt, 199 mg, 1.48 mmol), Compound 2-39 (890 mg, 0.49 mmol), and N-

[1369] -195- FH13329100.6Attorney Docket No.: LCH-04125

[1370] methylmorpholine (0.32 mL, 2.95 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NaHCO3solution (50 mL) and saturated aq. NH4CI solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-40 (890 mg, 66%). ESI-MS m / z: [M / 2+H]+1370.61, [M / 3+H]+914.14.

[1371] Preparation of Compound 2-41

[1372] To a solution of Compound 2-40 (890 mg, 0.32 mmol) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (384 mg, 0.97 mmol) and pyridine (0.10 mL, 1.30 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was concentrated under reduced pressure, and the resulting residue was diluted with ethyl acetate (100 mL) and washed with brine (50 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-41 (1.28 g, crude), which was used for the next step without further purification. ESI-MS m / z:

[1373] [M / 2+H]+1580.56, [M / 3+H]+1054.06.

[1374] Example 24: Preparation of Compound 2-44

[1375]

[1376] -196- FH13329100.6Attorney Docket No.: LCH-04125

[1377]

[1378] -197- FH13329100.6Attorney Docket No.: LCH-04125

[1379] Preparation of Compound 2-42

[1380] To a solution of Compound 2-41 (450 mg, 0.14 mmol) in N,N-dimethylformamide (2 mL) was added exatecan mesylate (159 mg, 0.30 mmol) in N,N-dimethylformamide (3 mL) and N, N-diisopropylethylamine (0.20 mL, 1.14 mmol) at room temperature under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford Compound 2-42 (550 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M / 2+H]+1831.35, [M / 3+H]+1221.44.

[1381] Preparation of Compound 2-43

[1382] To a solution of Compound 2-42 (115 mg, 0.031 mmol) in tetrahydrofuran / methanol (0.5 mL / 0.5 mL) was added lithium hydroxide monohydrate (10 mg, 0.25 mmol) in water (0.5 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 3 hours at this temperature. Then the reaction mixture was neutralized with acetic acid and concentrated under reduced pressure. Then the resulting residue was purified by HPLC to afford Compound 2-43 (60 mg, 56%). ESI-MS m / z: [M / 2+H]+1691.42, [M / 3+H]+1128.07.

[1383] Preparation of Compound 2-44

[1384] To a solution of Compound 2-43 (60 mg, 0.018 mmol) in acetonitrile (1 mL) was added phosphoric acid (85%, 1.5 mL) at 0 °C. After stirring at room temperature for 5 hours, the reaction mixture was purified by HPLC to afford Compound 2-44 (37 mg, 67%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1558.64, [M / 3+H]+1039.39.

[1385] -198- FH13329100.6Attorney Docket No.: LCH-04125

[1386] Example 25: Preparation of Compound 2-46

[1387]

[1388] Preparation of Compound 2-45

[1389] -199- FH13329100.6Attorney Docket No.: LCH-04125

[1390] To a solution of Compound 2-14 (1.90 g, 1.38 mmol) in dichloromethane (30 mL) were added Compound 1-8 (1.47 g, 4.62 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC HCl, 609 mg, 6.30 mmol), 1 -hydroxybenzotriazole (HOBt, 448 mg, 3.31 mmol) and / V-methy I morpholine (0.91 mL, 8.28 mmol) under N2. After stirring at room temperature for 12 hours, the reaction mixture was diluted with ethyl acetate (50 mL), washed with saturated aq. NaHCCL solution (30 mL) and saturated aq. NH4CI solution (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 2-45 (1.3 g, 41%) as a colorless oil. ESI-MS m / z: [M+Na]+2330.22.

[1391] Preparation of Compound 2-46

[1392] To a solution of Compound 2-45 (670 mg, 0.29 mmol) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (286 mg, 0.725 mmol) and pyridine (0.093 mL, 1.16 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with dichloromethane (100 mL) and washed with saturated aq. NaHCO3solution (50 mL), aq. 0.5 N HCl solution (50 mL), and aq. 2% NaOH solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-46 (995 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M / 2+H]+1364.73.

[1393] Example 26: Preparation of Compound 2-49

[1394]

[1395] -200- FH13329100.6Attorney Docket No.: LCH-04125

[1396]

[1397] Preparation of Compound 2-47

[1398] To a solution of Compound 2-46 (200 mg, 0.07 mmol) and Monomethyl auristatin F methyl ester (MMAF-OMe,109 mg, 0.15 mmol) in / V. / V-dimethylformamide (3 mL) were added

[1399] -201- FH13329100.6Attorney Docket No.: LCH-04125

[1400] l-hydroxy-7-azabenzotriazole (HO At, 3 mg, 0.02 mmol) and A, A-di isopropylethylamine (0.1 mL, 0.59 mmol) at 0 °C under N2. The reaction mixture was warmed to room temperature and stirred for 12 hours. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (20 mL), distilled water (20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-47 (220 mg, 78%) as a white solid. ESI-MS m / z: [M / 3+H]+1285.75.

[1401] Preparation of Compound 2-48

[1402] To a solution of Compound 2-47 (220 mg, 0.06 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (24 mg, 0.57 mmol) in water (1 mL) at -78 °C. After stirring at -5 °C for 6 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-48 (140 mg, 69%) as a white solid. ESI-MS m / z: [M / 3+H]+1183.02.

[1403] Preparation of Compound 2-49

[1404] To a solution of Compound 2-48 (140 mg, 0.04 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.3 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-49 (65 mg, 49%) as a white solid. ESI-MS m / z: [M / 3+H]+1130.82.

[1405] -202- FH13329100.6Attorney Docket No.: LCH-04125

[1406] Example 27: Preparation of Compound 2-52

[1407]

[1408] -203- FH13329100.6Attorney Docket No.: LCH-04125

[1409]

[1410] Preparation of Compound 2-50

[1411] To a solution of Compound 2-46 (100 mg, 0.04 mmol) and Monomethyl auristatin E (MMAE, 57 mg, 0.08 mmol) in A. A-dimethylformamide (5 mL) were added l-hydroxy-7-azabenzotriazole (HOAt, 1 mg, 0.01 mmol) and N, / V-di isopropylethylamine (0.1 mL, 0.4 mmol) at 0 °C under N2. After stirring at room temperature for 20 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (30 mL), distilled water (30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-50 (160 mg, quant.) as a white solid, which was used for the next step without further purification. ESI-MS m / z:

[1412] [M / 3+H]+1267.240.

[1413] Preparation of Compound 2-51

[1414] To a solution of Compound 2-50 (160 mg, 0.04 mmol) in tetrahydrofuran (1 mL) and methanol (0.5 mL) was added lithium hydroxide monohydrate (17 mg, 0.42 mmol) in water (4 mL) at -78 °C. The reaction mixture was stirred at -5 °C for 5 hours. The reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-51 (91 mg, 61%) as a white solid. ESI-MS m / z:

[1415] [M / 3+H]+1173.445.

[1416] Preparation of Compound 2-52

[1417] To a solution of Compound 2-51 (88 mg, 0.03 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.6 mL) at 0 °C. The reaction mixture was stirred at room temperature

[1418] -204- FH13329100.6Attorney Docket No.: LCH-04125

[1419] for 5 hours and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-52 (23 mg, 27%) as a white solid. ESI-MS m / z: [M / 3+H]+1121.674.

[1420] Example 28: Preparation of Compound 2-57

[1421]

[1422] 2-56 2-57

[1423] Preparation of Compound 2-53

[1424] To a solution of (2S)-2-bromopropanoic acid (2 g, 13.1 mmol) and benzyl alcohol (1.5 mL, 14.4 mmol) in toluene (4 mL) was added -toluenesulfonic acid hydrate (56 mg, 0.29 mmol). After stirring at 100 °C for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NaHCO3solution (30 mL), distilled water (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-53 (2.9 g, 91%). ’H-NMR (400 MHz, CDCl3) 87.41-7.35 (m, 5H), 5.21 (d, J = 3.8 Hz, 2H), 4.47-4.36 (m, 1H), 1.85 (d, 3H).

[1425] Preparation of Compound 2-54

[1426] To a solution of A-Boc-hydroxylamine (350 mg, 2.63 mmol) in A. A-dimethylformamide (3 mL) were added potassium carbonate (0.38 g, 2.76 mmol) and Compound 2-53 (0.67 g, 2.76 mmol). After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (30 mL), distilled water (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-54 (350 mg, 45%). ESI-MS m / z: [M+Na]+318.30, [(M-Boc)+H]+196.26. 'H-NMR (400 MHz, CDCl3) 87.56 (d, 1H), 7.40-7.34 (m, 5H), 5.26-5.13 (m, 2H), 4.58-4.48 (m, 1H), 1.48 (d, J = 2.3 Hz, 12H).

[1427] -205- FH13329100.6Attorney Docket No.: LCH-04125

[1428] Preparation of Compound 2-55

[1429] To a solution of Compound 2-54 (350 mg, 1.19 mmol) in methanol (8 mL) were added palladium / charcoal (10 wt. %, 70 mg) under hydrogen atmosphere. After stirring at room temperature for 3 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-55 (243 mg, quant.). ESI-MS m / z: [M+Na]+228.24.

[1430] Preparation of Compound 2-56

[1431] To a solution of Compound 2-55 (256 mg, 1.25 mmol) in A, A-di methylformamide (5 mL) were added Compound 1-5 (150 mg, 1.15 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 568 mg, 1.50 mmol), and N, / V-di isopropylethylamine (0.4 mL, 2.31 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (30 mL), saturated aq. NaHCO3solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-56 (229 mg, 63%). ESI-MS m / z: [M+Na]+340.31. ’H- NMR (400 MHz, CDCl3) 87.66 (s, 1H), 7.42 (s, 1H), 4.35-4.27 (m, 1H), 3.70-3.56 (m, 4H), 3.55-3.35 (m, 4H), 1.55-1.41 (m, 12H).

[1432] Preparation of Compound 2-57

[1433] To a solution of Compound 2-56 (229 mg, 0.72 mmol) in tetrahydrofuran (7 mL) were added triphenylphosphine (208 mg, 0.79 mmol) and distilled water (0.26 mL, 14.4 mmol) at 0 °C under N2. After stirring at 60 °C for 3 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-57 (157 mg, 75%). ESI-MS m / z: [M+H]+292.35.1H-NMR (400 MHz, CDCl3) 87.69-7.64 (m, 1H), 4.32 (q, J = 6.5 Hz, 1H), 3.64-3.51 (m, 5H), 3.41 (s, 1H), 2.91 (d, J = 5.6 Hz, 2H), 1.51-1.41 (m, 12H).

[1434] -206- FH13329100.6Attorney Docket No.: LCH-04125

[1435] Example 29: Preparation of Compound 2-62

[1436]

[1437] -207- FH13329100.6Attorney Docket No.: LCH-04125

[1438]

[1439] Preparation of Compound 2-58

[1440] To a solution of Compound 2-57 (250 mg, 0.18 mmol) in A, A-di methylformamide (5 mL) were added Compound 2-12 (59 mg, 0.20 mmol), A, A, A’, A’-tetramethyLO-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU, 83.8 mg, 0.22 mmol), and A. A-diisopropylethylamine (0.08 mL, 0.72 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (20 mL) and washed with saturated aq. NH4CI solution (20 mL), saturated aq. NaHCO₃ solution (20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-58 (240 mg, 80%). ESI-MS m / z: [M+Na]+1653.79.

[1441] Preparation of Compound 2-59

[1442] To a solution of Compound 2-58 (240 mg, 0.15 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 50 mg) under hydrogen atmosphere. After stirring at room temperature for 1 hour, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-59 (200 mg, quant.) as a colorless oil. ESI-MS m / z:

[1443] [M+H]+1362.85.

[1444] Preparation of Compound 2-60

[1445] To a solution of Compound 2-18 (297 mg, 0.31 mmol) in A, A-di methylformamide (4 mL) were added Compound 2-59 (204 mg, 0.15 mmol), A, A, A’, A’-tetramethyLO-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU, 142 mg, 0.37 mmol), and A, A-diisopropylethylamine

[1446] -208- FH13329100.6Attorney Docket No.: LCH-04125

[1447] (0.13 mL, 0.75 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted under reduced pressure. The resulting residue was purified by reverse phase column chromatography to afford Compound 2-60 (430 mg, 89%) as a yellow solid. ESI-MS m / z:

[1448] [M / 3+H]+1073.66.

[1449] Preparation of Compound 2-61

[1450] To a solution of Compound 2-60 (430 mg, 0.13 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (24 mg, 0.57 mmol) in water (1 mL) at -78 °C. After stirring at -5 °C for 6 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-61 (68 mg, 17%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1469.86.

[1451] Preparation of Compound 2-62

[1452] To a solution of Compound 2-61 (68 mg, 0.02 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-62 (57 mg, 85%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1391.79.

[1453] Example 30: Preparation of Compound 2-66

[1454]

[1455] 2-65 2-66

[1456] Preparation of Compound 2-63

[1457] To a solution of A-Boc-hydroxylamine (500 mg, 3.75 mmol) in A. A-dimethylformamide (10 mL) were added ethyl 1 -bromocyclobutanecarboxylate (0.58 mL, 3.75 mmol) and potassium carbonate (545 mg, 3.94 mmol). After stirring at room temperature for 16 hours under N2, ethyl 1-bromocyclobutanecarboxylate (1.16 mL, 7.50 mmol) was additionally added to the reaction mixture and stirred at 60 °C for 24 hours. Then the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL), and brine (50 mL). The organic layer was dried

[1458] -209- FH13329100.6Attorney Docket No.: LCH-04125

[1459] over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-63 (500 mg, 51%). 'H-NMR (400 MHz, CDCl3) 87.48 (s, 1H), 4.25 (q, J = 7.2 Hz, 2H), 2.50-2.33 (m, 4H), 2.19-2.07 (m, 1H), 2.03-1.90 (m, 1H), 1.49 (s, 9H), 1.33 (t, J = 7.1 Hz, 3H).

[1460] Preparation of Compound 2-64

[1461] To a solution of Compound 2-63 (500 mg, 1.93 mmol) in tetrahydrofuran / methanol (5 mL / 5 mL) was added lithium hydroxide monohydrate (243 mg, 5.78 mmol) in distilled water (5 mL) at 0 °C under N2. After stirring at room temperature for 6 hours, the reaction mixture was adjusted to pH 3 with aq. 1 M HC1 solution and extracted with ethyl acetate (20 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure to afford Compound 2-64 (430 mg, crude), which was used for the next step without further purification. ESI-MS m / z: [M+Na]+254.31.

[1462] Preparation of Compound 2-65

[1463] To a solution of Compound 2-64 (430 mg, 1.86 mmol) and Compound 1-5 (220 mg, 1.69 mmol) in A. A-dimethylformamide (10 mL) were added A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 833 mg, 2.20 mmol) and N, N-diisopropylethylamine (0.88 mL, 5.07 mmol) at 0 °C. After stirring at room temperature for 18 hours under N2, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. After concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-65 (496 mg, 85%). ESI-MS m / z: [M+H]+344.39, [M+Na]+366.38.

[1464] Preparation of Compound 2-66

[1465] To a solution of Compound 2-65 (496 mg, 1.44 mmol) in tetrahydrofuran (5 mL) was added triphenylphosphine (416 mg, 1.59 mmol) at room temperature. After stirring for 30 minutes under N2, distilled water (0.52 mL, 28.89 mmol) was added thereto and the reaction mixture was refluxed for 4 hours. Then the reaction mixture was concentrated and purified by column chromatography to afford Compound 2-66 (415 mg, 90%). ESI-MS m / z: [M+H]+318.39.

[1466] -210- FH13329100.6Attorney Docket No.: LCH-04125

[1467] Example 31: Preparation of Compound 2-71

[1468]

[1469] -211- FH13329100.6Attorney Docket No.: LCH-04125

[1470]

[1471] Preparation of Compound 2-67

[1472] To a solution of Compound 2-12 (49 mg, 0.15 mmol) and Compound 2-66 (190 mg, 0.14 mmol) in N, / V-di methylformamide (5 mL) were added A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 69 mg, 0.180 mmol) and N, N- diisopropylethylamine (0.059 mL, 0.42 mmol) at 0 °C. After stirring at room temperature for 3 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-67 (214 mg, 92%). ESI-MS m / z: [M+H]+1658.50, [M / 2+H]+829.59.

[1473] Preparation of Compound 2-68

[1474] To a solution of Compound 2-67 (214 mg, 0.13 mmol) in methanol (3 mL) was added palladium / charcoal (10 wt. %, 40 mg). After stirring at room temperature for 3 hours under hydrogen atmosphere, the reaction mixture was filtered through a celite pad and washed with methanol (100 mL). The filtrate was concentrated to afford Compound 2-68 (170 mg), which was used for the next step without further purification. ESI-MS m / z: [M+H]+1389.25, [M / 2+H]+695.42.

[1475] Preparation of Compound 2-69

[1476] To a solution of Compound 2-68 (90 mg, 0.065 mmol) and Compound 2-18 (128 mg, 0.14

[1477] -212- FH13329100.6Attorney Docket No.: LCH-04125

[1478] mmol) in / V, / V-di methylformamide (3 mL) were added M / V. / V’. A’-tetramethyl-O-f I / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 56 mg, 0.150 mmol) and N, N-diisopropylethylamine (0.045 mL, 0.26 mmol) at 0 °C. After stirring at room temperature for 18 hours under N2, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-69 (198 mg, 94%). ES MS m / z: [M / 2+H]+1623.54, [M / 3+H]+1082.69.

[1479] Preparation of Compound 2-70

[1480] To a solution of Compound 2-69 (198 mg, 0.061 mmol) in tetrahydrofuran / methanol (1.5 mL / 1.5 mL) was added lithium hydroxide monohydrate (20 mg, 0.49 mmol) in distilled water (1.5 mL) at -50 °C under N2. The reaction mixture was warmed to 0 °C and kept for 3 hours at this temperature. Then the reaction mixture was neutralized with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-70 (91 mg, 50%). ESI-MS m / z: [M / 2+H]+1483.23.

[1481] Preparation of Compound 2-71

[1482] To a solution of Compound 2-70 (91 mg, 0.031 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-71 (38 mg, 44%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1405.19, [M / 3+H]+937.17.

[1483] Example 32: Preparation of Compound 2-75

[1484]

[1485] Preparation of Compound 2-72

[1486] To a solution of Compound 1-1 (1 g, 4.04 mmol) in diethyl ether (30 mL) was added

[1487] -213- FH13329100.6Attorney Docket No.: LCH-04125

[1488] lithium aluminum hydride (1.0 M in tetrahydrofuran, 8.08 mL, 8.08 mmol) at 0 °C under N2. After stirring at 0 °C for 3 hours, the reaction mixture was quenched with distilled water (1 mL). The suspension was filtered through a celite pad and washed with diethyl ether (30 mL). The filtrate was concentrated under reduced pressure to afford Compound 2-72 (700 mg, 84%), which was used for the next step without further purification. 'H-NMR (400 MHz, CDCl3) 83.40 (d, J = 7.2 Hz, 2H), 1.48 (s, 9H), 1.20 (s, 6H).

[1489] Preparation of Compound 2-73

[1490] To a solution of Compound 2-72 (600 mg, 2.92 mmol) in tetrahydrofuran (5 mL) was added sodium hydride (60% dispersion in mineral oil, 1.09 g, 45.56 mmol) at 0 °C. After stirring at 0 °C for 30 minutes, 2-(2-azidoethoxy)ethyl 4-methylbenzenesulfonate (650 mg, 2.28 mmol) was added to the reaction mixture at room temperature. After stirring for 16 hours, the reaction mixture was quenched with distilled water (5 mL) and extracted to ethyl acetate (30 mL x 4). The organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-73 (970 mg, quant.).

[1491] Preparation of Compound 2-74

[1492] To a solution of Compound 2-73 (970 mg, 2.28 mmol) in tetrahydrofuran (5 mL) were added triphenylphosphine (787 mg, 3.0 mmol) and distilled water (0.41 mL, 22.8 mmol) at 0 °C under N2. The reaction mixture was stirred at 60 °C for 3 hours and then cooled to room temperature. Benzyl chloroformate (0.42 mL, 2.96 mmol) and A, A-diisopropylethylamine (0.8 mL, 4.56 mmol) were added to the reaction mixture. After stirring for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-74 (210 mg, 22%) as a brown oil. ESI-MS m / z: [M+H]+449.167.1H-NMR (400 MHz, CDCl3) 87.38-7.29 (m, 5H), 5.10 (d, J = 3.2 Hz, 2H), 3.68-3.45 (m, 6H), 3.41 (d, J = 13.1 Hz, 4H), 1.46 (d, J = 3.5 Hz, 9H), 1.21 (s, 6H).

[1493] Preparation of Compound 2-75

[1494] To a solution of Compound 2-74 (210 mg, 0.49 mmol) in methanol (5 mL) was added palladium / charcoal (10 wt. %, 30 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated

[1495] -214- FH13329100.6Attorney Docket No.: LCH-04125

[1496] under reduced pressure to afford Compound 2-75 (136 mg, 94%) as a yellow oil. ESI-MS m / z:

[1497] [M+H]+293.27.

[1498] -215- FH13329100.6Attorney Docket No.: LCH-04125

[1499] Example 33: Preparation of Compound 2-80

[1500]

[1501] -216- FH13329100.6Attorney Docket No.: LCH-04125

[1502]

[1503] Preparation of Compound 2-76

[1504] To a solution of Compound 2-12 (190 mg, 0.14 mmol) in A-di methylformamide (5 mL) were added Compound 2-75 (45 mg, 0.15 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU, 69 mg, 0.18 mmol), and N, / V-di isopropylethyl amine (0.06 mL, 0.42 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was concentrated, diluted with ethyl acetate (20 mL) and washed with saturated aq. NH4CI solution (20 mL), saturated aq. NaHCO₃ solution (20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-76 (140 mg, 61%). ESI-MS m / z: [M+H]+1654.55.

[1505] Preparation of Compound 2-77

[1506] To a solution of Compound 2-76 (140 mg, 0.09 mmol) in methanol (5 mL) were added palladium / charcoal (10 wt. %, 15 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-77 (90 mg, 77%) as a yellow oil. ESI-MS m / z:

[1507] [M+H]+1363.57.

[1508] Preparation of Compound 2-78

[1509] To a solution of Compound 2-77 (90 mg, 0.07 mmol) in A-dimethylformamide (3 mL) were added Compound 2-18 (131 mg, 0.14 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU, 58 mg, 0.15 mmol), and A. A-diisopropylethylamine -217- FH13329100.6Attorney Docket No.: LCH-04125

[1510] (0.06 mL, 0.33 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (30 mL), saturated aq. NaHCCL solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-78 (140 mg, 66%) as an orange oil. ES MS m / z: [M / 2+H]+1610.08.

[1511] Preparation of Compound 2-79

[1512] To a solution of Compound 2-78 (140 mg, 0.04 mmol) in tetrahydrofuran (2 mL) and methanol (2 mL) was added lithium hydroxide monohydrate (14.6 mg, 0.35 mmol) in water (2 mL) at -78 °C. After stirring at -5 °C for 2 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-79 (90 mg, 70%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1469.93.

[1513] Preparation of Compound 2-80

[1514] To a solution of Compound 2-79 (90 mg, 0.03 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 2 mL) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 2-80 (60 mg, 78%) as a yellow solid. ESI-MS m / z: [M / 2+H]+1391.97.

[1515] Example 34: Preparation of Compound 2-82

[1516]

[1517] Preparation of Compound 2-81

[1518] To a solution of Compound 2-3 (6.9 g, 24.5 mmol) in dichloromethane (50 mL) were added A, A-diisopropylethylamine (6.4 mL, 36.7 mmol) and (4-nitrophenyl)-2-trimethylsilylethyl carbonate (7.6 g, 26.9 mmol) at 0 °C. After stirring at room temperature for 16 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq. NH4Cl solution (30 mL x 3) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 2-81 (9 g, 86%). ESI-MS m / z: [M+H]+426.21.

[1519] Preparation of Compound 2-82

[1520] -218- FH13329100.6Attorney Docket No.: LCH-04125

[1521] To a solution of Compound 2-81 (5.59 g, 13.1 mmol) in dichloromethane (50 mL) were added triethylamine (5.5 mL, 39.4 mmol) and p-toluenesulfonyl chloride (3.2 g, 17.0 mmol) at 0 °C. After stirring at room temperature for 5 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with aq. 10% citric acid solution (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 2-82 (7.3 g, 95%). ESI-MS m / z: [M+H]+580.07.

[1522] Example 35: Preparation of Compound 2-84

[1523]

[1524] Preparation of Compound 2-83

[1525] To a solution of pentaethylene glycol (150 g, 629 mmol) in tetrahydrofuran (900 mL) was added potassium terLbutoxide (1.7 M in tetrahydrofuran, 180 mL, 307 mmol) at 0 °C. After stirring at 0 °C for 30 minutes under N2, propargyl bromide (80% in toluene, 34.8 mL, 315 mmol) was added slowly at 0 °C. Then the reaction mixture was gradually warmed to 50 °C. After stirring for 16 hours, the solid was filtered and the filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-83 (57 g, 65%). ESI-MS m / z: [M+H]+277.39, [M+Na]+299.39.

[1526] Preparation of Compound 2-84

[1527] To a solution of Compound 2-83 (57 g, 206 mmol) in dichloromethane (300 mL) were added 4-(dimethylamino)pyridine (DMAP, 5.0 g, 41 mmol) and p-toluenesulfonyl chloride (79 g, 412 mmol). Then triethylamine (58 mL, 412 mmol) was added slowly at 0 °C. The reaction mixture was gradually warmed to room temperature. After stirring for 16 hours, the reaction mixture was diluted with dichloromethane (200 mL) and washed with distilled water (200 mL), and brine (200 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-84 (75 g, 85%). ESI-MS m / z: [M+H]+431.43, [M+Na]+

[1528] -219- FH13329100.6Attorney Docket No.: LCH-04125

[1529] 453.42.

[1530] Example 36: Preparation of Compound 2-86

[1531]

[1532] 2-85 2-86 Preparation of Compound 2-85

[1533] To a solution of 2-bromoethanol (3 g, 24.01 mmol) in distilled water (30 mL) was added sodium azide (4.68 g, 72.02 mmol) at room temperature under N2. After stirring at 80 °C for 16 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-85 (1.75 g, 83%), which was used for the next step without further purification.1H-NMR (400 MHz, CDCl3) 83.92 (s, 2H), 3.55 (s, 2H), 1.99 (bs, 1H).

[1534] Preparation of Compound 2-86

[1535] To a solution of l-bromo-2,3,4-tri-O-acetyl-a-D-glucuronic acid methyl ester (300 mg, 0.76 mmol) in dichloromethane (5 mL) were added 4 A molecular sieve (450 mg), Compound 2-85 (131 mg, 1.51 mmol), and silver (I) carbonate (312 mg, 1.13 mmol) at 0 °C under N2. After stirring at room temperature for 16 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-86 (201 mg, 66%) as a white solid. ’H-NMR (400 MHz, CDCl3) 85.31-5.23 (m, 2H), 5.04 (t, J = 7.6 Hz), 4.65 (d, J = 7.2 Hz, 1H), 4.12-4.03 (m, 2H), 3.76 (s, 3H), 3.75-3.64 (m, 1H), 3.55-3.48 (m, 1H), 3.33-3.24 (m, 1H), 2.05 (s, 3H), 2.02 (s, 6H).

[1536] -220- FH13329100.6Attorney Docket No.: LCH-04125

[1537] Example 37: Preparation of Compound 2-92

[1538]

[1539] Preparation of Compound 2-87

[1540] To a solution of Compound 2-8 (1.2 g, 3.94 mmol) in / V. / V-dimethylfomiamide (15 mL) were added potassium carbonate (3.8 g, 27.6 mmol) and Compound 2-82 (4.57 g, 7.88 mmol) under N2. The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with dichloromethane (30 mL). The organic layer was washed with saturated aq. NH4CI solution (10 mL x 3), saturated aq. NaHCO3solution (10 mL x 3), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 2-87 (4.5 g, quant.). ES MS m / z: [M+H]+1120.10.

[1541] -221- FH13329100.6Attorney Docket No.: LCH-04125

[1542] Preparation of Compound 2-88

[1543] To a solution of Compound 2-87 (3.5 g, 3.12 mmol) in methanol (10 mL) was added palladium / charcoal (10 wt. %, 1.05 g) under hydrogen atmosphere. After stirring at room temperature for 3 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 2-88 (2.5 g, 80%). ESI-MS m / z: [M+H]+1000.20.

[1544] Preparation of Compound 2-89

[1545] To a solution of Compound 2-88 (1.2 g, 1.20 mmol) in A, A-dimethylformamide (15 mL) were added potassium bicarbonate (240 mg, 2.40 mmol) and Compound 2-84 (567 mg, 1.32 mmol) under N2. After stirring at 50 °C for 48 hours, the reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate (30 mL). The organic layer was washed with saturated aq. NH4CI solution (10 mL x 3), saturated aq. NaHCO3solution (10 mL x 3), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 2-89 (1.5 g, 99%). ESI-MS m / z: [M+Na]+1280.00.

[1546] Preparation of Compound 2-90

[1547] To a solution of Compound 2-89 (1.0 g, 0.79 mmol) in tetrahydrofuran (6 mL) was added aq. 1 N NaOH solution (7 mL, 0.795 mmol) at 0 °C under N2. After 7 hours, the reaction mixture was titrated with aq. 1 N HCl solution to pH 3-4 at 0 °C and extracted with dichloromethane (10 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-90 (850 mg, 85%). ESI-MS m / z: [M+Na]+1244.08

[1548] Preparation of Compound 2-91

[1549] To a solution of Compound 2-90 (464 mg, 0.37 mmol) in A-di methylformamide (5 mL) were added Compound 1-7 (228 mg, 0.75 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 212 mg, 0.56 mmol), and A. A-diisopropylethylamine (0.19 mL, 1.12 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (50 mL). The organic layer was washed with saturated aq. NH4CI solution (50 mL), saturated aq. NaHCCL solution (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-91 (570 mg, 99%). ESI-MS m / z: [M+H]+1531.08, [M / 2+H]+765.86.

[1550] -222- FH13329100.6Attorney Docket No.: LCH-04125

[1551] Preparation of Compound 2-92

[1552] To a solution of Compound 2-91 (570 mg, 0.37 mmol) in tetrahydrofuran (10 mL) was added tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 0.93 mL, 0.93 mmol). After stirring at 70 °C for 16 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by reverse phase column chromatography to afford Compound 2-92 (240 mg, 51%). ESI-MS m / z: M+H]+1241.93, [M / 2+H]+621.88.

[1553] -223- FH13329100.6Attorney Docket No.: LCH-04125

[1554] Example 38: Preparation of Compound 2-96

[1555]

[1556] -224- FH13329100.6Attorney Docket No.: LCH-04125

[1557]

[1558] Preparation of Compound 2-93

[1559] To a solution of Compound 2-92 (240 mg, 0.19 mmol) in / V-di methylformamide (5 mL) were added Compound 2-18 (402 mg, 0.42 mmol), A, A, A’, A’-tetramethyl-O-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU, 183 mg, 0.48 mmol), and A, A-di isopropylethylamine (0.16 mL, 0.97 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (30 mL), saturated aq. NaHCCh solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-93 (574 mg, 95%)

[1560] -225- FH13329100.6Attorney Docket No.: LCH-04125

[1561] as a brown oil. ESI-MS m / z: [M / 2+H]+1548.78, [M / 3+H]+1033.22.

[1562] Preparation of Compound 2-94

[1563] To a solution of Compound 2-93 (574 mg, 0.18 mmol) in methanol (4 mL) and tetrahydrofuran (5 mL) was added lithium hydroxide monohydrate (62 mg, 1.48 mmol) in distilled water (5 mL) at -50 °C. After stirring for 2 hours at 0 °C, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-94 (125 mg, 24%). ES MS m / z: [M / 2+H]+1408.89, [M / 3+H]+906.28.

[1564] Preparation of Compound 2-95

[1565] To a solution of Compound 2-94 (125 mg, 0.04 mmol) and Compound 2-86 (36 mg, 0.09 mmol), tris(3-hydroxypropyltriazolymethyl)amine (THPTA, 7 mg, 0.05 mmol) in ethanol (2.5 mL) were added copper (II) sulfate pentahydrate (10.8 mg, 0.04 mmol) in distilled water (1.2 mL), and sodium L-ascorbate (16.1 mg, 0.08 mmol) in distilled water (1.2 mL) under N2. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was dissolved in methanol (1 mL) and tetrahydrofuran (2 mL) was added lithium hydroxide monohydrate (9.3 mg, 0.22 mmol) in distilled water (1 mL) at -50 °C. After stirring for 2 hours at 0 °C, the reaction mixture was adjusted to pH 4-5 with acetic acid. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-95 (51.8 mg, 37% for 2 steps). ESI-MS m / z: [M / 2+H]+1540.91, [M / 3+H]+1027.30.

[1566] Preparation of Compound 2-96

[1567] To a solution of Compound 2-95 (51.4 mg, 0.017 mmol) in acetonitrile (1.5 mL) was added phosphoric acid (85%, 0.95 mL) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-96 (28.8 mg, 49%). ESIMS m / z: [M / 2+H]+1615.50, [M / 3+H]+1077.11.

[1568] -226- FH13329100.6Attorney Docket No.: LCH-04125

[1569] Example 39: Preparation of Compound 2-99

[1570]

[1571] -227- FH13329100.6Attorney Docket No.: LCH-04125

[1572]

[1573] Preparation of Compound 2-97

[1574] To a solution of Compound 2-46 (204 mg, 0.07 mmol) in / V-dimethylforiTiamide (3 mL) were added DXd2 (99 mg, 0.15 mmol; prepared by the method described in US Patent No.

[1575] 10,117,952 B2) and A. A-diisopropylethylamine (0.05 mL, 0.29 mmol) under N2. After stirring at room temperature for 4 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4CI solution (10 mL), distilled water (10 mL), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-97 (254 mg, crude). ESI-MS m / z:

[1576] [M / 2+H]+1702.09, [M / 3+H]+1135.05.

[1577] Preparation of Compound 2-98

[1578] To a solution of Compound 2-97 (254 mg, crude) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (25 mg, 0.59 mmol) in water (1 mL) at -78 °C. The reaction mixture was stirred at -5 °C for 4 hours. The reaction mixture was adjusted to pH 4- 5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-98 (80 mg, 34% in 2 steps) as a yellow solid. ESI-MS m / z: [M / 2+H]+1561.83, [M / 3+H]+1041.60.

[1579] Preparation of Compound 2-99

[1580] To a solution of Compound 2-98 (80 mg, 0.03 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 0.4 mL) at 0 °C. After stirring at room temperature for 5 hours, the reaction

[1581] -228- FH13329100.6Attorney Docket No.: LCH-04125

[1582] mixture was purified by HPLC to afford Compound 2-99 (53 mg, 70%) as a yellow solid. ESIMS m / z: [M / 2+H]+1483.60, [M / 3+H]+989.53.

[1583] -229- FH13329100.6Attorney Docket No.: LCH-04125

[1584] Example 40: Preparation of Compound 2-103

[1585]

[1586] -230- FH13329100.6Attorney Docket No.: LCH-04125

[1587]

[1588] Preparation of Compound 2-101

[1589] To a solution of Compound 2-46 (140 mg, 0.05 mmol) and Compound 2-100 (76.5 mg, 0.11 mmol; prepared by the method described in WO 2023 / 209441 Al) in N, N-dimethylformamide (5 mL) were added l-hydroxy-7-azabenzotriazole (HOAt, 2.1 mg, 0.02 mmol) and A, A-diisopropylethylamine (0.04 mL, 0.26 mmol) at 0 °C under N2. The reaction mixture was warmed to room temperature and stirred for 12 hours. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NH4CI solution (20 mL), distilled water (20 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-101 (140 mg, 84%) as a white solid. ES MS m / z:

[1590] [M / 3+H]+1087.99.

[1591] Preparation of Compound 2-102

[1592] To a solution of Compound 2-101 (140 mg, 0.04 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (14 mg, 0.34 mmol) in water (1 mL) at -78 °C. After stirring at 0 °C for 3 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-102 (84 mg, 66%) as a white solid. ESI-MS m / z: [M / 3+H]+994.45.

[1593] Preparation of Compound 2-103

[1594] To a solution of Compound 2-102 (84 mg, 0.03 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.3 mL) at 0 °C under N2. After stirring at room temperature for 2 hours,

[1595] -231- FH13329100.6Attorney Docket No.: LCH-04125

[1596] the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-103 (61 mg, 77%) as a white solid. ESI-MS m / z: [M / 3+H]+942.53.

[1597] -232- FH13329100.6Attorney Docket No.: LCH-04125

[1598] Example 41: Preparation of Compound 2-107

[1599]

[1600] -233- FH13329100.6Attorney Docket No.: LCH-04125

[1601]

[1602] Preparation of Compound 2-105

[1603] To a solution of Compound 2-46 (140 mg, 0.05 mmol) in / V. / V-dimethylfomiamide (5 mL) were added Compound 2-104 (68 mg, 0.11 mmol; prepared by the method described in WO 2023 / 209441 Al) and AW-diisopropylethylamine (0.09 mL, 0.51 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4CI solution (10 mL), distilled water (10 mL), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 2-105 (100 mg, 62%) as a colorless oil. ES MS m / z: [M / 2+H]+1558.66, [M / 3+H]+1039.85.

[1604] Preparation of Compound 2-106

[1605] To a solution of Compound 2-105 (100 mg, 0.03 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (13 mg, 0.32 mmol) in water (2 mL) at -78 °C. The reaction mixture was stirred at -5 °C for 2 hours. The reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-106 (36 mg, 39%) as a white solid. ESI-MS m / z:

[1606] [M / 2+H]+1418.67, [M / 3+H]+946.54.

[1607] Preparation of Compound 2-107

[1608] To a solution of Compound 2-106 (36 mg, 0.01 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 1 mL) at 0 °C. After stirring at room temperature for 1 hour, the reaction mixture was purified by HPLC to afford Compound 2-107 (13.6 mg, 40%) as a white solid. ESI- -234- FH13329100.6Attorney Docket No.: LCH-04125 MS m / z: [M / 2+H]+1341.23, [M / 3+H]+894.43.

[1609] -235- FH13329100.6Attorney Docket No.: LCH-04125

[1610] Example 42: Preparation of Compound 2-112

[1611]

[1612] Preparation of Compound 2-109

[1613] -236- FH13329100.6Attorney Docket No.: LCH-04125

[1614] To a solution of Compound 1-33 (320 mg, 0.22 mmol) in dichloromethane (5 mL) were added triphosgene (27 mg, 0.09 mmol) and 1 -methylimidazole (0.05 mL, 0.68 mmol) at 0 °C under N2. After stirring at 0 °C for 30 minutes, Compound 2-108 (411 mg, 0.45 mmol; prepared by the method described in US Patent No. 11,654,197 B2) was added to the reaction mixture at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with saturated aq. sodium bicarbonate solution (20 mL) and distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-109 (237 mg, 53%). ESI-MS m / z: [M+H]+1941.61.

[1615] Preparation of Compound 2-110

[1616] To a solution of Compound 2-109 (237 mg, 0.12 mmol) in tetrahydrofuran (1 mL) and water (1 mL) was added acetic acid (1 mL) at 0 °C under N2. After stirring at room temperature for 20 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. sodium bicarbonate solution (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-110 (151 mg, 72%). ESI-MS m / z:

[1617] [M+H]+1713.42

[1618] Preparation of Compound 2-111

[1619] To a solution of Compound 2-110 (151 mg, 0.08 mmol) in dichloromethane (3 mL) was added Dess-Martin periodinane (82 mg, 0.19 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with dichloromethane (30 mL) and washed with saturated aq. sodium bicarbonate solution (10 mL) and distilled water (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-111 (148 mg, 98%). ESI-MS m / z: [M+H]+1710.26.

[1620] Preparation of Compound 2-112

[1621] To a solution of Compound 2-111 (148 mg, 0.08 mmol) in tetrahydrofuran (1 mL) and methanol (0.5 mL) was added lithium hydroxide monohydrate (25 mg, 0.60 mmol) in water (1.5 mL) at -78 °C. After stirring at 0 °C for 3 hours, the reaction mixture was adjusted to pH 4-5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC

[1622] -237- FH13329100.6Attorney Docket No.: LCH-04125 to afford Compound 2-112 (53 mg, 42%). ESI-MS m / z: [M+H]+1678.20.

[1623] -238- FH13329100.6Attorney Docket No.: LCH-04125

[1624] Example 43: Preparation of Compound 2-114

[1625]

[1626] Preparation of Compound 2-113

[1627] -239- FH13329100.6Attorney Docket No.: LCH-04125

[1628] To a solution of Compound 2-112 (50 mg, 0.03 mmol) and Compound 2-35 (24 mg, 0.01 mmol) in ethanol (3.5 mL) were added tris(3-hydroxypropyltriazolymethyl)amine (THPTA, 4.45 mg, 0.008 mmol), copper (II) sulfate pentahydrate (12 mg, 0.05 mmol), and sodium L-ascorbate (13 mg, 0.06 mmol) in distilled water (0.5 mL) under N2. After stirring at room temperature for 2 hours, the reaction mixture was purified by HPLC to afford Compound 2-113 (49 mg, 68%). ESIMS m / z: [M / 3+H]+1429.30.

[1629] Preparation of Compound 2-114

[1630] To a solution of Compound 2-113 (49 mg, 0.01 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.2 mL) at 0 °C under N2. After stirring at room temperature for 1 hour, the reaction mixture was purified by HPLC to afford Compound 2-114 (21 mg, 44%). ESI-MS m / z: [M / 4+H+] 1033.65.

[1631] Example 44: Preparation of Compound 2-116

[1632]

[1633] Preparation of Compound 2-115

[1634] To a solution of Compound 2-6 (1 g, 2.44 mmol) in dichloromethane (22 mL) was added Dess-Martin periodinane (1.55 g, 3.65 mmol) under N2. After stirring at room temperature for 16 hours, saturated aq. sodium thiosulfate pentahydrate solution (10 mL) and saturated aq. NaHCCL solution (20 mL) were added to the reaction mixture. The reaction mixture was stirred until the solid completely dissolved. The resulting mixture was diluted with dichloromethane (40 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 2-115 (876 mg, 88%). ESI-MS m / z: [(M-tBu)+H]+353.47, [M+Na]+431.52. ‘H-NMR (400 MHz, CDCl3) 89.74 (s, 1H), 4.17 (s, 1H), 3.78-3.56 (m, 23H),

[1635] -240- FH13329100.6Attorney Docket No.: LCH-04125

[1636] 2.50 (t, J = 6.8 Hz, 2H), 1.46 (s, 9H).

[1637] Preparation of Compound 2-116

[1638] To a solution of 3-azido-l-propanamine hydrochloride (100 mg, 0.73 mmol) in 1,2-dichloroethane (10 mL) were added / V. / V-diisopropylethylamine (0.12 mL, 0.73 mmol), Compound 2-115 (876 mg, 2.14 mmol) and sodium triacetoxyborohydride (388 mg, 1.83 mmol) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with dichloromethane (40 mL) and washed with 1 N aq. NaOH solution (25 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford Compound 2-116 (637 mg, 98%). ESI-MS m / z: [M+H]+886.13.1H NMR (400 MHz, CDCl3) 83.72 (t, J = 13.2 Hz, 4H), 3.68-3.58 (m, 40H), 3.48 (t, J = 5.2 Hz, 4H), 3.33 (t, J = 6.8 Hz, 2H), 2.72 (t, J = 6.0 Hz, 4H), 2.61 (t, J = 6.8 Hz, 2H), 2.52 (t, J = 13.2 Hz, 4H), 1.73 (t, J = 6.8 Hz, 2H), 1.45 (s, 18H).

[1639] -241- FH13329100.6Attorney Docket No.: LCH-04125

[1640] Example 45: Preparation of Compound 2-125

[1641]

[1642] -242- FH13329100.6Attorney Docket No.: LCH-04125

[1643]

[1644] Preparation of Compound 2-117

[1645] To a solution of 2-[2-(2-azidoethoxy)ethoxy]ethanol (10 g, 57.08 mmol) in dichloromethane (250 mL) were added triethylamine (24.1 mL, 171.2 mmol) and a solution of p-toluenesulfonyl chloride (16.3 g, 85.6 mmol) in dichloromethane (200 mL) at 0 °C. The reaction mixture was gradually warmed to room temperature and stirred for 16 hours. The reaction mixture was diluted with dichloromethane (200 mL) and washed with distilled water (200 mL), and brine (200 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 2-117 (18 g, 95%). ESI-MS m / z: [M+Na]+352.05.

[1646] Preparation of Compound 2-118

[1647] To a solution of Compound 2-8 (7.6 g, 24.98 mmol) in / V. / V-dimethylformamide (60 mL) were added potassium iodide (207 mg, 1.25 mmol), cesium carbonate (20.3 g, 62.4 mmol), and Compound 2-117 (18.1 g, 54.9 mmol) in / V. / V-dimethylformamide (10 mL). After stirring at 50 °C for 4 hours under N2, the reaction mixture was diluted with ethyl acetate (500 mL) and washed with water (200 mL), and brine (200 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-118 (15.2 g, 98%). ‘H-NMR (400 MHz, CDCl3) 87.41 (d, J = 8.4 Hz, 2H), 7.29 (s, 2H), 6.89-6.82 (m, 2H), 5.06 (s, 2H), 4.18 (t, J = 4.8 Hz, 4H), 3.91-3.84 (m, 3H), 3.80 (s, 3H), 3.74 (dd, J = 5.8, 3.4 Hz, 4H), 3.69-3.58 (m, 8H), 3.34 (t, J = 5.1 Hz, 4H).

[1648] Preparation of Compound 2-119

[1649] -243- FH13329100.6Attorney Docket No.: LCH-04125

[1650] To a solution of Compound 2-118 (15.2 g, 24.6 mmol) in dichloromethane (100 mL) were added anisole (40 mL, 368 mmol) and trifluoroacetic acid (9.4 mL, 122.9 mmol) at 0 °C. After stirring at room temperature for 2 hours under N2, the reaction mixture was concentrated under reduced pressure and purified by column chromatography to afford Compound 2-119 (10 g, 81%).1H-NMR (400 MHz, CDCl3) 87.37 (s, 2H), 4.24 (t, J = 4.7 Hz, 4H), 3.88 (s, 6H), 3.77-3.74 (m, 4H), 3.72-3.66 (m, 10H), 3.40 (t, J = 5.0 Hz, 4H).

[1651] Preparation of Compound 2-120

[1652] To a solution of Compound 2-119 (1 g, 2.00 mmol) in A, A-di methylformamide (10 mL) were added cesium carbonate (1.31 g, 4.01 mmol), potassium iodide (3.33 mg, 0.02 mmol) and Compound 2-84 (1.04 g, 2.41 mmol) under N2. After stirring at room temperature for 48 hours, the reaction mixture was diluted with ethyl acetate (60 mL). The organic layer was washed with saturated aq. NH4CI solution (30 mL x 2) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography to afford Compound 2-120 (1.08 g, 71%) as a pale yellow oil. ESI-MS m / z:

[1653] [M+H]+757.83, [M+Na]+779.81.1H-NMR (400 MHz, CDCl3) 87.30 (s, 2H), 4.24-4.18 (m, 8H), 3.90-3.86 (m, 7H), 3.80 (t, J = 5.2 Hz, 2H), 3.76-3.70 (m, 5H), 3.70-3.62 (m, 25H), 3.39 (t, J = 5.2 Hz, 4H), 2.44 (t, J = 2.0 Hz, 1H).

[1654] Preparation of Compound 2-121

[1655] To a solution of Compound 2-120 (1.08 g, 1.43 mmol) in tetrahydrofuran / methanol (5 mL / 2 mL) was added aq. 1 N NaOH solution (2.85 mL, 2.85 mmol) at 24 °C under N2. After 3 hours, the reaction mixture was titrated with aq. 3 N HO solution to pH 3-4 and extracted with dichloromethane (40 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-121 (1.07 g, quant.) as a pale yellow oil, which was used for the next step without further purification. ESI-MS m / z: [M+H]+743.73. 'H-NMR (400 MHz, CDCl3) 87.36 (s, 2H), 4.25 (t, J = 4.8 Hz, 2H), 4.24-4.19 (m, 6H), 3.89 (t, J = 4.8 Hz, 4H), 3.80 (t, J = 5.2 Hz, 2H), 3.76-3.73 (m, 4 H), 3.72-3.67 (m, 15H), 3.65 (s, 4H), 3.63-3.61 (m, 6H), 3.39 (t, J= 3.2 Hz, 4H), 2.44 (t, J= 2.0 Hz, 1H).

[1656] Preparation of Compound 2-122

[1657] To a solution of Compound 2-121 (1.07 g, 1.44 mmol) in N, A-di isopropylethyl amine (10 mL) were added Compound 1-7 (0.66 g, 2.16 mmol), A, A, A’, A’-tetramethyLO-(lH-benzotriazol-

[1658] -244- FH13329100.6Attorney Docket No.: LCH-04125

[1659] 1-yl)uronium hexafluorophosphate (HBTU, 0.87 g, 2.30 mmol), and / V. / V-di isopropylethylamine (0.75 mL, 4.32 mmol) under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4CI solution (30 mL x 2), saturated aq. NaHCO3solution (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-122 (1.48 g, quant.) as a pale yellow oil. ESI-MS m / z: [M+H]+1031.28.

[1660] Preparation of Compound 2-123

[1661] To a solution of Compound 2-122 (1.48 g, 1.44 mmol) in tetrahydrofuran (15 mL) were added triphenylphosphine (942 mg, 3.59 mmol) and distilled water (1.03 mL, 57.47 mmol) at 0 °C under N2. After stirring at 70 °C for 23 hours, the reaction mixture was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 2-123 (1 g, 71%) as a pale yellow oil. ESI-MS m / z: [M+H]+979.29, [M / 2+H]+490.30.

[1662] Preparation of Compound 2-124

[1663] To a solution of Compound 2-123 (300 mg, 0.31 mmol) in dichloromethane (150 mL) were added Compound 1-8 (371 mg, 0.77 mmol), A, A, A’, A’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 291 mg, 0.77 mmol), and A. A-diisopropylethylamine (0.16 mL, 0.92 mmol) under N2. After stirring at room temperature for 14 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4CI solution (30 mL x 2), saturated aq. NaHCO3solution (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2-124 (431 mg, 73%) as a white solid. ESI-MS m / z: [M / 2+H]+956.85.

[1664] Preparation of Compound 2-125

[1665] To a solution of Compound 2-124 (431 mg, 0.22 mmol) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (222 mg, 0.56 mmol) and pyridine (0.07 mL, 0.90 mmol) at 0 °C under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NaHCCh solution (30 mL), saturated aq. NH4CI solution (30 mL), and aq. 0.5% NaOH solution (30 mL x 3). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-125 (487 mg, crude), which was used for the next step without further

[1666] -245- FH13329100.6Attorney Docket No.: LCH-04125 purification. ESI-MS m / z: [M / 2+H]+1167.19.

[1667] -246- FH13329100.6Attorney Docket No.: LCH-04125

[1668] Example 46: Preparation of Compound 2-129

[1669]

[1670] -247- FH13329100.6Attorney Docket No.: LCH-04125

[1671]

[1672] Preparation of Compound 2-126

[1673] To a solution of Compound 2-125 (120 mg, 0.05 mmol) and exatecan mesylate (60 mg, 0.11 mmol) in / V. / V-dimethylformamide (5 mL) were added / V. / V-di isopropylethylamine (0.04 mL, 0.34 mmol) at 0 °C under N2. The reaction mixture was warmed to room temperature and stirred

[1674] -248- FH13329100.6Attorney Docket No.: LCH-04125

[1675] for 2 hours. The reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq. NH4CI solution (20 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-126 (146 mg, crude) as a yellow foam solid, which was used for the next step without further purification. ESI-MS m / z: [M / 2+H]+1491.05, [(M-Boc) / 3+H]+912.73.

[1676] Preparation of Compound 2-127

[1677] To a solution of Compound 2-126 (146 mg, 0.05 mmol) in tetrahydrofuran / methanol (2 mL / 1.5 mL) was added lithium hydroxide monohydrate (17 mg, 0.41 mmol) in water (3 mL) at -60 °C under N2. The reaction mixture was slowly warmed to 5 °C for 2 hours. Then, the reaction mixture was adjusted to pH ~6 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-127 (57.8 mg, 43% for 2 steps). ESI-MS m / z: [M / 2+H]+1278.31, [(M-Boc) / 3+H]+819.19.

[1678] Preparation of Compound 2-128

[1679] To a solution of Compound 2-127 (57.8 mg, 0.02 mmol) and Compound 2-116 (30 mg, 0.03 mmol) in dimethyl sulfoxide (3 mL) were added copper (II) sulfate pentahydrate (4.52 mg, 0.02 mmol) in distilled water (0.5 mL), and sodium L-ascorbate (6.72 mg, 0.03 mmol) in distilled water (0.5 mL). After stirring at room temperature for 1 hour under N2, the reaction mixture was purified by HPLC to afford Compound 2-128 (56.9 mg, 73%) as a yellow solid. ESI-MS m / z:

[1680] [M / 3+H]+1147.66.

[1681] Preparation of Compound 2-129

[1682] To a solution of Compound 2-128 (56.9 mg, 0.017 mmol) in acetonitrile (2 mL) was added phosphoric acid (85%, 4 mL) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was purified by HPLC to afford Compound 2-129 (46.5 mg, 87%) as a yellow solid. ESL MS m / z: [M / 2+H]+1615.50, [M / 3+H]+1077.11.

[1683] -249- FH13329100.6Attorney Docket No.: LCH-04125

[1684] Example 47: Preparation of Compound 2-133

[1685]

[1686] -250- FH13329100.6Attorney Docket No.: LCH-04125

[1687]

[1688] Preparation of Compound 2-130

[1689] To a solution of Compound 2-125 (150 mg, 0.06 mmol) and Compound 2-100 (96 mg, 0.14 mmol) in N, / V-dimethylformamide (5 mL) were added / V. / V-di isopropylethylamine (0.056 mL, 0.32 mmol) at 0 °C under N2. The reaction mixture was warmed to room temperature and stirred for 16 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with -251- FH13329100.6Attorney Docket No.: LCH-04125

[1690] saturated aq. NH4CI solution (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-130 (184 mg, crude) as a white foam solid, which was used for the next step without further purification. ESI-MS m / z: [M / 2+H]+1433.33, [(M-Boc) / 3+H]+922.18.

[1691] Preparation of Compound 2-131

[1692] To a solution of Compound 2-130 (184 mg, 0.06 mmol) in tetrahydrofuran / methanol (2 mL / 2 mL) was added lithium hydroxide monohydrate (22 mg, 0.51 mmol) in water (3 mL) at -60 °C under N2. The reaction mixture was slowly warmed to 5 °C for 2 hours. Then, the reaction mixture was adjusted to pH ~6 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-131 (44.5 mg, 26% for 2 steps). ESI-MS m / z: [M / 2+H]+1292.59, [(M-Boc) / 3+H]+828.64.

[1693] Preparation of Compound 2-132

[1694] To a solution of Compound 2-131 (44.5 mg, 0.017 mmol) and Compound 2-116 (30 mg, 0.03 mmol) in dimethyl sulfoxide (3 mL) were added copper (II) sulfate pentahydrate (3.44 mg, 0.01 mmol) in distilled water (0.3 mL), and sodium L-ascorbate (5.12 mg, 0.03 mmol) in distilled water (0.3 mL). After stirring at room temperature for 3 hours under N2, the reaction mixture was purified by HPLC to afford Compound 2-132 (35.5 mg, 59%) as a white solid. ESI-MS m / z:

[1695] [M / 3+H]+1157.36.

[1696] Preparation of Compound 2-133

[1697] To a solution of Compound 2-132 (35.5 mg, 0.01 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.5 mL) at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-133 (24.3 mg, 72%) as a white solid. ESI-MS m / z: [M / 3+H]+1086.65, [M / 4+H]+815.17.

[1698] -252- FH13329100.6Attorney Docket No.: LCH-04125

[1699] Example 48: Preparation of Compound 2-137

[1700]

[1701] -253- FH13329100.6Attorney Docket No.: LCH-04125

[1702]

[1703] Preparation of Compound 2-134

[1704] To a solution of Compound 2-125 (180 mg, 0.08 mmol) and Compound 2-104 (96 mg, 0.16 mmol) in / V. / V-dimethylformamide (5 mL) were added / V. / V-diisopropylethylamine (0.09 mL, 0.54 mmol) at 0 °C under N2. The reaction mixture was warmed to room temperature and stirred

[1705] -254- FH13329100.6Attorney Docket No.: LCH-04125

[1706] for 16 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. NH4CI solution (30 mL x 2). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-134 (209 mg, crude) as a beige foam solid, which was used for the next step without further purification. ESI-MS m / z: [(M-Boc) / 3+H]+874.30, [M / 3+H]+907.60, [M / 2+H]+1361.55.

[1707] Preparation of Compound 2-135

[1708] To a solution of Compound 2-134 (209 mg, 0.08 mmol) in tetrahydrofuran / methanol (2 mL / 2 mL) was added lithium hydroxide monohydrate (25.8 mg, 0.62 mmol) in water (3 mL) at -60 °C under N2. The reaction mixture was slowly warmed to 5 °C for 2 hours. Then, the reaction mixture was adjusted to pH ~6 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-135 (109 mg, 58% for 2 steps) as a white solid. ESI-MS m / z: [M / 2+H]+1220.29, [(M-Boc) / 3+H]+780.71.

[1709] Preparation of Compound 2-136

[1710] To a solution of Compound 2-135 (103 mg, 0.04 mmol) and Compound 2-116 (44.9 mg, 0.05 mmol) in dimethyl sulfoxide (3 mL) were added copper (II) sulfate pentahydrate (8.44 mg, 0.03 mmol) in distilled water (0.5 mL), and sodium L-ascorbate (12.56 mg, 0.06 mmol) in distilled water (0.5 mL). After stirring at room temperature for 2 hours under N2, the reaction mixture was purified by HPLC to afford Compound 2-136 (94 mg, 66%) as a white solid. ESI-MS m / z:

[1711] [M / 3+H]+1109.31.

[1712] Preparation of Compound 2-137

[1713] To a solution of Compound 2-136 (94 mg, 0.028 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.5 mL) at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 2-137 (79 mg, 89%) as a white solid. ESI-MS m / z: [M / 3+H]+1038.68, [M / 4+H]+779.13.

[1714] -255- FH13329100.6Attorney Docket No.: LCH-04125 Example 49: Preparation of Compound 2-144

[1715]

[1716] Preparation of Compound 2-138

[1717] To a solution of dimethyl sulfoxide (0.60 mL, 8.45 mmol) in dichloromethane (25 mL)

[1718] -256- FH13329100.6Attorney Docket No.: LCH-04125

[1719] was added oxalyl chloride (0.58 mL, 6.76 mmol) at -78 °C under N2. After stirring at -78 °C for 10 minutes, tert-butyl N-{2-[2-(2-hydroxyethoxy)ethoxy]ethyl}carbamate (843 mg, 3.38 mmol) in dichloromethane (8.5 mL) was added and the reaction mixture was stirred at -78 °C for 1 hour. And then triethylamine (3.8 mL, 27.05 mmol) was added thereto and stirred for additional 1 hour. After removing the cooling bath, the reaction mixture was diluted with dichloromethane (40 mL) and washed with distilled water (30 mL) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 2-138 (836 mg, crude), which was used for the next step without further purification.1H-NMR (400 MHz, CDCl3) 8 9.67 (s, 1H), 4.09 (m, 2H), 3.67-3.27 (m, 6H), 2.55 (m, 2H), 1.38 (s, 9H).

[1720] Preparation of Compound 2-139

[1721] To a solution of 3 -azidopropylamin...

Claims

1. Attorney Docket No.: LCH-04125We claim:

1. A conjugate comprising a structure represented by formula la or a pharmaceutically acceptable salt thereof:whereinR1is H, alkyl or cycloalkyl; andR2is alkyl or cycloalkyl; or R1and R2combine to form a cycloalkyl.

2. The conjugate of claim 1, wherein R1is alkyl, preferably methyl.

3. The conjugate of claim 1, wherein R1is H.

4. The conjugate of any one of claims 1-3, wherein R2is alkyl, preferably methyl.

5. The conjugate of claim 1, wherein R1and R2combine to form a cycloalkyl, preferably cyclobutyl.

6. The conjugate of any one of claims 1-5, wherein the conjugate comprises a structure represented by formula lb:lbwhereinX1and X2are each independently N(R4), O, or S; andR4is H, alkyl, aryl, or aralkyl.

7. The conjugate of claim 6, wherein X1is N(R4).-595- FH13329100.6Attorney Docket No.: LCH-041258. The conjugate of claim 6 or 7, wherein R4is H.

9. The conjugate of any one of claims 6-8, wherein X2is O.

10. The conjugate of any one of claims 6-9, wherein the conjugate comprises a structure represented by formula Ic:IcwhereinL1is a covalent linker;T is a cleavage group; andnl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

11. The conjugate of any one of claims 6-9, wherein the conjugate comprises a structure represented by formula Id:IdwhereinL1is a covalent linker;each B is an active agent (e.g., a drug or a toxin); andnl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

12. The conjugate of any one of claims 1-9, wherein the conjugate comprises a structure represented by formula le:-596- FH13329100.6Attorney Docket No.: LCH-04125whereinL1is a covalent linker;T is a cleavage group;each B is an active agent (e.g., a drug or a toxin); andnl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

13. The conjugate of any one of claims 1-12, wherein the conjugate has a structure represented by formula If:whereineach B is an active agent (e.g., a drug or a toxin);L1is a covalent linker;L2is a covalent linker;Lg is a ligand or an active agent; andnl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

14. The conjugate of any one of claims 1-12, wherein the conjugate has a structure represented by formula Ig:-597- FH13329100.6Attorney Docket No.: LCH-04125whereineach B is an active agent (e.g., a drug or a toxin);T is a cleavage group;L1is a covalent linker;L2is a covalent linker;Lg is a ligand, an active agent, or a reactive group ( e.g., amino, azido, hydroxylamino, halo, keto, vinylpyridyl, maleimidyl, aldehyde, ester, amido, alkenyl, or alkynyl); andnl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

15. The conjugate of any one of claims 1-12, wherein the conjugate has a structure represented by formula Ih or li:liwhereineach B is an active agent (e.g., a drug or a toxin);T is a cleavage group;Rlaand R2aare each independently H, alkyl, alkylene, cycloalkyl, or arylalkyl;L1is a covalent linker; andnl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

16. The conjugate of claim 15, wherein Rlaand R2aeach independently represent an alkyl (e.g., methyl).-598- FH13329100.6Attorney Docket No.: LCH-0412517. The conjugate of claim 15 or 16, wherein Rlaor R2a, each independently, comprises anisoprenoid unit (e.g.,preferably wherein Rlaor R2ais18. A conjugate comprising a structure represented by formula Ij:IjwhereinX1and X2are each independently N(R4), O, or S; andR1and R2are each independently alkyl or cycloalkyl; or R1and R2combine to form a cycloalkyl.

19. The conjugate of claim 18, wherein R1is alkyl, preferably methyl.

20. The conjugate of claim 18, wherein R1is H.

21. The conjugate of any one of claims 14-20, wherein R2is alkyl, preferably methyl.

22. The conjugate of claim 18, wherein R1and R2combine to form a cycloalkyl, preferably cyclobutyl.

23. The conjugate of any one of claims 18-22, wherein X1is N(R4).

24. The conjugate of any one of claims 18-23, wherein R4is H.

25. The conjugate of any one of claims 18-24, wherein X2is O.

26. The conjugate of any one of claims 18-24, wherein the conjugate has a structure represented by formula Ik:-599- FH13329100.6Attorney Docket No.: LCH-04125Ikwhereineach B is an active agent (e.g., a drug or a toxin);L1is a covalent linker;X1and X2are each independently N(R4), O, or S;R1and R2are each independently alkyl or cycloalkyl; or R1and R2combine to form a cycloalkyl; andnl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

27. The conjugate of any one of claims 18-25, wherein the conjugate has a structure represented by formula II:whereineach B is an active agent (e.g., a drug or a toxin);each T is a cleavage group; andnl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

28. The conjugate of any one of claims 10, 12, 14, 15, and 27, wherein each T has a structure represented by formula II:-600- FH13329100.6Attorney Docket No.: LCH-04125IIwhereineach Rb1, Rb2, Rb3, and Rb4is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rb5is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;Wb1is independently -*C(O)-, -*C(O)N(Rb7)-, -*N(Rb7)C(O)-, -*(CH2)taiN(Rb7)C(O)-, -*C(O)O-, -*S(O2)N(Rb7)-, -*P(O)(Rb8)N(Rb7)-, -*S(O)N(Rb7)-, or -*P(O2)N(Rb7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula II,Rb7and Rb8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;each Jb1and Jb2is independently H or alkyl; orJb1and Jb2combine to form an oxo;tai is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nal is 0, 1, 2, or 3;Ab1represents a linkage to B; andAb2represents a linkage to L1.

29. The conjugate of claim 28, wherein each Rb1is H.

30. The conjugate of claim 28 or 29, wherein each Rb2is H.-601- FH13329100.6Attorney Docket No.: LCH-0412531. The conjugate of any one of claims 28-30, wherein each Rb3is H.

32. The conjugate of any one of claims 28-31, wherein each Rb4is H.

33. The conjugate of any one of claims 28-32, wherein each nal is 0.

34. The conjugate of any one of claims 28-33, wherein each Wb1is -*C(O)N(Rb7)-.

35. The conjugate of any one of claims 28-34, wherein each Rb7is H.

36. The conjugate of any one of claims 28-35, wherein nl is 1.

37. The conjugate of any one of claims 28-35, wherein nl is 2.

38. The conjugate of any one of claims 28-35, wherein nl is 3.

39. The conjugate of any one of claims 28-35, wherein nl is 4.

40. The conjugate of any one of claims 28-35, wherein nl is 5.

41. The conjugate of any one of claims 10-17 and 26-36, wherein L1is linear.

42. The conjugate of claim 41, wherein L1comprises a C1-C100 alkylene.

43. The conjugate of claim 41, wherein L1comprises a C1-C50 alkylene.

44. The conjugate of claim 42 or 43, wherein L1further comprises an oligoethylene glycol.

45. The conjugate of claim 44, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties.

46. The conjugate of claim 44, wherein the oligoethylene glycol comprises 1, 2, 3, 4, or 5 ethylene glycol moieties.-602- FH13329100.6Attorney Docket No.: LCH-0412547. The conjugate of claim 44, wherein the oligoethylene glycol comprises 5 ethylene glycol moieties.

48. The conjugate of claim 44, wherein the oligoethylene glycol comprises 6 ethylene glycol moieties.

49. The conjugate of any one of claims 10-17 and 41-48, wherein L1further comprises an amido moiety.

50. The conjugate of claim 49, wherein L1comprises 1, 2, 3, 4, 5, or 6 amido moieties.

51. The conjugate of claim 49, wherein L1comprises 1 or 2 amido moieties.

52. The conjugate of any one of claims 41-51, wherein L1further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

53. The conjugate of claim 52, wherein L1comprises a structure represented by formula Illa or Illb:Illa Illbwhereineach Ad1represents a linkage to T or B; andeach A2represents a linkage to X1.

54. The conjugate of any one of claims 10-17 and 26-40, wherein L1is branched.

55. The conjugate of claim 54, wherein L1comprises a C1-C100 alkylene.

56. The conjugate of claim 54, wherein L1comprises a C1-C50 alkylene.-603- FH13329100.6Attorney Docket No.: LCH-0412557. The conjugate of any one of claims 10-17 and 54-56, wherein L1further comprises an oligoethylene glycol.

58. The conjugate of claim 57, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties).

59. The conjugate of claim 57, wherein the oligoethylene glycol comprises 5 ethylene glycol moieties.

60. The conjugate of any one of claims 10-17 and 54-59, wherein L1further comprises an amido moiety.

61. The conjugate of claim 60, wherein L1comprises 1, 2, 3, 4, 5, or 6 amido moieties.

62. The conjugate of claim 60, wherein L1comprises 1 or 2 amido moieties.

63. The conjugate of any one of claims 10-17 and 54-62, wherein L1further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

64. The conjugate of claim 63, wherein L1comprises a structure represented by formula IVa or IVb:IVa IVbwhereineach Ae1represents a linkage to T or B; andeach A4represents a linkage to X1.

65. The conjugate of any one of claims 10-17 and 26-64, wherein L1is substituted with an oligoethylene glycol.-604- FH13329100.6Attorney Docket No.: LCH-0412566. The conjugate of claim 65, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

67. The conjugate of claim 65, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

68. The conjugate of any one of claims 65-67, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl).

69. The conjugate of any one of claims 65-68, wherein the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

70. The conjugate of any one of claims 10-17 and 26-69, wherein L1further comprises an amino acid (e.g., a hydrophilic amino acid).

71. The conjugate of any one of claims 10-17 and 26-69, wherein L1further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids).

72. The conjugate of claim 70 or 71, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine.

73. The conjugate of claim 70 or 71, wherein the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine.

74. The conjugate of claim 70 or 71, wherein the amino acid(s) are selected from aspartate and glutamate.

75. The conjugate of claim 70 or 71, wherein the amino acid(s) are sarcosine.-605- FH13329100.6Attorney Docket No.: LCH-0412576. The conjugate of any one of claims 54-75, wherein a) L1and (B)nior b) L1and (B-T)nicomprise:i) a branching unit covalently coupled to X1by a primary linker;ii) a first branch, which couples a first active agent, via a first cleavage group, to the branching unit; andiiia) a second branch, which couples a second active agent, via a second cleavage group, to the branching unit; oriiib) a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.

77. The conjugate of claim 76, wherein a) L1and (B)nior b) L1and (B-T)nicomprise a second branch which couples a second active agent, via a second cleavage group, to the branching unit.

78. The conjugate of claim 76, wherein a) L1and (B)nior b) L1and (B-T)nicomprise a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.

79. The conjugate of any one of claims 76-78, wherein the branching unit is an amino acid.

80. The conjugate of any one of claims 76-79, wherein the branching unit has a structure represented by formula Va, Vb, Vc, or Vd:Va Vb Vc Vd wherein-606- FH13329100.6Attorney Docket No.: LCH-04125G1, G2, G3are each independently a bond,R30is H or alkyl;R40is H, alkyl or L5-CO2R50;R50is H or alkyl; andL2, L3, L4, and L5are each independently a bond or alkylene.

81. The conjugate of any one of claims 76-79, wherein the branching unit has a structure represented by formula Vlb:wherein R30is H or alkyl.

82. The conjugate of any one of claims 76-79, wherein each cleavage group has a structure represented by formula VII:VII-607- FH13329100.6Attorney Docket No.: LCH-04125whereinBw is an active agent;each Rw2, Rw3, Rw4, and Rw5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rw6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;O-, -wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula VII; Rw7and Rw8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;twl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nwl is 0, 1, 2, or 3;Jw1is H or alkyl;Jw2is H or alkyl; orJw1and Jw2combine to form an oxo; andAw2represents a linkage to the secondary linker.

83. The conjugate of any one of claims 54-75, wherein a) L1and (B)nior b) L1and (B-T)nitogether have a structure represented by formula VIII or a pharmaceutically acceptable salt thereof:VIIIwhereinL1Acomprises a C1-C100 alkylene;-608- FH13329100.6Attorney Docket No.: LCH-04125X3is -N(R5)C(O)-, -C(O)N(R5)-, -C(O)N(R5)(CH2)Z-, -(CH2)ZC(O)N(R5) -C(O)-, -C(O)O-, -OC(O)-, -S(O2)N(R5)-, -N(R5)S(O2)-, -P(O)(R5)N(R6)-, -N(R6)P(O)(R5)-, -P(O)2N(R6)-, or -N(R6)P(O)2-;Y1and Y3are each independently O, N(R7), or S;Yais H;V1and V3are each independently a bond, N, NH, C, CH, or CH2;R5, R6, and R7are each independently H, alkyl, aryl, or aralkyl;each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;L3and L5each independently comprise an alkylene;T1and T3are each independently a bond, -O-, or a cleavage group;B1and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamide, aryl, heteroaryl, or heterocyclyl; orVI, T1and B1or V3, T3and B3together represent a branched moiety (e.g., a branched moiety substituted with one or more active agents); andml and m3 are each independently 1, 2, 3, or 4.

84. The conjugate any one of claims 54-75, wherein a) L1and (B)nior b) L1and (B-T)nitogether have a structure represented by formula IX or a pharmaceutically acceptable salt thereof:whereinL1Acomprises a C1-C100 alkylene;-609- FH13329100.6Attorney Docket No.: LCH-04125X3is -N(R5)C(O)-, -C(O)N(R5)-, -C(O)N(R5)(CH2)Z-, -(CH2)ZC(O)N(R5) -C(O)-, -C(O)O-, -OC(O)-, -S(O2)N(R5)-, -N(R5)S(O2)-, -P(O)(R5)N(R6)-, -N(R6)P(O)(R5)-, -P(O)2N(R6)-, or - N(R6)P(O)2-;Y1, Y2, and Y3are each independently O, N(R7), or S;V1, V2, and V3are each independently a bond, N, NH, C, CH, or CH2;R5, R6, and R7are each independently H, alkyl, aryl, or aralkyl;each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;L3, L4, and L5each independently comprise an alkylene;T1, T2, and T3are each independently a bond, -O-, or a cleavage group;B1, B2, and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamide, aryl, heteroaryl, or heterocyclyl; orV1, T1and B1; V2, T2and B2; or V3, T3and B3together represent a branched moiety (e.g., a branched moiety substituted with one or more active agents); andml, m2, and m3 are each independently 1, 2, 3, or 4.

85. The conjugate of claim 83 or 84, wherein L1Acomprises a C1-C50 alkylene.

86. The conjugate of any one of claims 83-85, wherein Y1is O.

87. The conjugate of any one of claims 83-86, wherein Y2is O.

88. The conjugate of any one of claims 83-87, wherein Y3is O.

89. The conjugate of any one of claims 83-88, wherein X3is -C(O)N(R2)-.

90. The conjugate of claim 89, wherein R2is H.

91. The conjugate of any one of claims 83-90, wherein L3comprises a C1-C100 alkylene.

92. The conjugate of any one of claims 83-90, wherein L3comprises a C1-C50 alkylene.-610- FH13329100.6Attorney Docket No.: LCH-0412593. The conjugate of any one of claims 83-92, wherein L3further comprises an oligoethylene glycol.

94. The conjugate of claim 93, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties).

95. The conjugate of any one of claims 83-94, wherein L3further comprises amidoalkoxy (e.g., amidomethoxy) or carboxyalkoxy (e.g., carboxymethoxy).

96. The conjugate of claim 93, wherein the oligoethylene glycol comprises 5 ethylene glycol moieties.

97. The conjugate of any one of claims 83-96, wherein L3further comprises an amido moiety.

98. The conjugate of claim 97, wherein L3comprises 1, 2, 3, 4, 5, or 6 amido moieties.

99. The conjugate of claim 97, wherein L3comprises 1 or 2 amido moieties.

100. The conjugate of claim 99, wherein L3comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl).

101. The conjugate of any one of claims 83-100, wherein L3further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

102. The conjugate of any one of claims 83-100, wherein L3comprises a structure represented by formula Xa or Xb:Xa Xbwherein-611- FH13329100.6Attorney Docket No.: LCH-04125each Ax1represents a linkage to V1; andeach Ax2represents a linkage to Y1.

103. The conjugate of any one of claims 83-102, wherein L3is substituted with an oligoethylene glycol.

104. The conjugate of claim 103, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

105. The conjugate of claim 103, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

106. The conjugate of any one of claims 103-105, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl).

107. The conjugate of any one of claims 103-105, wherein the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

108. The conjugate of any one of claims 83-107, wherein L3further comprises an amino acid (e.g., a hydrophilic amino acid).

109. The conjugate of any one of claims 83-107, wherein L3further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids).

110. The conjugate of claim 108 or 109, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine.

111. The conjugate of claim 108 or 109, wherein the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine.-612- FH13329100.6Attorney Docket No.: LCH-04125112. The conjugate of claim 108 or 109, wherein the amino acid(s) are selected from aspartate and glutamate.

113. The conjugate of claim 108 or 109, wherein the amino acid(s) are sarcosine.

114. The conjugate of any one of claims 83-113, wherein L3further comprises a polypeptoid (e.g., polysarcosine).

115. The conjugate of any one of claims 83-114, wherein V1is a bond.

116. The conjugate of any one of claims 83-114, wherein V1is N and V1, T1, and B1together represent a branched moiety having a structure represented by formula Xia or a pharmaceutically acceptable salt thereof:XiawhereinAx3represents a linkage to L3;Lx1and Lx2each independently comprise an alkylene;Tx1and Tx2are each independently a bond or a cleavage group; andBx1and Bx2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

117. The conjugate of any one of claims 83-114, wherein V1is CH and V1, T1, and B1together represent a branched moiety having a structure represented by formula Xlb or a pharmaceutically acceptable salt thereof:Xlb-613- FH13329100.6Attorney Docket No.: LCH-04125whereinAx3represents a linkage to L3;Lx1and Lx2each independently comprise an alkylene;Tx1and Tx2are each independently a bond or a cleavage group; andBx1and Bx2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

118. The conjugate of any one of claims 83-114, wherein V1is CH and V1, T1, and B1together represent a branched moiety having a structure represented by formula XIc or a pharmaceutically acceptable salt thereof:XIcwhereinAx3represents a linkage to L3; andLx1and Lx2each independently comprise an alkylene;Gx1, Gx2, and Gx3are each independently an alkylene,each Rx1is independently H, alkyl, or aralkyl;Tx1and Tx2are each independently a bond or a cleavage group; andBx1and Bx2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

119. The conjugate of any one of claims 83-114, wherein V1is C and V1, T1and B1together represent a branched moiety having a structure represented by formula Xld or a pharmaceutically acceptable salt thereof:-614- FH13329100.6Attorney Docket No.: LCH-04125XldwhereinAx3represents a linkage to L3;Lx1, Lx2, and Lx3each independently comprise an alkylene;Tx1, Tx2, and Tx3are each independently a bond or a self-immolative moiety; andBx1, Bx2, and Bx3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

120. The conjugate of claim 119, wherein the heteroaryl of Bx1, Bx2, or Bx3is further substituted with alkylene or amido.

121. The conjugate of claim 119, wherein the amido of Bx1, Bx2, or Bx3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

122. The conjugate of any one of claims 116-121, wherein Lx1comprises a C1-C100 alkylene.

123. The conjugate of any one of claims 116-121, wherein Lx1comprises a C1-C50 alkylene.

124. The conjugate of any one of claims 116-123, wherein Lx1further comprises a heteroaryl (e.g., triazolyl).

125. The conjugate of any one of claims 116-124, wherein Lx1further comprises an oligoethylene glycol.-615- FH13329100.6Attorney Docket No.: LCH-04125126. The conjugate of claim 125, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

127. The conjugate of claim 125, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

128. The conjugate of claim 127, wherein the oligoethylene glycol comprises 4 ethylene glycol moieties.

129. The conjugate of any one of claims 116-128, wherein Lx2comprises a C1-C100 alkylene.

130. The conjugate of any one of claims 116-128, wherein Lx2comprises a C1-C50 alkylene.

131. The conjugate of any one of claims 116-128, wherein Lx2further comprises an oligoethylene glycol.

132. The conjugate of claim 131, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

133. The conjugate of claim 131, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

134. The conjugate of any one of claims 119-133, wherein Lx3comprises a C1-C100 alkylene.

135. The conjugate of any one of claims 119-133, wherein Lx3comprises a C1-C50 alkylene.

136. The conjugate of any one of claims 119-135, wherein Lx3further comprises an oligoethylene glycol.-616- FH13329100.6Attorney Docket No.: LCH-04125137. The conjugate of claim 136, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

138. The conjugate of any one of claims 119-137, wherein Lx3further comprises a heteroaryl (e.g., triazolyl).

139. The conjugate of any one of claims 83-138, wherein T1, Tx1, Tx2, or Tx3have a structure represented by formula XII or a pharmaceutically acceptable salt thereof:XIIwhereineach Rx2, Rx3, Rx4, and Rx5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rx6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;-, -*C(O)O-,)N(Rx7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XII, Rx7and Rx8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Ja1is H or alkyl;-617- FH13329100.6Attorney Docket No.: LCH-04125Ja2is H or alkyl; orJa1and Ja2combine to form an oxo;tx1is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nx1is 0, 1, 2, or 3;Ax4represents a linkage to B1, Bx1, Bx2, or Bx3; andAx5represents a linkage to L3, Lx1, Lx2, or Lx3.

140. The conjugate of claim 139, wherein Rx2is H.

141. The conjugate of claim 139 or 140, wherein Rx3is H.

142. The conjugate of any one of claims 139-141, wherein Rx4is H.

143. The conjugate of any one of claims 139-141, wherein Rx5is H.

144. The conjugate of any one of claims 139-143, wherein nxl is 0.

145. The conjugate of any one of claims 134-144, wherein Wx1is -*C(O)N(Rx7)-.

146. The conjugate of claim 145, wherein Rx7is alkyl optionally substituted with heteroaryl (e.g., triazolyl).

147. The conjugate of claim 146, wherein when substituted, the heteroaryl of Rx7is substituted with oligoethylene glycol.

148. The conjugate of claim 146, wherein Rx7is substituted with oligoethylene glycol.

149. The conjugate of claim 147 or 148, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties.

150. The conjugate of claim 148, wherein the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl.-618- FH13329100.6Attorney Docket No.: LCH-04125151. The conjugate of claim 150, wherein the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol.

152. The conjugate of claim 150, wherein the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine).

153. The conjugate of claim 152, wherein the polypeptoid is substituted with an acyl.

154. The conjugate of claim 150, wherein the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol.

155. The conjugate of any one of claims 147-149, wherein the oligoethylene glycol is substituted with alkyl (e.g., hydroxyalkyl or carboxy alkyl).

156. The conjugate of any one of claims 139-155, wherein Rx7is H.

157. The conjugate of any one of claims 139-156, wherein Ja1is H.

158. The conjugate of any one of claims 139-157, wherein Ja2is H.

159. The conjugate of any one of claims 139-156, wherein Ja1and Ja2combine to form oxo.

160. The conjugate of any one of claims 139-159, wherein B1is an active agent.

161. The conjugate of any one of claims 139-160, wherein ml is 1.

162. The conjugate of any one of claims 139-160, wherein ml is 2.

163. The conjugate of any one of claims 139-160, wherein ml is 3.

164. The conjugate of any one of claims 83-115, wherein each T1is a bond.-619- FH13329100.6Attorney Docket No.: LCH-04125165. The conjugate of any one of claims 83-119 and 164, wherein each B1, Bx1, Bx2, and Bx3is independently H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., glucuronidyl or morpholinyl).

166. The conjugate of claim 165, wherein each B1is H, hydroxyl, amino, ( e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., glucuronidyl or morpholinyl).

167. The conjugate of any one of claims 84-166, wherein L4comprises a C1-C100 alkylene.

168. The conjugate of any one of claims 84-167, wherein L4comprises a C1-C50 alkylene.

169. The conjugate of any one of claims 84-168, wherein L4further comprises an oligoethylene glycol.

170. The conjugate of claim 169, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties).

171. The conjugate of claim 169, wherein the oligoethylene glycol comprises 5 ethylene glycol moieties.

172. The conjugate of claim 169, wherein the oligoethylene glycol comprises 6 ethylene glycol moieties.

173. The conjugate of any one of claims 84-172, wherein L4further comprises an amido moiety.

174. The conjugate of claim 173, wherein L4comprises 1, 2, 3, 4, 5, or 6 amido moieties.

175. The conjugate of claim 173, wherein L4comprises 1 or 2 substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxylamido).-620- FH13329100.6Attorney Docket No.: LCH-04125176. The conjugate of claim 175, wherein L4comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl).

177. The conjugate of any one of claims 84-176, wherein L4further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

178. The conjugate of any one of claims 84-176, wherein L4comprises a structure represented by formula Xllla or Xlllb:Xllla Xlllbwhereineach Ay1represents a linkage to V2; andeach Ay2represents a linkage to Y2.

179. The conjugate of any one of claims 84-178, wherein L4is substituted with an oligoethylene glycol.

180. The conjugate of claim 179, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

181. The conjugate of claim 179, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

182. The conjugate of any one of claims 179-181, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl).

183. The conjugate of any one of claims 179-181, wherein the oligoethylene glycol is substituted with amino (e.g., dimethylamino).-621- FH13329100.6Attorney Docket No.: LCH-04125184. The conjugate of any one of claims 84-183, wherein L4further comprises an amino acid (e.g., a hydrophilic amino acid).

185. The conjugate of any one of claims 84-183, wherein L4further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids).

186. The conjugate of claim 184 or 185, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine.

187. The conjugate of claim 184 or 185, wherein the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine.

188. The conjugate of claim 184 or 185, wherein the amino acid(s) are selected from aspartate and glutamate.

189. The conjugate of claim 184 or 185, wherein the amino acid(s) are sarcosine.

190. The conjugate of any one of claims 84-189, wherein L4further comprises a polypeptoid (e.g., polysarcosine).

191. The conjugate of any one of claims 84-190, wherein V2is a bond.

192. The conjugate of any one of claims 84-190, wherein V2is N and V2, T2, and B2together represent a branched moiety having a structure represented by formula XlVa or a pharmaceutically acceptable salt thereof:XlVawhereinAy3represents a linkage to L4; and-622- FH13329100.6Attorney Docket No.: LCH-04125Ly1and Ly2each independently comprise an alkylene;Ty1and Ty2are each independently a bond, or a cleavage group; andBy1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

193. The conjugate of any one of claims 84-190, wherein V2is CH and V2, T2, and B2together represent a branched moiety having a structure represented by formula XlVb or a pharmaceutically acceptable salt thereof:XlVbwhereinAy3represents a linkage to L4; andLy1and Ly2each independently comprise an alkylene;Ty1and Ty2are each independently a bond or a cleavage group; andBy1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

194. The conjugate of any one of claims 84-190, wherein V2is CH and V2, T2, and B2together represent a branched moiety having a structure represented by formula XIVc or a pharmaceutically acceptable salt thereof:XIVcwhereinAy3represents a linkage to L4; andLy1and Ly2each independently comprise an alkylene;-623- FH13329100.6Attorney Docket No.: LCH-041250 0Gy1, Gy2, and Gy3are each independently an alkylene,;each Ry1is independently H, alkyl, or aralkyl;Ty1and Ty2are each independently a bond or a cleavage group; andBy1and By2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

195. The conjugate of any one of claims 84-190, wherein V2is C and V2, T2and B2together represent a branched moiety having a structure represented by formula XlVd or a pharmaceutically acceptable salt thereof:XlVdwhereinAy3represents a linkage to L4;Ly1, Ly2, and Ly3each independently comprise an alkylene;Ty1, Ty2, and Ty3are each independently a bond or a cleavage group; andBy1, By2, and By3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

196. The conjugate of claim 195, wherein the heteroaryl of By1, By2, or By3is further substituted with alkylene or amido.

197. The conjugate of claim 195, wherein the amido of By1, By2, or By3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

198. The conjugate of any one of claims 192-197, wherein Ly1comprises a C1-C100 alkylene.-624- FH13329100.6Attorney Docket No.: LCH-04125199. The conjugate of any one of claims 192-197, wherein Ly1comprises a C1-C50 alkylene.

200. The conjugate of any one of claims 192-199, wherein Ly1further comprises a heteroaryl (e.g., triazolyl).

201. The conjugate of any one of claims 192-200, wherein Ly1further comprises an oligoethylene glycol.

202. The conjugate of claim 201, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

203. The conjugate of claim 201, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

204. The conjugate of any one of claims 192-203, wherein Ly2comprises a C1-C100 alkylene.

205. The conjugate of any one of claims 192-203, wherein Ly2comprises a C1-C50 alkylene.

206. The conjugate of any one of claims 192-205, wherein Ly2further comprises an oligoethylene glycol.

207. The conjugate of claim 206, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

208. The conjugate of claim 206, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

209. The conjugate of any one of claims 195-208, wherein Ly3comprises a C1-C100 alkylene.

210. The conjugate of any one of claims 195-208, wherein Ly3comprises a C1-C50 alkylene.-625- FH13329100.6Attorney Docket No.: LCH-04125211. The conjugate of any one of claims 195-210, wherein Ly3further comprises an oligoethylene glycol.

212. The conjugate of claim 211, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

213. The conjugate of any one of claims 195-212, wherein Ly3further comprises a heteroaryl (e.g., triazolyl).

214. The conjugate of any one of claims 84-213, wherein T2, Ty1, Ty2, or Ty3has a structure represented by formula XV or a pharmaceutically acceptable salt thereof:whereineach Ry2, Ry3, Ry4, and Ry5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Ry6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;Wy1is independently - -*C(O)O-, -*S(-626- FH13329100.6Attorney Docket No.: LCH-04125wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XV,Ry7and Ry8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Jb1is H or alkyl;Jb2is H or alkyl; orJb1and Jb2combine to form an oxo;tyl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nyl is 0, 1, 2, or 3;Ay4represents a linkage to B2, By1, By2, or By3; andAy5represents a linkage to L4, Ly1, Ly2, or Ly3.

215. The conjugate of claim 214, wherein Ry2is H.

216. The conjugate of claims 214 or 215, wherein Ry3is H.

217. The conjugate of any one of claims 214-216, wherein Ry4is H.

218. The conjugate of any one of claims 214-217, wherein Ry5is H.

219. The conjugate of any one of claims 214-218, wherein each nyl is 0.

220. The conjugate of any one of claims 214-219, wherein Wy1is -*C(O)N(Ry7)-.

221. The conjugate of claim 220, wherein Ry7is alkyl optionally substituted with heteroaryl (e.g., triazolyl).

222. The conjugate of claim 221, wherein when substituted, the heteroaryl of Ry7is substituted with oligoethylene glycol.

223. The conjugate of claim 221, wherein Ry7is substituted with oligoethylene glycol.-627- FH13329100.6Attorney Docket No.: LCH-04125224. The conjugate of claim 222 or 223, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties.

225. The conjugate of claim 224, wherein the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl.

226. The conjugate of claim 225, wherein the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol.

227. The conjugate of claim 225, wherein the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine).

228. The conjugate of claim 227, wherein the polypeptoid is substituted with an acyl.

229. The conjugate of claim 225, wherein the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol.

230. The conjugate of any one of claims 222-224, wherein the oligoethylene glycol is substituted with alkyl (e.g., hydroxyalkyl or carboxy alkyl).

231. The conjugate of any one of claims 214-230, wherein Ry7is H.

232. The conjugate of any one of claims 214-231, wherein Jc1is H.

233. The conjugate of any one of claims 214-232, wherein Jc2is H.

234. The conjugate of any one of claims 214-231, wherein Jc1and Jc2combine to form oxo.

235. The conjugate of any one of claims 83-234, wherein B2is an active agent.

236. The conjugate of any one of claims 83-235, wherein m2 is 1.

237. The conjugate of any one of claims 83-235, wherein m2 is 2.-628- FH13329100.6Attorney Docket No.: LCH-04125238. The conjugate of any one of claims 83-235, wherein m2 is 3.

239. The conjugate of any one of claims 83-191, wherein each T2is a bond.

240. The conjugate of any one of claims 84-197 and 239, wherein each B2, By1, By2, and By3is independently H, hydroxyl, guanidyl, sulfate, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

241. The conjugate of claim 240, wherein each B2is H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamide), or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

242. The conjugate of any one of claims 84-191, wherein B2is alkyl (e.g., ethyl) substituted with phosphonate.

243. The conjugate of any one of claims 84-191, wherein B2is alkyl (e.g., ethyl) substituted with phosphatyl.

244. The conjugate of any one of claims 84-191, wherein B2is alkyl substituted with hydroxyl (e.g., 1, 2, 3, 4, 5, or 6 hydroxyl groups).

245. The conjugate of any one of claims 84-191 and 241, wherein B2is amido (e.g., piperazineamido).

246. The conjugate of any one of claims 84-191 and 241, wherein B2is heterocyclyl (e.g., piperazyl).

247. The conjugate of any one of claims 84-191 and 241, wherein B2is alkoxy (e.g., methoxy).

248. The conjugate of any one of claims 84-191 and 241, wherein B2is carboxyl.-629- FH13329100.6Attorney Docket No.: LCH-04125249. The conjugate of any one of claims 84-191, wherein B2is heteroaryl (e.g., tetrazolyl).

250. The conjugate of any one of claims 84-191 and 241, wherein B2is hydroxyl.

251. The conjugate of any one of claims 84-191 and 241, wherein B2is amino (e.g., dimethyl amino).

252. The conjugate of any one of claims 83-251, wherein L5comprises a C1-C100 alkylene.

253. The conjugate of any one of claims 83-251, wherein L5comprises a C1-C50 alkylene.

254. The conjugate of any one of claims 83-253, wherein L5further comprises an oligoethylene glycol.

255. The conjugate of claim 254, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties).

256. The conjugate of claim 254, wherein the oligoethylene glycol comprises 6 ethylene glycol moieties.

257. The conjugate of any one of claims 83-256, wherein the oligoethylene glycol further comprises an amido moiety.

258. The conjugate of claim 257, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, or 6 amido moieties.

259. The conjugate of claim 257, wherein the oligoethylene glycol comprises 1 or 2 amido moieties.

260. The conjugate of claim 259, wherein L5comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl).-630- FH13329100.6Attorney Docket No.: LCH-04125261. The conjugate of any one of claims 83-260, wherein L5further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

262. The conjugate of any one of claims 83-260, wherein L5comprises a structure represented by formula XVIa or XVIb:XVIa XVIbwhereineach Az1represents a linkage to T3; andeach Az2represents a linkage to V3.

263. The conjugate of any one of claims 83-262, wherein L5is substituted with an oligoethylene glycol.

264. The conjugate of claim 263, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

265. The conjugate of claim 263, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

266. The conjugate of any one of claims 263-265, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl).

267. The conjugate of any one of claims 263-266, wherein the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

268. The conjugate of any one of claims 83-267, wherein L5further comprises an amino acid (e.g., a hydrophilic amino acid).-631- FH13329100.6Attorney Docket No.: LCH-04125269. The conjugate of any one of claims 83-268, wherein L5further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids).

270. The conjugate of claim 268 or 269, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine.

271. The conjugate of claim 268 or 269, wherein the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine.

272. The conjugate of claim 268 or 269, wherein the amino acid(s) are selected from aspartate and glutamate.

273. The conjugate of claim268 or 269, wherein the amino acid(s) are sarcosine.

274. The conjugate of any one of claims 83-273, wherein L5further comprises a polypeptoid (e.g., polysarcosine).

275. The conjugate of any one of claims 83-274, wherein V3is a bond.

276. The conjugate of any one of claims 83-274, wherein V3is N and V3, T3and B3together represent a branched moiety having a structure represented by formula XVIIa or a pharmaceutically acceptable salt thereof:XVIIawhereinAz3represents a linkage to L5;Lz1and Lz2each independently comprise an alkylene;Tz1and Tz2are each independently a bond or a cleavage group; andBz1and Bz2are each independently an active agent (e.g., a drug or a toxin).-632- FH13329100.6Attorney Docket No.: LCH-04125277. The conjugate of any one of claims 83-274, wherein V3is CH and V3, T3, and B3together represent a branched moiety having a structure represented by formula XVIIb or a pharmaceutically acceptable salt thereof:XVIIbwhereinAz3represents a linkage to L5;Lz1and Lz2each independently comprise an alkylene;Tz1and Tz2are each independently a bond or a cleavage group; andBz1and Bz2are each independently an active agent ( e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

278. The conjugate of any one of claims 83-274, wherein V3is CH and V3, T3, and B3together represent a branched moiety having a structure represented by formula XVIIc or a pharmaceutically acceptable salt thereof:XVIIcwhereinAz3represents a linkage to L5; andLz1and Lz2each independently comprise an alkylene;0 0Gz1, Gz2, and Gz3are each independently an alkylene,each Rz1is independently H, alkyl, or aralkyl;Lz1and Lz2each independently comprise an alkylene;Tz1and Tz2are each independently a bond or a cleavage group; and-633- FH13329100.6Attorney Docket No.: LCH-04125Bz1and Bz2are each independently an active agent (e.g., a drug or a toxin).

279. The conjugate of any one of claims 83-274, wherein V3is C and V3, T3, and B3together represent a branched moiety having a structure represented by formula XVIId or a pharmaceutically acceptable salt thereof:XVIIdwhereinAz3represents a linkage to L5;Lz1, Lz2, and Lz3each independently comprise an alkylene;Tz1, Tz2, and Tz3are each independently a bond or a self-immolative moiety; andBz1, Bz2, and Bz3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, or heteroaryl.

280. The conjugate of claim 279, wherein the heteroaryl of Bz1, Bz2, or Bz3is further substituted with alkylene or amido.

281. The conjugate of claim 279, wherein the amido of Bz1, Bz2, or Bz3is further substituted with methyl or hexane-2,3,4,5,6-pentol.

282. The conjugate of any one of claims 276-281, wherein Lz1comprises a C1-C100 alkylene.

283. The conjugate of any one of claims 276-281, wherein Lz1comprises a C1-C50 alkylene.

284. The conjugate of any one of claims 276-283, wherein Lz1further comprises a heteroaryl (e.g., triazolyl).-634- FH13329100.6Attorney Docket No.: LCH-04125285. The conjugate of any one of claims 276-284, wherein Lz1further comprises an oligoethylene glycol.

286. The conjugate of claim 285, wherein Lz1comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

287. The conjugate of claim 286, wherein Lz1comprises 1, 2, 3, or 4 ethylene glycol moieties.

288. The conjugate of any one of claims 276-287, wherein Lz2comprises a C1-C100 alkylene.

289. The conjugate of any one of claims 276-287, wherein Lz2comprises a C1-C50 alkylene.

290. The conjugate of any one of claims 276-289, wherein Lz2further comprises an oligoethylene glycol.

291. The conjugate of claim 290, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

292. The conjugate of claim 290, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

293. The conjugate of any one of claims 279-292, wherein Lz3comprises a C1-C100 alkylene.

294. The conjugate of any one of claims 279-293, wherein Lz3comprises a C1-C50 alkylene.

295. The conjugate of any one of claims 279-294, wherein Lz3further comprises an oligoethylene glycol.

296. The conjugate of claim 295, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).-635- FH13329100.6Attorney Docket No.: LCH-04125297. The conjugate of any one of claims 279-296, wherein Lz3further comprises a heteroaryl (e.g., triazolyl).

298. The conjugate of any one of claims 83-297, wherein T3, Tz1, Tz2, or Tz3has a structure represented by formula XVIII or a pharmaceutically acceptable salt thereof:whereineach Rz2, Rz3, Rz4, and Rz5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rz6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamide;Wz1is -*C(O)-, -*C(O)N(Rz7)-, -*N(RZ7)C(O)-, -*(CH2)tziN(Rz7)C(O)-, -*C(O)O-, -*S(O2)N(Rz7)-, -*P(O)( RZ8)N(RZ7)-, -*S(O)N(RZ7)-, or -*P(O2)N(Rz7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XVIII, Rz7and Rz8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Jc1is H or alkyl;Jc2is H or alkyl; orJc1and Jc2combine to form an oxo;tzl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nzl is 0, 1, 2, or 3;-636- FH13329100.6Attorney Docket No.: LCH-04125Az4represents a linkage to B3, Bz1, Bz2, or Bz3; andAz5represents a linkage to L5, Lz1, Lz2, or Lz3.

299. The conjugate of claim 298, wherein Rz2is H.

300. The conjugate of claim 298 or 299, wherein Rz3is H.

301. The conjugate of any one of claims 298-300, wherein Rz4is H.

302. The conjugate of any one of claims 298-301, wherein Rz5is H.

303. The conjugate of any one of claims 298-302, wherein nzl is 0.

304. The conjugate of any one of claims 298-303, wherein Wz1is -*C(O)N(Rz7)-.

305. The conjugate of claim 304, wherein Rz7is alkyl optionally substituted with heteroaryl (e.g., triazolyl).

306. The conjugate of claim 305, wherein when substituted, the heteroaryl of Rz7is substituted with oligoethylene glycol.

307. The conjugate of claim 305, wherein Rz7is substituted with an oligoethylene glycol.

308. The conjugate of claim 306 or 307, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties.

309. The conjugate of claim 307, wherein the oligoethylene glycol is substituted with alkyl, amido, amino, or carboxyl.

310. The conjugate of claim 309, wherein the alkyl is substituted with amido and the amido is substituted with hexane-2,3,4,5,6-pentol.-637- FH13329100.6Attorney Docket No.: LCH-04125311. The conjugate of claim 309, wherein the alkyl is substituted with amido and the amido is substituted with a polypeptoid (e.g., polysarcosine).

312. The conjugate of claim 311, wherein the polypeptoid is substituted with an acyl.

313. The conjugate of claim 309, wherein the alkyl is substituted with amino and the amino is substituted with hexane-2,3,4,5,6-pentol.

314. The conjugate of any one of claims 307-309, wherein the oligoethylene glycol is substituted with alkyl (e.g., hydroxyalkyl or carboxy alkyl).

315. The conjugate of any one of claims 298-314, wherein Rz7is H.

316. The conjugate of any one of claims 298-315, wherein Jc1is H.

317. The conjugate of any one of claims 298-316, wherein Jc2is H.

318. The conjugate of any one of claims 298-315, wherein Jc1and Jc2combine to form oxo.

319. The conjugate of any one of claims 83-318, wherein B3is an active agent.

320. The conjugate of any one of claims 83-319, wherein m3 is 1.

321. The conjugate of any one of claims 83-319, wherein m3 is 2.

322. The conjugate of any one of claims 83-319, wherein m3 is 3.

323. The conjugate of any one of claims 83-322, wherein each T3is a bond.

324. The conjugate of any one of claims 83-281 and 323, wherein each B3, Bz1, Bz2, and Bz3is independently H, hydroxyl, amino, (e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamido), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).-638- FH13329100.6Attorney Docket No.: LCH-04125325. The conjugate of claim 324, wherein each B3is H, hydroxyl, amino, ( e.g., dimethyl amino), phosphoryl, sulfonamide, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

326. The conjugate of any one of claims 1-14, wherein the conjugate comprises a structure selected from:-639- FH13329100.6Attorney Docket No.: LCH-04125-640- FH13329100.6Attorney Docket No.: LCH-04125-641- FH13329100.6Attorney Docket No.: LCH-04125-642- FH13329100.6Attorney Docket No.: LCH-04125-643- FH13329100.6Attorney Docket No.: LCH-04125-644- FH13329100.6Attorney Docket No.: LCH-04125-645- FH13329100.6Attorney Docket No.: LCH-04125-646- FH13329100.6Attorney Docket No.: LCH-04125-647- FH13329100.6Attorney Docket No.: LCH-04125-648- FH13329100.6Attorney Docket No.: LCH-04125-649- FH13329100.6Attorney Docket No.: LCH-04125-650- FH13329100.6Attorney Docket No.: LCH-04125-651- FH13329100.6Attorney Docket No.: LCH-04125-652- FH13329100.6Attorney Docket No.: LCH-04125-653- FH13329100.6Attorney Docket No.: LCH-04125-655- FH13329100.6Attorney Docket No.: LCH-04125-656- FH13329100.6Attorney Docket No.: LCH-04125-657- FH13329100.6Attorney Docket No.: LCH-04125-658- FH13329100.6Attorney Docket No.: LCH-04125-659- FH13329100.6Attorney Docket No.: LCH-04125-660- FH13329100.6Attorney Docket No.: LCH-04125-661- FH13329100.6Attorney Docket No.: LCH-04125-662- FH13329100.6Attorney Docket No.: LCH-04125-663- FH13329100.6Attorney Docket No.: LCH-04125-664- FH13329100.6Attorney Docket No.: LCH-04125-665- FH13329100.6Attorney Docket No.: LCH-04125-666- FH13329100.6Attorney Docket No.: LCH-04125-667- FH13329100.6Attorney Docket No.: LCH-04125-668- FH13329100.6Attorney Docket No.: LCH-04125-669- FH13329100.6Attorney Docket No.: LCH-04125-670- FH13329100.6Attorney Docket No.: LCH-04125-671- FH13329100.6Attorney Docket No.: LCH-04125-672- FH13329100.6Attorney Docket No.: LCH-04125-673- FH13329100.6Attorney Docket No.: LCH-04125and-674- FH13329100.6Attorney Docket No.: LCH-04125or a pharmaceutically acceptable salt thereof.

327. The conjugate of any one of claims 13, 14, 15, and 28-326, wherein L2comprises a C1-C100 alkylene.

328. The conjugate of any one of claims 13, 14, 15, and 28-326, wherein L2comprises a Ci-C50 alkylene.

329. The conjugate of any one of claims 13, 14, 15, and 28-326, wherein L2further comprises an oligoethylene glycol.-675- FH13329100.6Attorney Docket No.: LCH-04125330. The conjugate of claim 329, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

331. The conjugate of claim 329, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

332. The conjugate of any one of claims 13, 14, 15, and 28-331, wherein L2is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide.

333. The conjugate of any one of claims 13, 14, 15, and 28-332, wherein L2further comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties).

334. The conjugate of claim 333, wherein L2comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl).

335. The conjugate of any one of claims 13, 14, 15, and 28-334, wherein L2further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

336. The conjugate of any one of claims 13, 14, 15, and 28-334, wherein L2comprises a structure represented by formula XIXa or XlXb:XIXa XIXbwhereineach At1represents a linkage to X1; andeach A6represents a linkage to Lg.

337. The conjugate of any one of claims 13, 14, 15, and 28-336, wherein L2comprises a structure represented by formula XXa, XXb, or XXc:-676- FH13329100.6Attorney Docket No.: LCH-04125whereineach A5represents a linkage to X1; andeach A6represents a linkage to Lg.

338. The conjugate of any one of claims 13, 14, 15, and 28-337, wherein L2further comprises a structure represented by formula XXI:XXIwherein pl is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;each A7represents a linkage to X1; andeach A8represents a linkage to Lg.

339. The conjugate of claim 338, wherein pl is 1, 2, 3, 4, or 5.

340. The conjugate of any one of claims 13, 14, 15, and 28-339, wherein L2is substituted with an oligoethylene glycol.

341. The conjugate of claim 340, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).-677- FH13329100.6Attorney Docket No.: LCH-04125342. The conjugate of claim 340, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

343. The conjugate of any one of claims 340-342, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl).

344. The conjugate of any one of claims 340-342, wherein the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

345. The conjugate of any one of claims 13, 14, 15, and 28-344, wherein L2further comprises an amino acid (e.g., a hydrophilic amino acid).

346. The conjugate of any one of claims 13, 14, 15, and 28-344, wherein L2further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids e.g., hydrophilic amino acids).

347. The conjugate of claims 345 or 346, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine.

348. The conjugate of claim 345 or 346, wherein the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine.

349. The conjugate of claim 345 or 346, wherein the amino acid(s) are selected from aspartate and glutamate.

350. The conjugate of claim 345 or 346, wherein the amino acid(s) are sarcosine.

351. The conjugate of any one of claims 3, 14, 15, and 288-350, wherein L2further comprises a polypeptoid (e.g., poly sarcosine).-678- FH13329100.6Attorney Docket No.: LCH-04125352. The conjugate of any one of claims 13, 14, 15, and 28-351, wherein Lg is a reactive group.

353. The conjugate of claim 352, wherein Lg is amino, azido, hydroxylamino, halo, keto, aldehyde, ester, amido, alkenyl, or alkynyl.

354. The conjugate of claim 352, wherein Lg is355. The conjugate of claim 352, wherein Lg is vinylpyridyl.

356. The conjugate of claim 352, wherein Lg is maleimidyl.

357. The conjugate of claim 352, wherein Lg is azido.H / — \HCJ358. The conjugate of claim 352, wherein Lg is alkynyl (e.g., H ).

359. The conjugate of any one of claims 13, 14, 15, and 28-351, wherein Lg is an antibody.

360. The conjugate of claim 359, wherein the antibody is a humanized antibody or a human antibody.

361. The conjugate of claim 359 or 360, wherein the antibody is selected from a monoclonal antibody, a domain antibody (dAb), a single chain antibody (scAb), a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an scFab fragment, an Fv fragment, a dsFv fragment, a single chain variable fragment (scFv), an scFv-Fc fragment, a single domain heavy chain antibody, a single domain light chain antibody, a variant antibody, a multimeric antibody, a minibody, a diabody, a bispecific antibody, and a multispecific antibody.-679- FH13329100.6Attorney Docket No.: LCH-04125362. The conjugate of any one of claims 11-15 and 26-361, wherein each active agent is independently a chemotherapeutic agent or a toxin, or a combination thereof.

363. The conjugate of any one of claims 11-15 and 26-361, wherein each active agent is independently a chemotherapeutic compound, a cytotoxic compound, an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, an antiparasitic agent, and a combination thereof.

364. The conjugate of claim 362 or 363, wherein each of B1, B2, B3, Bx1, Bx2, By1, By2, Bz1,-680- FH13329100.6Attorney Docket No.: LCH-04125-681- FH13329100.6Attorney Docket No.: LCH-04125365. The conjugate of any one of claims 11-15 and 26-361, wherein each active agent is a cytotoxic compound selected from a mitotic inhibitor, a DNA alkylating agent, an RNA targeting agent and a topoisomerase inhibitor, or a combination thereof.

366. The conjugate of claim 365, wherein the cytotoxic compound is a thailanstatin or an amatoxin.

367. The conjugate of claim 365, wherein the cytotoxic compound is selected from an auristatin, a maytansinoid, a tubulisin, a calicheamicin, a duocarmycin, a pyrrolobenzodiazepine, and a camptothecin, or a combination thereof.

368. The conjugate of any one of claims 11-15 and 26-361, wherein the active agent is selected from:(a) erlotinib, bortezomib, fulvestrant, sunitinib, letrozole, imatinib mesylate, PTK787 / ZK 222584, oxaliplatin, 5-fluorouracil, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, AG1478, AG1571, thiotepa, cyclophosphamide, busulfan, improsulfan, piposulfan, benzodepa, carboquone, meturedepa, uredepa, ethylenimine, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolmelamine, bullatacin, bullatacinone, camptothecin, topotecan, deruxtecan, SN-38, bryostatin, callystatin, CC-1065, adozelesin, carzelesin, bizelesin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, KW-2189, CB1-TM1, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotoxin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, calicheamicin gamma 1, calicheamicin omega 1, dynemicin, dynemicin A, clodronate, esperamicin, neocarzinostatin chromophore, aclacinomysins, actinomycin, antimycin, azaserine, bleomycins, carabicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubucin, liposomal doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin,-682- FH13329100.6Attorney Docket No.: LCH-04125puromycin, quelamycin, rodorubicin, streptomigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6- mercaptopurine, thiamiprine, thioguanine, ancitabine, azacytidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, folinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatrexate, demecolcine, diaziquone, elfornithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidainine, maytansine, ansamitocins, mitoguazone, mitoxantrone, mopidanmol, pentostatin, phenamet, pirarubicin, losoxantrone, 2-ethylhydrazide, procarbazine, polysaccharide-k, razoxane, rhizoxin, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2,2’,2”-trichlorotriethylamine, T-2 toxin, verracurin A, roridin A, and anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, arabinoside, paclitaxel, albumin-engineered nanoparticle formulation of paclitaxel, docetaxel, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, etoposide, vincristine, vinorelbine, novantrone, teniposide, daunomycin, aminopterin, ibandronate, CPT-11, topoisomerase inhibitor RFS 2000, difluoromethylornithine, retinoic acid, capecitabine, or pharmaceutically acceptable salts, solvates, or acids of any of the foregoing;(b) monokine, a lymphokine, a traditional polypeptide hormone, parathyroid hormone, thyroxine, relaxin, prorelaxin, a glycoprotein hormone, follicle stimulating hormone, thyroid stimulating hormone, luteinizing hormone, hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-oc, tumor necrosis factor-P, Mullerian inhibiting substance, mouse gonadotropin associated peptide, inhibin, activin, vascular endothelial growth factor, thrombopoietin, erythropoietin, an osteoinductive factor, an interferon, interferon-oc, interferon-P, interferon-y, a colony stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage-CSF, granulocyte-CSF, an interleukin (IL), IL-1, IL-loc, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, a tumor necrosis factor, polypeptide factor, LIF, kit ligand, or a combination of any of the foregoing;(c) diphtheria toxin, botulinum toxin, tetanus toxin, dysentery toxin, cholera toxin, amanitin a--683- FH13329100.6Attorney Docket No.: LCH-04125amanitin, pyrrolobenzodiazepine, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, an auristatin, tubulysin, geldanamycin, maytansinoid, SG2285, SG2057, cryptophycin, an enediyne antibiotic, epothilone, taltobulin, azonafide, a toxoid, or a combination of any of the foregoing;(d) an affinity ligand, wherein the affinity ligand is a substrate, an inhibitor, a stimulating agent, a neurotransmitter, a radioisotope, or a combination of any of the foregoing;(e) a radioactive label,32P,35S, a fluorescent dye, an electron dense reagent, an enzyme, biotin, streptavidin, digoxigenin, a hapten, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or a combination of any of the foregoing; (f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, and an anti-parasitic agent, or a combination of any of the foregoing;(g) tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, LY117018, onapristone, or toremifene;(h) 4(5)-imidazoles, megestrol acetate, exemestane, or anastrozole;(i) flutamide, nilutamide, bicalutamide, leuprolide, goserelin, or troxacitabine;(j) an aromatase inhibitor;(k) a protein kinase inhibitor;(l) a lipid kinase inhibitor;(m) an antisense oligonucleotide;(n) a ribozyme;(o) a vaccine; and(p) an anti-angiogenic agent.

369. The conjugate of claim 368, wherein the active agent is pyrrolobenzodiazepine.

370. The conjugate of any one of claims 11-15 and 26-361, wherein each active agent is selected from GENZ-644282, exatecan, monomethyl auristatin (e.g., monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF)), FL118, Dxd derivative (e.g., Dxd2), a stimulator of interferon genes agonist, and Toll-like receptor agonist e.g., TLR7 / 8), or a combination thereof.-684- FH13329100.6Attorney Docket No.: LCH-04125371. The conjugate of claim 370, wherein each active agent is selected from exatecan, monomethyl auristatin (e.g., monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF)), FLU 8, Dxd derivative (e.g., Dxd2), and a stimulator of interferon genes agonist, or a combination thereof.

372. The conjugate of any one of claims 11-15 and 26-361, wherein each active agent is exatecan.

373. The conjugate of any one of claims 11-15 and 26-361, wherein each active agent is a monomethyl auristatin.

374. The conjugate of any one of claims 11-15 and 26-361, wherein each active agent is monomethyl auristatin E (MMAE).

375. The conjugate of any one of claims 11-15 and 26-361, wherein each active agent is monomethyl auristatin F (MMAF).

376. The conjugate of any one of claims 11-15 and 26-361, wherein each active agent is FL118.

377. The conjugate of any one of claims 11-15 and 26-361, wherein each active agent is a stimulator of interferon genes agonist (STINGa).

378. The conjugate of claim 370, wherein the Toll-like receptor agonist is a TER7 / 8 agonist.

379. The conjugate of claim 370, wherein the Toll-like receptor agonist is a TER7 agonist.

380. The conjugate of claim 370, wherein the Toll-like receptor agonist is a TER8 agonist.

381. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is exatecan and a second active agent is a STINGa.-685- FH13329100.6Attorney Docket No.: LCH-04125382. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is MMAE and a second active agent is a STINGa.

383. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is MMAF and a second active agent is a STINGa.

384. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent issecond active agent is a STINGa.

385. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is MMAE and a second active agent is exatecan.

386. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is GENZ-644282 and a second active agent is a STINGa.

387. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is taltobulin and a second active agent is a STINGa.

388. The conjugate of any one of claims 11-15 and 26-361, wherein the conjugate comprises at least 3 active agents.

389. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is STINGa and a second active agent and a third active agent are each exatecan.

390. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is STINGa and a second active agent and a third active agent are each MMAE.-686- FH13329100.6Attorney Docket No.: LCH-04125391. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is STINGa and a second active agent and a third active agent are each MMAF.

392. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is MMAE and a second active agent and a third active agent are each exatecan.

393. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is MMAF and a second active agent and a third active agent are each exatecan.

394. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is MMAE and a second active agent and a third active agent are each a TLR7 / 8 agonist.

395. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is MMAE or MMAF and a second active agent and a third active agent are each396. The conjugate of any one of claims 11-15 and 26-361, wherein a first active agent is MMAF and a second active agent and a third active agent are each a TLR7 / 8 agonist.

397. A pharmaceutical composition comprising the conjugate of any one of claims 1-396 and a pharmaceutically acceptable excipient.

398. A method of treating a disease or disorder in a subject comprising administering a conjugate or composition of any one of claims 1-397 to the subject.

399. The method of claim 398, wherein the disease or disorder is cancer.-687- FH13329100.6Attorney Docket No.: LCH-04125400. The conjugate of any one of claims 83-325, wherein L1Acomprises a C1-C100 alkylene.

401. The conjugate of any one of claims 83-325, wherein L1Acomprises a C1-C50 alkylene.

402. The conjugate of any one of claims 83-325, wherein L1Afurther comprises an oligoethylene glycol.

403. The conjugate of claim 402, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

404. The conjugate of claim 403, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

405. The conjugate of any one of claims 83-325, wherein L1Ais substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamide.

406. The conjugate of any one of claims 83-325, wherein L1Afurther comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties).

407. The conjugate of claim 406, wherein L1Acomprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxy alkyl).

408. The conjugate of any one of claims 83-325, wherein L1Afurther comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

409. The conjugate of any one of claims 83-325, wherein L1Acomprises a structure represented by formula XXIIa or XXIIb:-688- FH13329100.6Attorney Docket No.: LCH-04125XXIIa XXIIbwhereineach At1represents a linkage to X1; andeach A9represents a linkage to Lg.

410. The conjugate of any one of claims 83-325, wherein L1Acomprises a structure represented by formula XXIIIa, XXIIIb, or XXIIIc:XXIIIa XXIIIb XXIIIcwhereineach A10represents a linkage to X1; andeach A11represents a linkage to Lg.

411. The conjugate of any one of claims 83-325, wherein L1Afurther comprises a structure represented by formula XXIV:XXIVwherein p2 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;each A12represents a linkage to X1; andeach A13represents a linkage to Lg.

412. The conjugate of claim 411, wherein p2 is 1, 2, 3, 4, or 5.-689- FH13329100.6Attorney Docket No.: LCH-04125413. The conjugate of any one of claims 83-325, wherein L1Ais substituted with an oligoethylene glycol.

414. The conjugate of claim 413, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

415. The conjugate of claim 414, wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

416. The conjugate of any one of claims 413-415, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxy ethyl).

417. The conjugate of any one of claims 413-415, wherein the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

418. The conjugate of any one of claims 83-325, wherein LIAfurther comprises an amino acid (e.g., a hydrophilic amino acid).

419. The conjugate of any one of claims 83-325, wherein L1Afurther comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids).

420. The conjugate of claims 418 or 419, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine.

421. The conjugate of claim 418 or 419, wherein the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine.

422. The conjugate of claim 418 or 419, wherein the amino acid(s) are selected from aspartate and glutamate.-690- FH13329100.6Attorney Docket No.: LCH-04125423. The conjugate of claim 418 or 419, wherein the amino acid(s) are sarcosine.

424. The conjugate of any one of claims 83-325, wherein L1Afurther comprises a polypeptoid (e.g., polysarcosine).

425. The conjugate of claim 15, wherein the conjugate is selected from:-691- FH13329100.6Attorney Docket No.: LCH-04125-692- FH13329100.6Attorney Docket No.: LCH-04125pharmaceutically acceptable salt thereof.

426. The conjugate of claim 18, wherein the conjugate is selected from:-693- FH13329100.6Attorney Docket No.: LCH-04125-694- FH13329100.6Attorney Docket No.: LCH-04125-695- FH13329100.6Attorney Docket No.: LCH-04125-696- FH13329100.6Attorney Docket No.: LCH-04125-697- FH13329100.6Attorney Docket No.: LCH-04125-698- FH13329100.6Attorney Docket No.: LCH-04125-699- FH13329100.6Attorney Docket No.: LCH-04125-700- FH13329100.6Attorney Docket No.: LCH-04125-701- FH13329100.6Attorney Docket No.: LCH-04125-702- FH13329100.6Attorney Docket No.: LCH-04125-703- FH13329100.6Attorney Docket No.: LCH-04125-704- FH13329100.6Attorney Docket No.: LCH-04125-705- FH13329100.6Attorney Docket No.: LCH-04125-706- FH13329100.6Attorney Docket No.: LCH-04125-707- FH13329100.6Attorney Docket No.: LCH-04125-708- FH13329100.6Attorney Docket No.: LCH-04125-709- FH13329100.6Attorney Docket No.: LCH-04125-710- FH13329100.6Attorney Docket No.: LCH-04125-711- FH13329100.6Attorney Docket No.: LCH-04125-712- FH13329100.6Attorney Docket No.: LCH-04125-713- FH13329100.6Attorney Docket No.: LCH-04125-714- FH13329100.6Attorney Docket No.: LCH-04125-715- FH13329100.6Attorney Docket No.: LCH-04125-716- FH13329100.6Attorney Docket No.: LCH-04125-717- FH13329100.6Attorney Docket No.: LCH-04125-718- FH13329100.6Attorney Docket No.: LCH-04125-719- FH13329100.6Attorney Docket No.: LCH-04125-720- FH13329100.6Attorney Docket No.: LCH-04125-721- FH13329100.6Attorney Docket No.: LCH-04125-722- FH13329100.6Attorney Docket No.: LCH-04125-723- FH13329100.6Attorney Docket No.: LCH-04125-724- FH13329100.6Attorney Docket No.: LCH-04125-725- FH13329100.6Attorney Docket No.: LCH-04125-726- FH13329100.6Attorney Docket No.: LCH-04125-727- FH13329100.6Attorney Docket No.: LCH-04125and-728- FH13329100.6Attorney Docket No.: LCH-04125; or a pharmaceutically acceptable salt thereof.-729- FH13329100.6